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Abstract 
The potential effects of introducing bone regeneration strategies into environments of 
disease and damage are often overlooked, despite the fact that many of the signalling 
pathways in inflammation have effects on bone development and healing. Embryonic 
stem cells (ESCs) are increasingly being used to develop models of disease and 
have potential in osteogenic-cell based therapies. Osteogenic differentiation 
strategies for ESCs are well established, but the response of these cells to tissue 
damage and inflammation has not yet been investigated, particularly in comparison to 
primary osteoblasts. Here, proinflammatory cytokines were used as part of an in vitro 
model to mimic elements of skeletal disease, such as rheumatoid arthritis and non-
union fractures. The response of osteogenically differentiated mouse embryonic stem 
cells (osteo-mESCs) to the proinflammatory cytokines interleukin 1-ȕ,/-ȕWXPRXU
necrosis factor-Į71)-ĮDQG LQWHUIHURQ-Ȗ ,)1-ȖZDVFRPSDUHG WR WKDWRISULPDU\
mouse calvarial osteoblasts, already well-described in literature and used as a 
³EHQFKPDUN´ LQ WKLV VWXG\ $OWKRXJK KLVWRORJ\ LPPXQRF\WRFKHPLVWU\ DQG 3&5
showed similarities in osteogenic differentiation of the osteo-mESCs and the primary 
calvarial cells, over 21 days in culture, there were marked differences in the response 
to the proinflammatory cytokines. Viability of the osteo-mESCs was maintained in 
response to cytokines, whereas viability of primary cells was significantly reduced. 
There were marked increases in nitric oxide (NO) and prostaglandin E2 (PGE2) 
production in primary calvarial cells over the entire 21-day culture period, but this was 
not seen with osteo-mESCs until day 21. The study then went on to look at the effects 
of proinflammatory signalling on the in vitro bone formation of the two cell types. 
Significant differences in the effects of proinflammatory cytokines on bone nodule 
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formation and matrix production were seen when comparing the osteo-mESCs and 
the calvarial cells. This study demonstrates that while osteo-mESCs share phenotypic 
characteristics with primary osteoblasts, there are some distinct differences in their 
biochemistry and response to cytokines. This is relevant to understanding 
differentiation of stem cells, developing in vitro models of disease, testing new drugs 
and developing cell therapies. 
An additional objective in this investigation was to look at tissue engineering 
strategies as a means of controlling inflammation in bone disease. The primary 
calvarial osteoblasts were utilised as an in vitro inflammation model, and used to 
study the effects of anti-inflammatory mediators. Anti-inflammatory-releasing porous 
scaffolds were manufactured from poly(lactic-co-glycolic acid) (PLGA) and 
poly(ethylene glycol) (PEG). The calvarial osteoblast inflammation model was used 
successfully to show successful release of diclofenac sodium from the PLGA/PEG 
scaffolds. This study demonstrates that there is much to consider in the development 
of regenerative strategies for bone disease, particularly the role that the effect and 
control of inflammation will play in bone healing.  
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Chapter 1:   
General Introduction 
1.1  Tissue Engineering and Regenerative 
Medicine 
1.1.1 Background and Overview 
Tissue engineering is a discipline that aims to combine the principles of engineering 
and life sciences in the production of biological substitutes to restore, maintain or 
improve tissue function. A tissue engineering strategy may be applied in vivo to 
induce regeneration within the body, or can be developed in vitro to provide a 
functional alternative before implantation into the body [1]. Classically, tissue 
engineering strategies involve three general principles: the use of isolated cells or cell 
substitutes; tissue-inducing substances such as signal molecules and growth factors 
and supportive matrices or scaffolds, with and without the incorporation of cells [2] 
(see figure 1.1). 
The field and term ³regenerative medicine´ has been more recently developed and 
encompasses the same final goal as tissue engineering: replacement or regeneration 
of human cells, tissues or organs. However, regenerative medicine tends to be more 
focused on biological principles, and revolves around the use of stem cells [3, 4]. The 
regenerative medicine term was originally embraced to distance researchers from the 
RULJLQDO³WLVVXH HQJLQHHULQJ´PRQLNHUDIWHUEXVLQHVVIDLOXUHRIHDUO\WLVVXHHQJLQHHULQJ
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Figure 1.1: Tissue engineering. The premise of tissue engineering is centred 
around three core elements: cells, signals and scaffolds; designed to work together to 
produce a regenerative therapy for the body. There are several possible cell sources: 
primary sources, adult stem cells and embryonic/induced pluripotent cells. Cells may 
be combined with a scaffold that is designed to complement the biology of the cells 
and the tissue. Bioreactor culture can be used to produce a 3D-tissue before 
implantation into the body or alternatively, cells and scaffolds can be implanted with 
minimum in vitro culture, allowing the body to serve as a natural bioreactor. 
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products. However more recently, the term has been used to encompass 
pharmaceutical and biotech products, such as those containing growth hormones and 
bone morphogenetic proteins (BMPs), rather than the cell therapies it was originally 
aimed at [5]'HVSLWHWKLVWKHWHUPV³WLVVXHHQJLQHHULQJ´DQG³UHJHQHUDWLYHPHGLFLQH´
are often used interchangeably. 
 
1.1.2 Stem Cell Research and Cell Therapies 
1.1.2.i Stem cell research 
Stem cells exist as part of the developmental continuum, playing a crucial role in the 
SURJUHVVLRQ RI KXPDQ OLIH 7KH WHUP ³VWHP FHOO´ FDQ EH D EURDG ODEHO 7KH EDVLF
definition incorporates cells that can continually divide and reproduce themselves, 
whilst maintaining the ability to differentiate into other cell types. A schematic of stem 
cell renewal can be seen in figure 1.2. This would include the totipotent stem cell that 
can give rise to all the cells of the developing embryo, including extra-embryonic 
tissues such as the placenta, the pluripotent embryonic stem cell (ESC), and the 
multipotent somatic adult stem cell, found within the mature human body.  
Stem cell research is a comparatively modern phenomenon and has a short history 
featuring some very large technical advances. The first stem cell was proven to exist 
in 1961 when the haematopoietic stem cell (HSC) was identified in the bone marrow 
[6]. The discovery of the mouse embryonic stem cell (mESC) in 1981 generated much 
promise, and allowed a simple way of studying embryogenesis and development [7-
9]. The first human embryonic stem cell (hESC) was isolated in 1998 [10] and with the 
development of induced pluripotent stem cells (iPSCs)  in 2006, the field of stem cell 
research is ever expanding [11] . 
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Figure 1.2: Stem cell renewal and differentiation. The purpose of stem cells is to 
give rise to specific differentiated cells, enabling our bodies to grow and function 
normally. Possible mechanisms of stem cell self-renewal are represented in figure A-
C. (A) Asymmetric division, replicating and differentiating is the most classic process, 
with one stem cell giving rise to two daughter cells, one remaining identical to itself 
and the other going on to differentiate. (B and C) Symmetric division, one stem cell 
either giving rise to two differentiating cells or two more stem cells. (D) Generation of 
progenitor / transit amplifying cells. The role of progenitor cells is to enter into several 
rounds of division increasing cell numbers. With each division the progenitor may 
become progressively more differentiated and eventually stops dividing, having 
acquired the characteristics of a fully differentiated cell type. 
B. Symmetric Division 
± Differentiating
C. Symmetric Division
- Replicating
D. Asymmetric Division. 
- amplification of cell 
numbers and 
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1.1.2.ii The cell therapy industry 
The cell therapy industry is considered by some to be distinct from regenerative 
medicine and is the therapeutic application of cells, regardless of cell type or clinical 
application [5]. Cell therapies have origins in blood transfusion, bone marrow 
transplantation and organ transplantation. Although the definition expresses that any 
cell type can be used, most often the cells are stem cell related. The market for cell 
therapies is rapidly expanding and clinical targets include heart disease, diabetes, 
neurodegenerative disorders, musculoskeletal disorders and spinal cord injury. The 
industry is now worth more than US$1 billion, and predicted to grow to more than 
US$3 billion by 2014 [12, 13]. Historically, the most successful cell therapies have 
been blood transfusions and bone marrow transplantations, but these were 
developed before a cell therapy industry existed. In recent times, progressing cell 
therapies to market can be difficult due to regulatory hurdles. Some therapies have 
been US Food and Drug Administration (FDA) and European Medicines Agency 
(EMA) approved, including Provenge (Dendreon Corporation), a cell-based cancer 
vaccine, and Carticel (Genzyme Biosurgery), an autologous cultured chondrocyte 
therapy [14]. Regulatory approval is not the only hurdle in getting cell therapies to 
market. The therapy needs to prove efficacy and improve upon existing medicine. 
This is where the importance of stem cell research is apparent. Knowledge of cell 
behaviour in different environments, and how control of cell behaviour may be 
integrated into a therapy, could play an important part in the success or failure of 
future cell-based products.  
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1.1.3  Bone Tissue Engineering 
1.1.3.i Background and clinical need 
Tissue engineering of bone is a rapidly expanding field and many different 
approaches are in creation. Clinical indications that call for a tissue-engineered bone 
substitute include defects caused by trauma, tumours and infections, non-union 
fractures and bone diseases such as osteoporosis and rheumatoid arthritis. The 
FXUUHQW ³JROG VWDQGDUG´ WUHDWPHQWV IRU GHIHFWV DUH DXWRORJRXV Rr allogeneic bone 
grafts, or the use of metals and ceramics to fill the defect and support the bone as it 
attempts to heal [15, 16]. Although many of the current strategies for bone 
regeneration produce relatively satisfactory results, there are limitations and 
drawbacks to each treatment. In many cases, autologous bone grafts cannot be 
performed due to unavailability and donor site morbidity. Allogeneic grafts also carry 
disadvantages due to immune rejection and pathogen transmission [17]. The use of 
synthetic bone substitutes are disadvantageous because they rarely have superior or 
similar biological and mechanical properties, compared to natural bone. 
 
1.1.3.ii Bone tissue engineering strategies 
Due to lack of available treatments and successful cures for the diseases mentioned 
above, the tissue engineering and regenerative medicine fields are hoping to be able 
to create new and successful therapies. Strategies investigated thus far include 
biomaterial scaffolds alone, scaffolds loaded with growth factors, cell therapies and 
scaffolds loaded with cells [17-19].  
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1.1.3.ii.a  Biomaterials Strategies 
A biomaterial scaffold needs to attempt to replicate the natural extracellular matrix 
(ECM) of the tissue and therefore will influence cell attachment, migration, 
proliferation and differentiation. Scaffolds for bone regeneration require 
biocompatibility, porosity, correct mechanical properties, biodegradability, 
osteoconductive properties to promote osteogenic cell adhesion and proliferation, and 
osteoinductive properties to recruit stem and progenitor cells [17]. These properties 
can be achieved in several different ways, by adjusting materials selection, material 
processing, surface engineering and incorporation of cells or growth factors.  
 
1.1.3.ii.b  Growth Factor Therapies 
Improved knowledge of bone healing and regeneration pathways has led to the 
identification of a number of key molecules that help to regulate the process. Some 
have been put into clinical use to enhance bone repair. The BMP family of molecules 
is one of the most extensively studied. BMPs are potent osteoinductive factors that 
can cause mitogenesis of mesenchymal stem cells (MSCs) and differentiation 
towards osteoblasts, inducing bone formation [20]. BMP-2 and BMP-7 have been 
licensed for clinical use since 2002 and 2001, respectively [21, 22]. The INFUSE® 
Bone Graft featuring BMP-2, manufactured by Medtronic, is used to treat 
degenerative disc disease. The OP-1 putty incorporating BMP-7, also a treatment for 
degenerative disc disease, was originally owned by Stryker but has since been sold 
to the Olympus Corporation [23]. Both Stryker and Medtronic have since encountered 
legal issues and have been indicted for encouraging doctors to use the product off-
label, for purposes not approved by the FDA. The BMP-2 treatment has been 
associated with complications such as bony overgrowth, osteoclast activity, local 
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inflammation, systemic toxicity, airway compression and carcinogenicity [24]. Despite 
this, researchers are still looking for methods of incorporating and delivering factors, 
such as BMPs, as regenerative therapies [25-27]. The unseen complications caused 
by the use of these therapies highlights the need for better understanding of the 
biology of bone regulation, particularly in the hope of being able to influence and 
control bone regeneration. 
 
1.1.3.ii.c  Cell therapies 
Cell therapies for bone repair have mostly been focused on the use of MSCs and 
bone marrow-derived osteoprogenitors and there have been some instances of use in 
animal studies and clinical trials, showing some success [28, 29]. The use of 
embryonic stem cells (ESCs) as cell-based therapies in bone regeneration is much 
further from clinical application but research has been initiated [18]. Human ESCs 
havH EHHQ VKRZQ WR SURGXFH PLQHUDOL]HG ³ERQH-OLNH´ WLVVXH in vitro and in animal 
models [30, 31]. 
 
1.1.3.iii Cell sources for bone tissue engineering 
1.1.3.iii.a  Embryonic stem cells 
ESCs are isolated from the inner cell mass of the blastocyst of a preimplantation 
embryo [7, 10]. This usually leads to the destruction of the embryo, provoking ethical 
objections from some sections of society, but there has been methods recently 
described that use a single cell biopsy from the embryo, that have less detrimental 
consequences [32]. The most common hESC lines have been derived from 
destruction of extraneous embryos from fertility treatment or embryos created from 
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somatic cell nuclear transfer (SCNT). The process of deriving ESCs from embryos 
and converting them to in vitro culture can be seen in figure 1.3. 
ESCs are characterised by the ability to self-renew indefinitely and are capable of 
differentiating into any cell of the body; this ability is termed pluripotency. Literature 
describes both in vivo and in vitro differentiation of cells into all three of the primary 
germ layers: mesoderm, endoderm and ectoderm [33]. This includes differentiation 
into cardiomyocytes [34], haematopoietic cells [35], neuronal cells [36], muscle cells 
[37], chondrocytes [38] and pancreatic islet cells [39]. 
Continuous in vitro culture of ESCs requires the maintenance of pluripotency. This is 
performed in mESCs by culturing in the presence of leukaemia inhibitory factor (LIF).  
LIF acts to suppress differentiation. In some cases, pluripotency can also be 
maintained by culturing upon a feeder layer of mouse embryonic fibroblasts (MEFs) 
with LIF [40].  LIF does not have the same effect upon hESCs. In this instance, 
maintenance of pluripotency is performed by culturing upon MEF feeder layers or on 
matrigel in MEF-conditioned media. In both situations, the presence of basic fibroblast 
growth factor (bFGF) is required [41]. Theoretically, ESCs can be put through infinite 
divisions in vitro, as long as pluripotency is maintained.  
Markers used to identify pluripotent mouse and human ESCs include stage specific 
embryonic antigen (SSEA)-3, transcription factors Oct 3/4 and Sox-2, zinc finger 
protein Rex-1 and transcriptional activator UTF-1 [42-45]. The marker SSEA-4 is only 
found in hESCs and SSEA-1 only in mESCs. Expression of certain markers differs 
between mouse and human ESCs, as discussed by Ginis et al., but the conclusion 
reached was that overall strategies for maintenance of pluripotency and differentiation 
remain similar across species [45]. 
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Figure 1.3: Derivation of ESC lines. The blastocysts are grown from in vitro 
fertilised embryos. Inner cell mass cells are separated from the blastocyst by 
immunosurgery and plated onto an inactivated mouse fibroblast feeder layer. 
Colonies can then be expanded and cloned. Taken from [46]. 
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To date, there have been few ESC based products to reach clinical trial. The Geron 
Corporation started phase I clinical trials for their product involving oligodendrocytes 
derived from hESCs, in January 2009. This was WKH ZRUOG¶V ILUVW K(6& WULDO LQ
humans. Since then, Geron have stopped stem cell research, due to economic 
concerns, but continue to monitor the patients that received the therapy. In 2011, 
Advanced Cell Technology started a phase I/II trial involving the injection of hESC-
derived pigment epithelium cells to treat macular degeneration [47]. The trial is still 
ongoing [48]. 
The use of ESCs as transplantable cells in clinical trials has been hampered by 
several obstacles of a scientific nature. Current differentiation protocols are often 
unsatisfactory and can result in a final cell population that is heterogeneous in 
character, although with one cell type dominating. There can be considerable 
variation in final cell yield from batch-to-batch cultures, despite identical differentiation 
protocols. Due to the number of cell lineages that ESCs can spontaneously 
differentiate into, derivation of a homogenous cell population will ultimately rely upon 
consistent cell selection and purification techniques. It is also critical that the cells 
function physiologically when compared to cells of the body. Efficacy, safety and 
methods to prevent immunological rejection, will need to be demonstrated in order for 
further ESC-based cell therapies to reach human trials. 
  
1.1.3.iii.b  Adult stem cells 
Adult stem cells, also known as somatic stem cells, can be isolated from several 
different tissue types. The most widely known example is the HSC, which can be 
found in the bone marrow. Clinically, the HSC has been utilised for many years in the 
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form of bone marrow transplants. HSCs can differentiate into all myeloid and 
lymphoid lineages [49].  
In the field of tissue engineering, particularly bone and cartilage engineering, the MSC 
is of particular interest. MSCs are present in the early limb bud and migrate from the 
mesoderm. They can then differentiate through many stages into the osteoblast that 
goes on to produce the bone matrix [50]. In vitro, MSCs have been shown to 
differentiate into cells of mesodermal origin including osteoblasts, chondroblasts, 
adipocytes and myoblasts, and can be isolated from various tissues such as bone 
marrow, adipose tissue and skeletal muscle [51]. MSCs isolated from different tissues 
can vary in their activity and properties. MSCs may exhibit limited plasticity, 
differentiating into cells outside of the mesenchymal lineage. The most widely used 
MSCs originate from the bone marrow stroma and were first identified in 1970 [52]. 
The advantages of using MSCs for therapeutic applications are differentiation 
capacity, ease of isolation and ability to amplify in vitro. However, MSCs are more 
limited in the number of divisions that can be performed in vitro than ESCs, due to 
asymmetric division and being more advanced in the developmental continuum. 
MSCs are generally identified and defined via expression of markers such as CD29, 
CD44, CD73, CD90, CD105 and the ability to differentiate into osteoblasts, 
chondroblasts and adipocytes in vitro. They should not express the haematopoietic 
cell surface markers CD34, CD45, CD14 and human leukocyte antigen (HLA) class II 
[53, 54].  
MSCs have had more success reaching therapeutic stage than ESCs and have been 
trialled as therapies for many clinical indications including graft-versus-host disease 
*9+'&URKQ¶VGLVHDVH FDUGLRYDVFXODU GLVHDVH GLDEHWHVDQGERQHDQGFDUWLODJH
defects [55]. 
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1.1.3.iii.c  Primary osteoblasts 
Both primary osteoblasts and osteoclasts can be extracted from bone and cultured in 
vitro. There are also several bone cell lines that can be used for in vitro culture, 
including the mouse calvarial MC3T3-E1 line and the human osteosarcoma lines 
Saos-2 and MG-63. These cells are not generally useful for tissue engineering 
purposes, as primary cells have very limited proliferative capacity in vitro and others 
are essentially cancer cells. However, they can be very useful in disease modelling 
and in vitro testing. 
 
1.1.3.iii.d  Induced pluripotent stem cells 
iPSCs  are the most recent major development in stem cell research and are derived 
by nuclear reprogramming, a procedure that causes a switch in gene expression from 
one cell type to another [56].  The advance of iPSC development caused much 
excitement in the world of tissue engineering and stem cell research [11]. iPSCs can 
now be created from both murine and human somatic cells by retroviral delivery of 
transcription factor genes such as Oct-4, Sox2, Klf4, c-Myc [57]. Although iPSCs do 
not carry the ethical controversy that surrounds ESCs, there are still concerns and 
limitations with their use, particularly in the utilisation of transfection systems and the 
genes required to reprogram the cells [58]. iPSCs have shown the ability to 
differentiate down the osteogenic lineage and show promise in the fields of 
regenerative medicine and disease modelling [59].  
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1.1.3.iv Osteogenic differentiation strategies 
When considering stem cells as a possible therapies or disease models for bone, 
osteogenic differentiation will need to be performed in order to create a cell that 
displays markers of osteoblasts and produces an ECM reminiscent of bone. 
Osteogenesis of stem cells is a complicated process, but has been reported in vitro 
using factors such as dexamethasone, ascorbic acid, beta-glycerophosphate, BMP-2, 
transforming growth factor-ȕ (TGF-ȕ) and 1,25 dihydroxy vitamin D3 [30, 60-62]. The 
differentiation of ESCs is normally commenced with the formation of an embryoid 
body, a spheroid structure that mimics early development [63, 64]. Cells within the 
embryoid body will undergo morphological changes and differentiate into early cells of 
the three germ layers [33]. The embryoid body can then be dissociated and culture in 
monolayer continued. Osteogenesis of ESCs without the embryoid body step has 
been reported, as this allows an easier and quicker protocol to be followed and the 
study of direct osteogenesis, but is not commonly used [65]. 
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1.2  Bone Physiology and Development 
Bone is a highly dynamic organ. Throughout human life, bone is constantly 
remodelled, with matrix resorption and new matrix deposition occurring concurrently, 
in a complex and highly balanced cycle. In order to produce regenerative strategies 
for bone and to understand bone disease, a familiarity with bone biology and 
development is required. 
 
1.2.1 Bone Structure and Biology 
Bone is an organ composed of cortical and trabecular structures, cartilage, 
haematopoietic tissue and connective tissue. There are many functions of bone 
including support of the body, protection of internal organs, movement, a site for 
haematopoiesis and mineral storage [66, 67]. Figure 1.4 shows the structure of bone. 
Cortical bone, also known as compact bone, accounts for around 80% of the total 
bone mass of the skeleton. It has a mechanical function and a high mineral content. 
Cortical bone has a complex structure made up of cylindrical units called osteons. 
Each osteon runs parallel to the long axis of the bone and contains a ring structure of 
lamellae. The lamellae are made up of collagen fibres that run parallel to one another, 
providing the torsional strength of bone. Trabecular bone, also known as spongy or 
cancellous bone, has a fine lattice structure, filled with bone marrow, blood vessels 
and fat. The lattice structure allows a reduction in weight without compromising the 
strength of the bone. Long bones have a structure comprising the diaphysis or shaft, 
containing the bone marrow cavity, and the epiphyses, the bone ends. Short, irregular 
and flat bones all have simpler structures comprising both cortical and trabecular 
bone, but no bone marrow. Bone comprises both organic and inorganic components. 
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Figure 1.4: The structure of bone. (A) Structure of long bone: (a) bone sectioned 
frontally, (b) Enlarged view of trabecular (spongy) and cortical (compact) bone, (c) 
Cross-sectional view of diaphysis of bone. (B) Structure of flat bone, consisting of 
trabecular bone sandwiched between cortical bone. Taken from [67]. 
 
A
B
Chapter 1 General Introduction 
  21 
The organic components include the cells and the osteoid. Osteoid is predominantly 
made up of collagen but also contains other matrix proteins, proteoglycans and 
glycoproteins. The inorganic phase of bone consists of hydroxyapatites; calcium 
phosphates present in crystalline form surrounding the collagen fibres.  
 
1.2.2 Bone Cells 
There are a number of different cell types found in bone, including preosteoblasts, 
osteoblasts and osteocytes that originate from the mesenchymal line and osteoclasts 
that originate from HSCs. Figure 1.5 shows the stages of osteoblast differentiation 
from MSC to osteocyte. 
 
1.2.2.i MSCs and osteoprogenitor cells 
Osteoprogenitor cells are derived from multipotent MSCs that are found in the bone 
marrow stroma and resemble young fibroblasts. Osteoprogenitors retain a 
proliferative capacity but can also express proteins associated with the mature 
osteoblast phenotype [68]. During bone development or healing, these cells migrate 
and differentiate into the osteoblast. There is no definitive marker for the 
osteoprogenitor cell, causing them to be difficult to identify within a cell population. 
The genetic regulation of MSC differentiation to osteoblasts is in part regulated by the 
transcription factor Runx2 also known as core binding factor a-1 (cbfa-1) [69]. Runx2 
plays an important role throughout skeletal development. Mice born without the 
Runx2 gene die immediately after birth and show a complete lack of skeletal 
ossification [70]. More recently, the transcription factor TAZ (transcriptional co-
activator with PDZ-binding motif) has been reported, which acts to specify osteoblast 
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Figure 1.5: Stages in the osteoblast lineage. Schematic diagram showing stages in 
the osteoblast lineage and some of the transcription factors that lead to osteoblast 
production from MSCs. Adapted from Hughes et al. [71]. 
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fate in bipotent osteoblast/adipocyte stem cells by leading to activation of Runx2 and 
repressing PPAR-ȖDWUDQVFULSWLRQIDFWRULPSRUWDQWLQDGLSRJHQHVLV[72]. There are a 
number of other transcription factors that regulate differentiation to the osteoblast: 
Msx-2 acts upstream of Runx2, whereas Dlx-5, activator protein-1 (AP-1) and osterix 
(OSX) run downstream, and are involved in matrix synthesis and deposition  .   
 
 
1.2.2.ii Osteoblasts 
Osteoblasts are the cells that originate from committed osteoprogenitor cells. 
Osteoblasts are responsible for the formation, organisation and subsequent 
mineralisation of bone ECM and are cuboid in shape [76]. A mature osteoblast will 
produce osteoid containing predominantly collagen I (col-I), but also a little collagen V 
and many bone specific proteins such as osteocalcin (OCN), osteopontin (OPN), 
osteonectin and bone sialoprotein (BSP) [66]. The secretory surface of osteoblasts 
runs close to the bone surface and is rich in the enzyme alkaline phosphatase (ALP). 
These proteins together have a calcium binding activity that leads to the 
hydroxyapatite crystal deposition seen in the mineralised matrix. Of these non-
collagenous matrix proteins, OCN is considered to be the most bone-specific, as 
expression in the adult is restricted to bone dentin and cementum. Some osteoblasts 
eventually become bone-lining cells that cover bone surfaces but most become 
osteocytes. After producing bone matrix, osteoblasts may also die by apoptosis, this 
mechanism is partially controlled by BMP-2 and is a method of regulating osteoblast 
number and function [77].  
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1.2.2.iii Osteocytes 
Osteocytes are terminally differentiated osteoblasts that have become trapped in 
lacunae inside the mineralized matrix of bone. They are the major cell type in mature 
bone. Osteocytes are connected by dendrites that reach through a system of 
canaliculi. Through these, they communicate with each other and the osteoblasts. 
This is believed to regulate the response of bone to the stresses of the external 
environment, communicating and maintaining electrical and metabolic activity [78]. 
    
1.2.2.iv Osteoclasts 
Osteoclasts are responsible for bone matrix resorption. Unlike osteoblasts, they are 
not derived from mesenchymal progenitors but are of a haematopoietic lineage. 
Osteoclast progenitor cells are derived from the mononuclear phagocyte lineage. 
Preosteoclasts fuse to form giant multinucleated osteoclasts [79].  In bone, they are 
ORFDWHGLQUHVRUSWLRQSLWVNQRZQDV+RZVKLS¶VODFXQDHZKHUHWKH\SURGXFHORFDOLVHG
acidic environment that is conducive to bone resorption. The osteoclast cell surface 
when attached to bone forms a region known as the ruffled border, which is rich in 
vesicles, phagosomes and residual bodies. Bone resorption is caused by the 
synthesis of lysosymal enzymes, particularly tartrate-resistant acid phosphatase 
(TRAP) and matrix metalloproteinases (MMPs) [80].  
 
1.2.3 Bone Development 
Both the words osteogenesis and ossification refer to the development of bone. The 
embryonic origin of the bones of the skeleton are the limb buds, these are 
Chapter 1 General Introduction 
  25 
mesodermal tissue covered by ectoderm. There are two types of ossification, 
endochondral and intramembranous. In endochondral ossification, MSCs condense 
at the limb bud and differentiate into chondroblasts. A matrix is secreted and a 
cartilage model of the bone is created surrounded by the perichondrium. The cartilage 
template grows and a vascular system develops, invading the perichondrium. Inner 
perichondrial cells differentiate into osteoblasts and a collar of bone is laid down 
around the mid-shaft. The osteoblasts also penetrate the centre of the shaft forming a 
diaphyseal ossification centre, where trabecular bone is deposited. The bone 
increases in width by appositional growth. In long bones, a secondary centre of 
ossification is developed at the cartilaginous ends of the bone, known as the 
epiphyseal ossification centre. This causes the ossification of the epiphyses of the 
bone. When completed, cartilage remains only at the ends of the bone and at the 
epiphyseal growth plate. It is from this growth plate that the bone can grow as a child 
matures. With the exception of the clavicles, endochondral ossification is responsible 
for the formation of most of the bones below the base of the skull.  
Intramembranous ossification is important in the development of the bones of the 
skull and clavicles, and in the healing of bone fractures. Intramembranous ossification 
does not involve a cartilage step; the formation of bone comes directly from the 
condensed mesenchyme. The MSCs differentiate directly into preosteoblasts that 
then aggregate and undergo proliferation, then differentiation into osteoblasts, which 
begin to secrete bone matrix from an ossification centre. First, an irregular and 
disorganised woven bone matrix is formed; later this is remodelled to mature lamellar 
bone [66, 67]. 
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1.2.4 Bone Remodelling 
&KDQJHVLQERQHDUFKLWHFWXUHRFFXUFRQWLQXRXVO\WKURXJKRXWDSHUVRQ¶VOLIHWLPH7KLV
is known as bone remodelling and is a balance of bone resorption by osteoclasts and 
bone deposition by osteoblasts. The process is coordinated by groups of adjacent 
osteoblasts and osteoclasts known as the bone remodelling units. Local mediators of 
this process are various growth factors and cytokines. Osteoclasts resorb matrix from 
the erosion cavity and then mononuclear cells differentiate into osteoblasts and lay 
down new matrix. Bone is remodelled in response to mechanical loading and strain, 
in order to retain form and function. Reduced bone loading can lead to decreased 
bone mineral density (BMD) in fracture patients and people subjected to prolonged 
low gravity conditions, such as astronauts [81]. Bone remodelling is often initiated by 
the presence of microfractures that appear under everyday activity and strain. Signals 
produced during microdamage activate the remodelling units that then allow control 
over BMD and routine fatigue damage [82]. Bone remodelling appears to be 
governed by a feedback system in which bone cells can sense the environmental 
strain around them and react to produce or remove bone in accordance. Signalling 
molecules that have been implicated in the adaptive response of bone to mechanical 
strain include glutamate, nitric oxide, prostaglandins and calcium [83-85] 
 
1.2.5 Regulation of Bone 
A large number of growth factors and cytokines are involved in the regulation of bone 
growth, remodelling and the proliferation and differentiation of bone cells [86]. Tables 
1.1 and 1.2 give brief descriptions of the effects of various growth factors and 
cytokines. 
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Table 1.1: Growth factor regulation of bone.  
Factor Regulatory Effect on Bone References 
Growth Factors 
  
Insulin-like  
growth factors  
(IGF-I & II) 
Stimulates longitudinal bone growth by acting 
on growth plate chondrocytes. 
Stimulates osteoblast proliferation and 
differentiation. 
Upregulates OSX. 
[87, 88] 
Transforming 
growth factor-ȕ
(TGF-ȕ 
Recruits and stimulates osteoprogenitors to 
proliferate during bone formation. 
In later stages of osteogenesis, can block 
differentiation and mineralisation. 
Regulates synthesis of collagen by growth 
plate chondrocytes. 
Inhibits Runx2 and Ocn genes. 
Inhibits interleukin-1 and 1,25(OH)2D3 (vitamin 
D) induced bone resorption and the formation 
of osteoclasts. 
[89-93] 
Fibroblast growth 
factors 
(FGF-1 and 2) 
Stimulates osteoblast proliferation in vitro. 
No direct effect on osteoblast differentiation. 
Increases apoptosis with prolonged exposure.  
[94-97] 
Platelet derived 
growth factor 
(PDGF) 
Synthesised by osteoblast and MSCs. 
Upregulates collagenase transcription in 
osteoblasts. 
Secreted by osteosarcoma cells. 
Mitogen for osteoblasts. 
[66, 98, 99] 
BMPs 
Directs MSCs down the osteoblast pathway. 
Can upregulate Runx2 at certain stages of 
osteogenesis. 
Regulates bone formation. 
Can independently induce ossification from 
non-skeletal MSCs. 
[100-102] 
Wnt Signalling 
Active in the early stages of osteoblast 
differentiation. 
Induces BMP-2 production and plays roles in 
BMP-induced osteogenic differentiation. 
Promotes osteogenesis indirectly through 
Runx2. 
Works with TGF-ȕto promote osteoblast 
proliferation. Has both stimulatory and 
inhibitory effects on TGF-ȕ. 
Wnt-3a induces BMP-9 
[103-109]  
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Table 1.2: Cytokine regulation of bone. 
Factor Regulatory Effect on Bone References 
Cytokines 
  
Interleukin-1 
(IL-1) 
ĮDQGȕ 
Produced by mesenchymal stem cells and 
osteoblasts. 
Can regulate both bone resorption and 
formation. 
Has been shown to inhibit osteoblast 
proliferation and enhance bone formation. 
Has also been shown to stimulate osteoblast 
proliferation and inhibit bone formation. 
Shown to inhibit col-I and OCN production. 
Increases production of other cytokines. 
[110-116] 
Interleukin-6  
(IL-6) 
Produced by osteoblasts 
Some inhibitory effect on osteogenic 
differentiation in vitro. 
May mediate some actions of IL-1 and 
regulate expression of other growth factors. 
[117-119] 
Tumour necrosis 
factor-Į 
(TNF-Į 
Produced by osteoblasts. 
Stimulates bone resorption and inhibits bone 
formation. 
Inhibits osteoblast differentiation 
Decreases production of col-I. 
Suppresses Runx2 and OSX expression. 
[120-122] 
Interferon-Ȗ 
 (IFN-Ȗ 
Antagonist to IL-1 and TNF-ĮERQHUHVRUSWLRQ 
Inhibits osteoblast proliferation. 
Inhibits collagen synthesis. 
Inhibits osteoclastogenesis. 
[121-123] 
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1.2.6 Bone Disease, Injury and Repair 
During the course of a lifetime, bones are subject to many different forces. Fractures 
are produced in healthy bone from moments of exceptional trauma that can twist and 
break the bone. In old age, fractures are more common due to bones becoming 
thinner, weaker and more brittle. Fractures can be classified in many different ways 
according to the orthopaedic trauma association (OTA) classification system [124].  
Normal bone repair, particularly in the case of fracture healing, involves four stages 
(table 1.3). In some cases, fractures fail to resolve themselves by healing in the 
normal way; these are commonly known as non-union fractures. Healing may also not 
occur when there is a large defect caused by blast injury, infection, surgical tumour 
resection or osteonecrosis. Bone diseases such as rheumatoid arthritis (RA), 
osteoarthritis (OA) and osteoporosis, can also disrupt bone healing and structure. RA 
is an inflammatory disorder, in which joints become inflamed, and is linked to 
autoimmunity. OA involves the degradation of joints of the skeleton and osteoporosis 
is a disease in which bone resorption occurs more efficiently than bone formation, 
disrupting the balance of bone remodelling. In addition, other disorders can cause a 
disruption to the bone balance including osteopetrosis, osteomalacia and rickets. 
There are many treatments available for all the above conditions but most are for pain 
management and containment of the disease. Although tissue engineering and 
regenerative medicine strategies can also be used for these purposes, the ultimate 
aim is to provide a cure and address the cause of the imbalance in bone healing.   
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Table 1.3: Stages of normal fracture healing. 
Stage of Healing Description 
1. Inflammation and 
haematoma 
formation 
Blood vessels in the periosteum are broken and torn by 
the trauma, causing a mass of clotted blood 
(haematoma) to form at the fracture site. Inflammatory 
exudate is released from blood vessels. 
Cells are deprived of nutrients and die. This attracts 
inflammatory cells and the tissue becomes painful and 
swollen. 
2.  Fibrocartilaginous 
callus formation 
Formation of granulation tissue. 
Capillaries grow into haematoma and phagocytic cells 
begin cleaning up the area. 
Fibroblasts and osteoblasts occupy the area and begin 
the process of reconstruction. Chondrocytes begin to 
secrete cartilage matrix. 
Repair tissue is called fibrocartilaginous callus and 
bridges the fracture. 
3. Bony callus 
formation 
Fibrocartilaginous callus is converted to bony callus or 
trabecular bone. 
Can take months for a firm union to be developed. 
Compressive forces can be withstood. 
4. Bone Remodelling Complete healing occurs by remodelling of the bony 
callus 
Trabecular bone converted to cortical bone in shaft 
walls. 
Final structure should resemble that of unbroken bone. 
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1.3  The Inflammatory Response 
1.3.1 Inflammation 
Inflammation is a protective response against trauma, intense heat, chemicals or 
infection by foreign organisms, and is part of the immune response. The major clinical 
symptoms of inflammation include heat, redness, pain and swelling in the affected 
area. The beneficial effects of the inflammatory response include prevention of the 
spread of damaging agents to other tissues, disposal of cell debris and pathogens, 
and the provision of a foundation for healing [67]. 
 
1.3.1.i The acute inflammatory process 
Inflammation is mediated by many local and systemic regulators. The inflammatory 
process after tissue injury begins with a flood of signals released into the extracellular 
fluid. Cells of the immune system play integral roles in inflammation and cells such as 
macrophages, monocytes and B-lymphocytes express surface membrane proteins 
called toll-like receptors (TLRs). Activation of certain TLRs, causes the release of 
cytokines that promote inflammation and can attract more cells of the immune system 
to the injured area [125]. Many cells produce these cytokines including injured tissue 
cells, macrophages, phagocytes, lymphocytes and mast cells. The released cytokines 
subsequently cause production of inflammatory mediators including additional 
cytokines, prostaglandins, histamine, kinins and complement proteins. The roles of 
these mediators can be found in table 1.4. One major effect of these mediators is 
vasodilation of the small blood vessels, causing more blood to flow into the area and  
d;k;lklk    
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Table 1.4: Physiological effects of inflammatory mediators. 
Mediator Physiological Effect 
Cytokines Signalling molecules such as interleukins (IL)-1,-6, -17, tumour 
necrosis factors (TNFs) and interferons (IFNs). 
Orchestrate inflammatory response. 
Attract leukocytes. 
Stimulate production of further inflammatory mediators.  
[126-129] 
Prostaglandins Derived from arachidonic acid by most cells. 
Increases effects of other inflammatory molecules.  
Sensitises blood vessels.  
Leads to production of free radicals that can go on to cause 
inflammation and pain.  
[130-132] 
 
Histamine Produced in response to mechanical injury, presence of 
microorganisms and chemicals by basophils and mast cells. 
Promotes vasodilation and increases permeability of local 
capillaries, leading to heat, redness, pain and swelling.  
[133] 
 
Kinins Includes bradykinin and kallidin and can be produced by most 
cells. 
Promotes vasodilation, induces chemotaxis of leukocytes and 
generation of more kinins.  
Can induce production of eicosanoids, more cytokines and nitric 
oxide. Induces pain.  
[132]. 
 
Complement 
Proteins 
Circulate in the blood. Causes lysis of microorganisms, 
enhances phagocytosis and intensifies inflammation.  
[134] 
 
Nitric Oxide (NO) Produced in large amounts during inflammation.  
Causes vasodilation, increasing temperature and swelling.  
[135]  
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the symptoms of redness and heat. The other major effect is permeabilisation of the 
local capillaries. This causes an exudate of fluid containing clotting proteins and 
antibodies to seep into tissue spaces. This exudate causes the swelling (oedema) 
that presses on the local nerve endings, causing pain sensation. Pain may also be 
caused by the sensitising effects of prostaglandins and kinins. The oedema allows 
dilution of harmful substances by the surge of fluids into the area, brings large 
quantities of nutrients and oxygen to help the repair process, and allows large clotting 
proteins to enter the area [67, 136].  
The inflammatory mediators cause phagocytes, such as neutrophils and 
macrophages to migrate to the area, and depending on the cause of the 
inflammation, these cells then act to resolve the issue. The first stage is leukocytosis, 
the release of large amounts of neutrophils from the bone marrow into the blood 
stream. The neutrophils flow into the injured area and are caught by endothelial cells 
that have expressed selectins due to cytokine signalling, such as P-selectin and E-
selectin. The neutrophils then bind to integrin receptors on the endothelial cells, 
arresting cell movement. The neutrophils migrate through capillary walls in a process 
called diapedesis and home to the area of injury through chemotaxis caused by the 
inflammatory mediators. This same process then attracts monocytes and 
macrophages. The function of these cells is to clear the injured area of pathogens, 
dead cells and other debris, so tissue repair can be initiated. The acute inflammatory 
response then ends [137]. 
   
1.3.1.ii Chronic Inflammation 
If the condition causing acute inflammation is not resolved, the inflammatory process 
may continue, leading to long-term chronic inflammation. Whereas acute 
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inflammation should be over within days, chronic inflammation may last for weeks, 
months or years. During this process an imbalance in the inflammatory signalling 
means that monocytes and macrophages are still attracted to the wound site, and 
inflammatory mediators and cytokines are still being produced [138]. Hence, heat, 
swelling, redness and pain are still present at the site of injury. Due to the large 
amount of macrophages at the injury site, tissue damage is a common problem in 
chronic inflammation. Chronic inflammation is present in many disease states 
LQFOXGLQJ5$DWKHURVFOHURVLV&URKQ¶VGLVHDVHDQN\ORVLQJVSRQG\OLWLVDQGGHUPDWLWLV
In many chronic inflammatory conditions, such as inflammatory bowel disease, cystic 
fibrosis and periodontitis, increased rates of osteoporosis and fractures occurs due to 
systemic increases in circulating proinflammatory cytokines [139-141]. 
 
1.3.2 Inflammation and Bone 
Many of the mediators of inflammation in bone, such as IL-1ȕ and TNF-Į, are also 
regulators of normal bone cell activity and bone development. Inflammatory effects in 
bone are due to changes in amounts, timings and combinations of cytokines. Due to 
the link between proinflammatory cytokines and bone development, inflammation can 
have great effect on bone structure, remodelling and growth. Systemic inflammatory 
effects throughout the body affect nutrient metabolism and hormone secretion, which 
can have knock-on effects on the skeleton.  
 
1.3.2.i Signalling during inflammation in bone  
A simplified diagram showing major pathways involved in inflammatory signalling in 
osteoblasts is shown in figure 1.6. Many of the effects of inflammation on osteoblasts  
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Figure 1.6: Signalling pathways in bone during inflammation. Simplified diagram 
showing major pathways involved in signalling in osteoblasts in response to 
inflammatory stimulus, such as proinflammatory cytokines. The major pathways 
involved include  the MAPK, NF-ț%DQG-$.67$7SDWKZD\V OHDGLQJ WRDn overall 
downregulation of osteogenic genes such as RUNX2, OCN, OSX and 
osteoprotegerin (OPG) and an upregulation of genes involved in inflammation such 
as COX-2 and iNOS. 
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are mediated by the NF-ț%WUDQVFULSWLRQIDFWRU, produced through I-ț%NLQDVHV,... 
Activation of this transcription factor by proinflammatory cytokine stimulation leads to 
increased production of more proinflammatory cytokines, inducible enzymes such as 
cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) and genes 
related to apoptosis [142]. The mitogen-activated protein kinase (MAPK) pathway, 
including p38, JNK and ERK, is also an important pathway during inflammation of 
bone, which plays a more complicated role, having both proinflammatory and anti-
inflammatory effects [143-145]. A third pathway involved in inflammation in bone is 
the JAK/STATs  (janus kinase/signal transducers and activators of transcription) 
system, that is activated by chemical inflammatory signals; this pathway goes to on to 
effect gene transcription including the production of apoptotic genes, additionally 
having an inhibitory effect on the MAPK pathway [145-147] .  
Locally to bone, mediators of inflammation such as the proinflammatory cytokines and 
activation of the pathways described above, causes changes in cell proliferation, 
differentiation and activity, causing the process of bone remodelling to be affected 
[148]. The predominant mediators of this are the eicosanoids and the proinflammatory 
cytokines. Eicosanoids are signalling molecules derived from arachidonic acid, and 
include prostaglandins, prostacyclins, leukatrienes and thromboxins. There is 
evidence that prostaglandins have a role in bone remodelling, but expression and 
response to is very much altered during the inflammatory response [149]. The 
proinflammatory cytokines IL-1, TNF-Į, IL-6 and IFN-Ȗ all have regulatory roles in 
normal bone modelling as discussed above. During inflammation, these cytokines are 
produced in higher concentrations both systemically and locally and having an effect 
on bone healing and remodelling. The overall effects of inflammation on bone are 
very difficult to predict in vitro due to the large number of different factors involved 
[148].  
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1.3.3 Tissue Engineering and the Inflammatory Response 
1.3.3.i Stem cells and inflammation 
There has been more research into the effect of inflammation on MSCs than ESCs. 
MSCs have been described as having both anti-inflammatory and immunomodulatory 
effects [150]. They have been reported to inhibit T-lymphocyte activation and 
proliferation, secretion of IFN-Ȗ and natural killer (NK) cell activity, leading to 
suppression of inflammation [151-153]. There has been less investigation into the 
effects of inflammation on ESCs, but like MSCs, ESCs have been described as being 
immunoprivileged, as they do not appear to provoke an immune response when 
implanted within a foreign body. An immune response to implanted cells is normally 
triggered by the presence of major histocompatibility complex (MHC) cell surface 
antigens such as class I and class II HLAs. On non-differentiated hESCs, levels of 
these antigens are minimal, but as cells differentiate, levels of expression increase 
[154-156]. Although the immune reaction and inflammation are separate phenomena, 
they are very much linked through the cells and proteins involved, and this 
immunoprivileged state may have an effect on ESC implantation into an inflammatory 
environment. ESCs are derived from the embryo and within embryos, wound healing 
occurs rapidly and perfectly, without scar formation. This is in part because the initial 
inflammatory signals are not released after embryonic wounding; and inflammation, 
particularly the role of macrophages, is not necessary for tissue repair [157, 158]. It 
remains to be discovered whether the lack of a role for inflammation in wound healing 
and the response of ESCs to inflammatory signalling is linked.  
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1.3.3.ii Modulation of inflammation through tissue engineering 
Inflammation may play a large part in the success or failure of a regenerative 
medicine or tissue engineering strategy, particularly in bone regeneration. The 
process of implanting a therapy will induce a foreign body reaction, causing 
inflammation, which may help or hinder eventual regeneration. In the case of non-
union fractures, large bone-defects or diseases such as RA or osteoporosis, the 
environment of implantation will likely be one of inflammation and imbalanced bone 
healing. Tissue engineering therapies are developed in vitro, and time and money is 
invested in refining growth, differentiation, scale-up and delivery of the final product. 
However, the effects of introducing this product into the damaged and diseased 
environment have not been investigated. For this reason, it is important to consider 
the effects that inflammatory signalling molecules will have on response and 
differentiation of implanted cells. There have been few strategies developed that aim 
to modulate the inflammatory response to aid bone regeneration, and to provide a 
level of control over inflammation. Providing this may help develop a more successful 
strategy for bone regeneration.  
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1.4  Aims and Objectives of the Study 
There are two distinct aims of the research presented in this study, incorporating the 
general aim of looking at bone tissue engineering strategies in the context of 
inflammation. The first is to study the possible effect that an inflammatory 
environment (in the form of proinflammatory cytokines) may have on the response 
and osteogenic differentiation of cells postulated for bone repair. The second aim is to 
investigate the possibility of incorporating a level of control of the inflammatory 
response into bone regeneration strategies. 
The specific objectives of this study are: 
 Development of an in vitro simulation of an inflammatory environment using 
proinflammatory cytokine signalling. 
 Assessment of the biochemical responses of osteogenically differentiated 
mESCs to proinflammatory cytokine signalling, and comparison to the 
responses of primary calvarial osteoblasts. 
 Examination of mechanisms involved in any differences in responses between 
the two cell types. 
 Assessment of osteogenic differentiation of mESCs compared to differentiation 
of primary calvarial osteoblasts. 
 Examination of the effect of proinflammatory cytokine signalling on the 
osteogenic differentiation of mESCs and calvarial osteoblasts. 
 Examination of the effect of anti-inflammatory mediators on the in vitro 
simulation of the inflammatory environment. 
 Development of a bone regeneration strategy that offers some control over 
inflammation.
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Chapter 2:  Materials and Methods 
This chapter focuses on the experimental methodologies used throughout the study. 
Many methods are utilised in more than one results chapter and form the basis for 
several of the experiments performed. The study focuses on the use of two cell types: 
primary calvarial osteoblasts extracted from neonatal mice, and osteogenically 
differentiated mESCs. General cell culture processes and osteogenic differentiation 
techniques for both cell types are described below. Assay and staining procedures 
used throughout the results are justified and explained. The processes of magnetic-
activated cell sorting (MACS) of the mESCs and manufacture of porous anti-
inflammatory releasing scaffolds are explained, despite only appearing in one 
chapter, as they are key techniques within the study. Further detail describing 
individual experimental design is available in the separate results chapters.  
 
2.1  Materials 
This section describes the origin of the major cell types and key chemicals, 
consumables and materials used throughout the study. 
2.1.1 Cells 
Neonatal CD-1 mice used to obtain the primary calvarial cells were obtained from the 
Biomedical Science Unit, University of Nottingham, UK. Mice were killed by qualified 
personnel using a physical method. The CD-1 mouse is an outbred albino mouse 
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strain described as suitable for multipurpose use and there is a history of use of this 
strain within the research group.  
Mouse ESCs were a gift from Dr Vasso Episkopou, Imperial College, UK. The 
mESCs were originally derived from mouse columnar epiblast epithelium (CEE) [159, 
160]. They are a well-characterised and immortalised cell line. All mESCs were used 
between passages 18-30 post receipt. 
SNL fibroblasts were also a gift from Dr Vasso Episkopou. They are a well-
established cell line, established by Dr Allan Bradley [161], predominantly utilised as 
feeder layers for the support of mESCs. Initial passage number was unknown; cells 
were not used past passage 20 post receipt. 
 
 
2.1.2 General Chemicals, Cytokines and Primers 
Most chemicals were purchased from Sigma-Aldrich (Poole, UK) unless otherwise 
stated in the methods section. Sterile preparation of cell culture medium and 
chemicals was performed by filtration through 0.22 µm filters or by autoclaving at 
121°C for 1 hour, using a Prestige Medical 20100 autoclave (Scientific Laboratory 
Supplies, Nottingham, UK).  
 
2.1.2.i Foetal bovine serum 
Foetal bovine serum (FBS) batch testing was carried out to determine optimal serum 
for growth and osteogenic differentiation of mESCs and mouse primary calvarial cells. 
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Description of the batch testing procedure and results can be found in Appendix I. 
Serum for mESC culture and differentiation was purchased from Biosera (East 
Sussex, UK), product code FB1001H, lot number S08670S1810. Serum for mouse 
primary calvarial cells was purchased from Sigma-Aldrich, product code F9665, lot 
number 070M3397. 
 
 
2.1.2.ii Recombinant Cytokines 
The proinflammatory cytokines IL-ȕ 71)-Į DQG ,)1-Ȗ ZHre used throughout the 
study, forming the basis of the inflammatory signalling. Recombinant human IL-ȕ
recombinant human TNF-ĮDQGUHFRPELQDQWPRXVH,)1-ȖZHUHSXUFKDVHGfrom R&D 
Systems, Abingdon, UK. IL-ȕ DQG 71)-Į KDYH a cross-species reactivity between 
human and mouse that IFN-ȖGRHVQRWSRVVHVV. Recombinant interleukin-1 receptor 
antagonist (IL-1ra), used as an anti-inflammatory mediator was also purchased from 
R&D Systems. 
 
 
2.1.2.iii Antibodies 
Various antibodies were used throughout the body of work, in immunocytochemical 
staining procedures and MACS. Table 2.1 lists all primary antibodies used, with 
species details and dilutions. Table 2.2 lists the secondary antibody used. The Alexa-
Fluor antibodies are fluorescent conjugated, emitting at the stated value. 
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Table 2.1: List of primary antibodies. 
Antigen Source Species Working Dilution 
iNOS 
Thermo 
Scientific 
Rabbit 1:4 
COX-2 Millipore Rabbit 1:500 
PGES Sigma Rabbit 1:100 
Osteocalcin Millipore Rabbit 1:200 
Osteopontin R&D Systems Goat 1:588 
Collagen-I Millipore Rabbit 1:200 
Cadherin-11 R&D Systems Goat 
1:67 (Immuno) 
2 µg/mL (MACS) 
 
 
Table 2.2: List of secondary antibodies. 
Antibody Source Species Dilution 
Anti-rabbit IgG 
(Alexa Fluor-488 
and Alexa Fluor -516 ) 
 
Invitrogen 
 
Donkey 
 
1:200 
 
Anti-goat IgG 
(Alexa Fluor 516 ) 
 
Invitrogen 
 
Donkey 
 
1:200 
 
Anti-goat IgG 
(Biotinylated) Vector Rabbit 10 µg/mL (MACS) 
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2.1.2.iv Primers and primer design  
Primers were required for the RT-qPCR procedures. Primer designs for the mouse 
genes Rpl32, Runx2, Col1a1 and Opn, were kindly provided by Ms Frieda Chen, 
Aubin Lab, Centre for Skeletal Biology, University of Toronto. The primer for NOS2 
(iNOS) was designed using NCBI Primer-Blast online software. Validation and 
optimisation of this primer was performed at the University of Toronto with assistance 
from Ms Frieda Chen, using positive control RNA extracted from adult mouse spleen. 
 
Table 2.3: List of PCR primers 
Gene 
Name 
Product 
Size (bp) Sequences 
Annealing 
Temperature 
Rpl32 100 
(Fwd) TTAAGCGAAACTGGCGGAAAC 
(Rvs) TTGTTGCTCCCATAACCGATG 59°C 
Runx2 146 
(Fwd) TGTTCTCTGATCGCCTCAGTG 
(Rvs) CCTGGGATCTGTAATCTGACTCT 59°C 
Col1a1 103 
(Fwd) GCTCCTCTTAGGGGCCACT 
(Rvs) CCACGTCTCACCATTGGGG 59°C 
Opn 134 
(Fwd) AGCAAGAAACTCTTCCAAGCAA 
(Rvs) GTGAGATTCGTCAGATTCATCCG 59°C 
NOS2 131 
(Fwd) AGGCTCATCCAGAGCCCGGAG 
(Rvs) AGGGTGGTGCGGCTGGACTT 56°C 
 
 
2.1.3 Consumables 
Consumable labware used for routine cell culture and experimental work included: 
tissue culture flasks (25 cm2, 75 cm2, 175 cm2 and three layer 450 cm2), (Nunc, 
Chapter 2 Materials and Methods 
  45 
(Fisher, Loughborough, UK)); tissue-culture treated 6-well, 24-well, 12-well and 96-
well plates (Falcon, Becton and Dickinson, Oxford, UK); polycarbonate 24-well 
transwell inserts (Corning, NY); 100 µm/70 µm cell strainers, cryovials, sterile 
steriological pipettes, pipette tips (1mL, 200 µL 20 µL and 10 µL), 0.22 µm filters 
(Fisher Scientific, Loughborough, UK); 7 mL bijoux, 100 mL sterile plastic containers, 
cell scrapers, 10 cm sterile petri dishes, glass Pasteur pipettes, syringes (various 
volumes) (Scientific Laboratory Supplies); 15 mL/50 mL centrifuge tubes (Grenier Bio 
One, Stonehouse, UK); and 30 mL universal tubes and 1.5 mL/0.5 mL Eppendorf 
tubes (Sarstedt, Leicester, UK).  
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2.2  Methods 
2.2.1 Cell Culture 
All cell culture was performed using aseptic technique, in a class II microbiological 
safety cabinet (Envair, Haslington, UK), fitted with high efficiency particulate air 
(HEPA) filters, unless otherwise stated. All cell cultures were kept in a Sanyo MCO-
17AIC incubator (Sanyo Electric, Biomedical, Wood Dale, IL) at 37°C in a humidified 
atmosphere containing 5% CO2. 
 
2.2.1.i SNL fibroblasts 
SNL fibroblasts are a mouse fibroblast STO (SIM (Sandoz Inbred Mice) Thioguanine-
resistant and Ouabain-resistant) immortalised cell line, transformed with neomycin 
resistance and murine LIF genes. They are a well-established feeder layer for the in 
vitro support of mESC proliferation and maintenance of pluripotency. 
61/ ILEUREODVWV ZHUH PDLQWDLQHG LQ 61/ FXOWXUH PHGLXP FRQWDLQLQJ 'XOEHFFR¶V
0RGLILHG(DJOH¶V0HGLXP'0(0,QYLWURJHQ3DLVOH\8.ZLWK (v/v) FBS, 100 
U/mL penicillin and 100 µg/mL streptomycin (Pen-Strep, Invitrogen), 2 mM L-
Glutamine and 500 µM 2-mercaptoethanol. DMEM acts as a buffered liquid support 
for cell growth and contains amino acids, salts, glucose, vitamins, iron and phenol red 
as a pH indicator, providing an environment suitable for general cell maintenance and 
proliferation. FBS is added to supply nucleotides and various factors, including 
antibodies and growth factors, to support cell proliferation. L-Glutamine is added to 
cope with rate of cell growth, as it is a conditionally essential amino acid and Pen-
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Strep acts to minimise bacterial infection. The supplement, 2-mercaptothanol is 
added to the medium as a reducing agent, to help to control the effects of harmful by-
products of cell proliferation. This supplement is predominantly added for the 
purposes of mESC culture, for which the SNL culture medium is utilised as a base. 
SNL cultures were maintained as monolayers in T75 cm3 flasks.  
Cells were allowed to reach 80-90% confluency before detachment and passaging 
using a standard trypsinisation protocol. The cell monolayer was rinsed with 
phosphate buffered saline (PBS), before treatment with trypsin/ethylene 
diaminetetraacetic acid (EDTA), at 37°C for 4 minutes (based on visual detachment). 
Trypsin is a serine protease that is used to detach cells from the tissue culture plastic. 
Trypsin predominantly cleaves peptide bonds and breaks cell-cell junctions and cell 
matrix attachments, as well as lifting cells from the flask surface. Trypsin was 
inactivated using an equal volume of serum-containing medium, the resulting cell 
suspension transferred to a universal tube and centrifuged for 5 minutes at 180 x g. 
Supernatant was aspirated and the cell pellet resuspended in the appropriate volume 
of medium and re-plated at the desired cell density. A typical passaging ratio was 1:5, 
to allow the cells to become confluent after 3-4 days. Medium was changed every 2-3 
days. 
 
2.2.1.ii Inactivated SNL fibroblast feeder layer preparation 
Feeder layers of inactivated SNL fibroblasts were required for the successful growth 
and maintenance of pluripotent mESCs. The inactivation process involves treating the 
SNL fibroblasts with a solution of mitomycin-C that crosslinks DNA, halting cells in the 
G1 phase of the cell cycle.  
Chapter 2 Materials and Methods 
  48 
T25 cm2 flasks were prepared for feeder layers by coating in a solution of 0.1% (w/v) 
bovine gelatin in PBS for 1-2 hours at 37°C. Gelatin adsorbs to the flask and provides 
a base layer for the attachment of cell membrane integrins. Confluent cultures of 
SNLs were treated with a 10 mL solution of mitomycin-C (Merck Millipore, Frankfurt, 
Germany), and incubated for 2 hours at 37°C. Mitomycin-C solution was removed and 
the cell monolayer detached from the flask using trypsin/EDTA, as described above. 
The cell suspension was centrifuged at 180 x g for 5 minutes and the resulting cell 
pellet resuspended in an appropriate volume of medium and counted using an 
improved Neubauer haemocytometer, viewed under an inverted light microscope. 
Excess gelatin was aspirated from T25 cm2 flasks and replaced with 5 mL SNL 
culture medium. The correct volume of cell suspension was then added to each flask 
to produce a final cell density of 1.6 x 104 cells/cm2. Flasks were incubated at 37°C 
overnight, to allow adhesion of the fibroblasts. Feeder layers were used for mESC 
culture within 1 week. 
 
2.2.1.iii Mouse embryonic stem cell culture 
Mouse ESCs were maintained on inactivated SNL feeder layers in mESC medium 
(SNL culture medium containing 500 U/mL LIF (Millipore, Watford, UK)). LIF was 
added to mESC culture medium to help maintain pluripotency of the cells during 
continuous culture. Cells were cultured until approximately 80% confluent. Confluency 
was judged by eye when individual cell colonies began to touch. 
Cells were passaged using trypsin/EDTA treatment at room temperature with gentle 
agitation, until gaps appeared in the cell monolayer, indicating detachment from 
feeder layer. Cell suspension was transferred to a 25 mL universal tube and an equal 
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volume serum-containing medium added to inactivate the trypsin/EDTA. Suspension 
was centrifuged at 180 x g for 5 minutes, the cell pellet resuspended in the 
appropriate volume of culture medium and cells seeded at the desired cell density, on 
an SNL feeder layer. Typical passage ratio was 1:5 to achieve confluency in 2 days, 
but was adjusted as required. Cells were monitored closely for visual changes in 
morphology, indicating the beginnings of differentiation. Medium changes occurred 
daily. 
 
2.2.1.iv Isolation and culture of mouse primary calvarial cells 
Mouse primary calvarial cells are well described in literature, both in terms of 
response to proinflammatory cytokines and osteogenic differentiation [127, 162, 163]. 
Thus, they were chosen as a comparison to the less well-described mESCs.   
Primary calvarial cells were isolated in-house from 1-3 day old CD-1 mice using a 
collagenase digestion technique. Calvaria were extracted from the skulls of the 
neonatal mice (see figure 2.1) and washed in PBS containing 100 U/mL penicillin, 25 
µg/mL amphotericin B and 100 µg/mL streptomycin. Extraction was performed in a 
laminar flow hood (Envair, Haslingden, UK) using sterilised dissection equipment, 
viewed under a Nikon SMZ546 stereo dissection microscope illuminated with a KL 
1500 portable light source. The antibiotics and antifungal were used to ensure that no 
infection was carried from the mice into cell culture.  
Dissected calvariae were transferred in PBS containing antibiotic and antifungal, to a 
class II microbiological safety cabinet. PBS solution was removed and calvariae were 
cut up using sterile scissors to increase surface area. The calvaria were digested in a 
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Figure 2.1: Extraction of the mouse calvariae. (A) One day old CD1 mouse (B) 
Initial skin incision (C) Skin pulled back to reveal skull and brain removed (D) View of 
neonatal skull (2 halves of calvaria with brain removed (E) Fully extracted neonatal 
mouse calvariae. 
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solution containing 1.4 mg/mL collagenase IA and 0.5 mg/mL trypsin II S for 12 
minutes under constant agitation (Stuart Roller Mixer SRT6) at 37°C. The first 
population of cells released from the calvariae was aspirated and discarded. The 
calvariae were then suspended in a fresh aliquot of digestion solution and incubated 
for a further 12 minutes. This population of cells was also discarded. Fresh digestion 
solution was placed on the calvariae and digestion occurred for a further 12 minutes. 
This cell population was collected, an equal volume of FBS added and placed on ice. 
Two further cell populations were collected this way. The three populations on ice 
were pooled together. This serial digestion procedure was optimised to obtain a cell 
population rich in potential osteoblasts.  
The resulting cell suspension in FBS was filtered through a 70 µm cell strainer, to 
remove tissue debris, and centrifuged for 5 minutes at 300 x g. The cell pellet was 
resuspended in primary calvarial cell medium containing Minimum Essential Medium 
$OSKD Į0(0 /RQ]D ZLWK  (v/v) FBS, 100 U/mL penicillin, 100 µg/mL 
streptomycin and 2 mM L-*OXWDPLQHĮ0(0LVDQHQULFKHGPLQLPDOHVVHQWLDOPHGLXP
often used in the culture of osteoblasts. Cells were seeded in T75 cm2 flasks, 
dependent on original number of calvariae, and incubated at 37°C for 24 hours. 
Removal of non-adherent haematopoietic cells was performed after 24 hours by 
washing with PBS twice before a medium change. Cells were allowed to become 80-
90% confluent before a standard cryopreservation step (see Appendix II) at a density 
of 800,000 ± 1,000,000 cells/mL. 
Cell were reanimated from cryopreservation, maintained in cell culture flasks in 
primary calvarial cell medium, and used experimentally up to passage 3.  
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2.2.1.v Induction of osteogenic differentiation 
2.2.1.v.a  Embryonic stem cell osteogenic differentiation 
To initiate the process of osteogenesis, the mESCs were induced to form embryoid 
bodies (EBs) by a mass suspension method. The mESCs were detached from the 
feeder layer by treatment with trypsin, as with passaging. After centrifugation, the cell 
pellet was resuspended in SNL culture medium, without LIF, and transferred to a non-
adherent 10 cm petri dish at a density of 200,000 cells/mL, in 10 mL SNL culture 
medium. The cells were incubated under static conditions at 37°C for 3 days. Under 
these conditions, the mESC cells spontaneously aggregated to form EBs containing 
cells of the three germ layers.  
After 3 days culture, the EBs were dissociated using trypsin treatment, to a single cell 
suspension, allowing culture as a cell monolayer. EBs were collected in a 15 mL 
falcon tubes, and allowed to settle under gravity. The supernatant was aspirated and 
EBs washed twice in PBS and allowed to settle again. EBs were resuspended in 10 
mL trypsin and incubated under constant agitation, on a Stuart Roller Mixer SRT6, for 
10 minutes at 37°C. This process breaks up the EBs gently, creating a single cell 
suspension. This suspension was centrifuged for 5 minutes at 180 x g, the cell pellet 
UHVXVSHQGHG LQ 61/ FXOWXUH PHGLXP DQG SDVVHG WKURXJK D  ȝP FHOO VWUDLQHU WR
remove any remaining large aggregates and extraneous ECM. Viable cells were 
counted using a Neubauer haemocytometer and a trypan blue exclusion technique 
(see Appendix III). Viable cells were added at the cell density of 10,600 cells/cm2, to 
tissue culture well-plates that had been pre-coated with 0.1% (w/v) gelatin. Plates 
were then incubated at 37°C overnight.  
After 24 hours, dissociated EB cultures were changed to osteogenic medium by 
supplementing the SNL culture medium with 50 µg/mL ascorbate-2-phosphate, 50 
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P0 ȕ-GlyceURSKRVSKDWH %*3 DQG LQ VRPH FDVHV  ȝ0 GH[DPHWKDVRQH &HOOV
were incubated for the desired time-period with medium changes every 1-2 days. 
Throughout this study, from the moment the medium is changed to osteogenic, these 
cells are known as osteo-mESCs. 
The supplements used to initiate osteogenic differentiation have been well described 
[60, 164]. Ascorbate 2-phosphate provides the ascorbic acid source that is vital for 
collagen production [165]. BGP provides an organic phosphate source allowing 
mineralisation of the ECM [162]. Dexamethasone is a glucocorticoid steroid. It is often 
used for in vitro osteogenic differentiation protocols, but the mechanism of action is 
not well understood. As dexamethasone is also an anti-inflammatory, it was used 
carefully throughout these studies, so as not to inhibit inflammatory signalling. 
    
 
2.2.1.v.b  Primary calvarial cell osteoinduction 
Primary calvarial cells were reanimated from cryopreservation and cultured to 
passage 2, in standard tissue culture flasks. Trypsin/EDTA was used to detach the 
cells from the flasks. Cells were counted using trypan blue exclusion and a Neubauer 
haemocytometer. Primary calvarial cells were seeded in tissue-culture treated plates 
at a density of 10,600 cells/cm2 and allowed to adhere overnight at 37°C. Culture was 
changed to osteogenic by supplementation of the primary calvarial medium with 50 
µg/mL ascorbate-2-SKRVSKDWH  P0 %*3 DQG LQ VRPH FDVHV  ȝ0
dexamethasone. Cells were incubated for the desired time-period with medium 
changes every 1-2 days. 
 
Chapter 2 Materials and Methods 
  54 
2.2.1.vi Proinflammatory cytokine stimulation 
Throughout this study, the proinflammatory cytokines IL-ȕ71)-ĮDQG ,)1-ȖZHUH
added to the cell culture medium, in varying concentrations and combinations, to 
simulate an inflammatory environment. Addition of the cytokines occurred at various 
times of osteogenic differentiation of both the osteo-mESCs and primary calvarial 
cells.  
The cytokines arrived in lyophilised form and were reconstituted in PBS containing 
0.1% (w/v) bovine serum albumin (BSA) and stored at -20°C in aliquots of various 
concentrations, before dilution when used experimentally. 
 
2.2.1.vii Anti-inflammatory mediator addition to culture medium 
Several anti-inflammatory mediators were added to the culture medium and used 
during experiments to inhibit proinflammatory cytokine stimulation. Dexamethasone, 
prednisolone, piroxicam and ibuprofen had low solubility in water, so were first 
dissolved in dimethyl sulfoxide (DMSO). A mass of drug was weighed that would 
result in a concentration of 1 mM. Drug was fully dissolved in 1 mL DMSO, before 
medium added to make a total volume of 10 mL. This solution was then diluted further 
in medium to achieve the desired concentration. Control cultures that contained no 
drug in the media were adjusted to contain the same concentration of DMSO. 
Diclofenac sodium has solubility in water, so was dissolved in medium without DMSO 
at 37°C, to make a stock concentration of 1 mM, which could be further diluted. The 
recombinant protein IL-1ra was purchased lyophilised and reconstituted in PBS 
containing 0.1% (w/v) BSA, DV SHU WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV EHIRUH EHLQJ
further diluted in medium.    
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2.2.2 Viability, Proliferation and Cytotoxicity Assays 
Several methods of detecting changing in cell viability, and cytotoxicity of agents 
added to the cell culture medium, were used throughout this investigation. 
 
2.2.2.i MTS Assay 
One method used to detect changes in cell viability, as well as the cytotoxic effects of 
adding proinflammatory agents to the culture medium, was the CellTiter AQueous One 
Solution Proliferation® Assay (Promega, Southampton, UK), also known as the MTS 
assay. This assay detects viable cells in culture through a tetrazolium compound [3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt]  (MTS), which with the help of an electron coupling reagent, 
phenazine ethosulphate (PES), is bioreduced by cells into a soluble coloured 
formazan product. This product can be detected by reading optical absorbance at 490 
nm. Conversion is completed through NADH or NADPH produced by dehydrogenase 
enzymes in metabolically active cells. Thus, the optical absorbance is directly 
proportional to the number of metabolically active, viable cells. 
To assess viability, osteo-mESCs and primary calvarial cells were grown in 96-well 
plates with various agents. At specific timepoints, 20 µL of MTS reagent was added to 
each cell-containing well, in 100 µL cell culture medium. Cells were incubated at 37°C 
for 1 hour before the absorbance was read at 490 nm, with a wavelength correction of 
690 nm, using a Tecan Infinite® 200 PRO plate reader. The wavelength correction 
accounts for variations in the optical properties across the assay plate, cell debris and 
fingerprints. Proliferation studies were performed using separate plates for each 
timepoint. 
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2.2.2.ii Lactate Dehydrogenase (LDH) Assay 
This assay was used to measure levels of cytotoxicity, possibly caused by agents 
added to the cell culture medium. The assay measures levels of LDH in cell 
supernatants, an enzyme that is released upon cell lysis. The assay works on the 
principle that LDH present within the sample causes oxidation of lactate to pyruvate, 
which in turn, catalyses the reduction of NAD+ to NADH. The second step of the 
reaction uses the NADH to catalyse the conversion of a tetrazolium salt to a coloured 
formazan product. Optical absorbance of the formazan at 492 nm is then directly 
proportional to the level of LDH within the sample. 
To assess cytotoxicity of the proinflammatory cytokines or anti-inflammatory 
mediators using LDH production, the CytoTox 96® Non-Radioactive Cytotoxicity 
assay (Promega) was used. Cell culture medium supernatants were taken at certain 
timepoints of culture. Lysis of an identical cell monolayer, using the lysis solution 
provided in the kit, was performed at this timepoint, to determine maximum LDH 
UHOHDVH RI WKH FHOOV /'+ OHYHOV ZHUH GHWHUPLQHG E\ DGGLQJ ȝ/ RI WKH VXEVWUDWH
VROXWLRQ WR  ȝ/ VDPSOH &HOO FXOWXUH PHGLXP FRQWUROV DQG /'+ SRVLWLYH FRQWUROV
were also performed. The reaction was incubated for 30 minutes at room 
temperature, before a stop solution was added. The absorbance values were then 
determined by reading the plate at 492 nm on the plate reader (Tecan) with a 
wavelength correction of 690 nm.  
Cytotoxicity values were determined by: 
Cytotoxicity (%) = Experimental LDH release x 100 
Maximum LDH release 
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2.2.2.iii /LYH'HDG)OXRUHVFHQFH$VVD\ 
7KH /LYH'HDG IOXRUHVFHQW VWDLQ ZDV XVHG WR YLVXDOLVH FKDQJHV LQ FHOO YLDELOLW\ LQ
response to cytotoxic agents. The Live/Dead® Viability/Cytotoxicity Assay kit contains 
two fluorescent probes: calcein AM; which is converted via intracellular esterase 
activity to the fluorescent calcein to indicate viable cells, that fluoresce green; and 
ethidium homodimer-1 (EthD-1), which enters non-viable cells with damaged 
membranes and binds to nucleic acids, fluorescing red. The assay can be used for 
imaging cells using fluorescent microscopy, as a quantitative assay using a 
fluorescent microplate reader or in flow cytometry. 
To assess cell viability, cell culture medium was aspirated or collected for other 
DVVD\VDQGFHOOVZHUH LQFXEDWHGZLWK/LYH'HDGVROXWLRQFRQWDLQLQJȝ0FDOFHLQ
$0DQGȝ0(WK'-1 in PBS, for 30 minutes at room temperature. Cells were washed 
in PBS before imaging using an inverted fluorescent microscope, with 
excitation/emission wavelength of 495/515 nm for calcein AM and 495/635nm for 
EthD-1. 
 
2.2.3 Nitric Oxide Production 
NO is produced in response to proinflammatory cytokines, through the inducible nitric 
oxide synthase (iNOS) pathway and can give an estimate of the inflammatory 
response. Although both nitrite (NO2-) and nitrate (NO3-) are both stable end-products 
of NO, measurement of nitrite has been shown to be a good indicator of NO 
production in vitro, due to a strong correlation between the levels of nitrite and nitrate 
produced [166].  
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To determine nitrite release, the Griess Reagent System (Promega) was used. In the 
Griess reaction the acidified NO2- ion reacts with sulphanilamide to produce a 
diazonium ion, which then couples to N-(1-napthyl)ethylenediamine (NED) to form a 
chromophoric azo-derivative that absorbs light at 540-570 nm.  
Cell supernatant samples were centrifuged to remove particulates and 50 µL was 
transferred to a 96-well plate. To perform the Griess assay, an equal volume of 1%  
(v/v) sulphanilamide in 5% (v/v) phosphoric acid was added to the samples and the 
plate incubated for 5 minutes at room temperature. NED (50 µL of 0.1% (v/v) in water) 
was added and the plate incubated at room temperature for 5 minutes. Absorbance at 
540 nm was recorded immediately, using a plate reader, with a wavelength correction 
at 690 nm. Nitrite concentrations were determined using standard curves, prepared 
from serial dilutions of sodium nitrite, prepared each time the assay was performed. 
 
2.2.4 Prostaglandin E2 Production 
Levels of prostaglandin E2 (PGE2) in the cell culture medium can be used as an 
indicator of the cellular response to proinflammatory cytokines. PGE2 production was 
DVVHVVHG XVLQJ WKH 3DUDPHWHU 3*(2 Assay (R&D Systems), an enzyme 
immunoassay (EIA) based on competitive binding. The PGE2 in the sample competes 
with horseradish peroxidase (HRP)-labelled PGE2, for binding sites on a PGE2 
monoclonal antibody. A substrate solution determines the level of HRP-labelled PGE2 
bound to the antibody, causing a colour development. This colour is inversely 
proportional to the concentration of PGE2 in the sample. 
Cell supernatant samples were centrifuged to remove debris and a 3-fold dilution 
performed using assay buffer. Sample (150 µL) was added to a 96-well microplate 
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coated with a goat anti-mouse polyclonal antibody and a solution of PGE2 monoclonal 
antibody was added. The plate was incubated at room temperature for one hour on 
an orbital microplate shaker at 500 rpm, to allow PGE2 in the sample to bind to the 
antibody. HRP-conjugated PGE2 was then added and the plate incubated at room 
temperature on the shaker for 2 hours, allowing the HRP-conjugated PGE2 to bind to 
any remaining antibody. All antibody-bound material attaches to the coated 
microplate. The plate was washed three times with wash buffer, substrate solution 
added and a colour change developed. After 30 minutes static incubation at room 
temperature, a stop solution was added, causing another colour change, which was 
measured for optical absorbance at 450 nm, with wavelength correction at 570 nm. 
PGE2 concentration within the sample was determined using standard curves, 
prepared each time the assay was performed. 
 
2.2.5 DNA Quantification 
DNA quantification was used to correct determined levels of nitrite and PGE2 for cell 
number. Levels of DNA within a sample were determined via the Hoechst assay. 
Hoechst 33258 is a fluorescent bisbenzimide dye that binds to the A-T coupling in 
DNA. The more DNA within a sample, the more intense the fluorescence.  
Hoechst 33258 was diluted to 1 mg/mL in saline sodium citrate buffer (SSC), 
aliquoted and stored at -20°C. DNA standards were prepared by dissolving calf 
thymus DNA in SSC to a 1 mg/mL stock that was aliquoted and stored at -20°C.  
Samples were prepared by lysing a cell monolayer in 0.02% (w/v) sodium dodecyl 
sulphate solution (SDS) to release DNA. Samples were transferred to black 96-well 
plates. Standards were prepared from the calf thymus DNA, with a maximum of 20 
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ȝJP/ $ ZRUNLQJ VROXWLRQ RI +RHFKVW  ZDV SUHSDUHG DW  ȝJP/ LQ GLVWLOOHG
water. This was added to the sample and standards and thoroughly mixed. 
Fluorescence was recorded at excitation wavelength 360 nm and emission 
wavelength 460 nm. DNA concentration of the samples was determined using the 
standard curve prepared from calf thymus DNA. 
 
2.2.6 Cell Fixation 
Cell fixation at the end of an experiment ensures preservation of cell morphology and 
ECM architecture. Fixatives need to be suited to the end staining procedure. For the 
purposes of the histological stains used in this study, 10% (w/v) neutral-buffered 
formalin was used. Formalin is a good fixative for histology purposes as it forms 
cross-links between protein molecules and preserves a robust tissue structure. For 
formalin fixation, the cell monolayers were washed in PBS before incubation in  
formalin for 10 minutes. The formalin solution was then washed off three times with 
PBS and the fixed cell monolayers stored in PBS at 4°C, until staining.  
For immunocytochemical procedures, 4% (w/v) paraformaldehyde (PFA) fixation was 
employed. The PFA recipe can be found in Appendix IV. PFA is polymerised 
formaldehyde and therefore is a larger molecule that does not form as many cross-
links as formalin. This allows better tissue penetration of antibodies and the ability to 
perform steps such as permeabilisation and antigen retrieval that can improve 
immunocytochemical staining. The paraformaldehyde fixation protocol is similar to 
fixation with 10% (w/v) formalin although fixation time is increased to 15 minutes. 
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2.2.7 Immunocytochemistry 
Immunocytochemistry is a technique in which antibodies are used to target specific 
proteins or peptides. These antibodies can be labelled to allow the protein to be 
visualised and imaged. In this study, an indirect method of immunocytochemistry was 
performed, using primary and secondary antibodies. 
Fixed cell monolayers were washed in PBS and permeabilised in 0.1% (v/v) Triton-
X100 in PBS for 15 minutes. Permeabilisation allows the antibody to penetrate the 
cell membrane and can create a more accurate final stain. Monolayers were washed 
3 times in PBS for 5 minutes to remove Triton-X100 traces and a blocking step 
performed. The blocking solution is made up of PBS containing 1% (w/v) BSA and 
3% (v/v) serum from the animal in which the secondary antibody was raised. The 
blocking step prevents non-specific binding of the secondary antibody and a sharper 
final image. Blocking solution was blotted and the primary antibody solution applied.  
Primary antibodies used throughout this study can be found in Table 2.1. Antibodies 
were initially made-up to PDQXIDFWXUHU¶V LQVWUXFWLRQV WKHQ GLOXWHG LQ 3%6 FRQWDLQLQJ
1% (w/v) BSA, at concentrations stated in Table 2.1. Cell monolayers were incubated 
with primary antibody solution at 4°C overnight. Primary antibody solution was 
washed off 3 times in PBS containing 1% (w/v) BSA, each wash for 5 minutes. 
Secondary antibody solution was then applied and incubated at room temperature for 
1 hour. All secondary antibodies (see Table 2.1) were conjugated to a fluorescent tag 
and diluted in PBS containing 1% (w/v) BSA. After incubation, cell monolayers were 
washed 3 times in PBS and 1 µg/mL Hoechst 33258 applied for 30 minutes, to 
provide a nuclear stain, before final washing 3 times in PBS. Staining could then be 
imaged (see Section 2.2.11). 
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2.2.8 Real-time quantitative polymerase chain reaction (RT-
qPCR) 
RT-qPCR is based on the principle of the polymerase chain reaction (PCR) and 
allows a target DNA molecule to be amplified and quantified. To determine levels of a 
target gene within cell samples, ribonucleic acid (RNA) samples must first be 
extracted from cells and used to produce DNA via reverse transcription, creating 
complementary DNA (cDNA). PCR can then be performed using DNA polymerase, 
with specific primers, to amplify the target DNA. To achieve quantification of the level 
of amplification, a DNA binding fluorescent dye (in this case, SYBR green) can be 
used. This dye binds to the double stranded DNA whilst it is being created and with 
each amplification fluorescent intensity increases. This intensity can be recorded 
using a real-time PCR instrument. Using fluorescent intensity data, quantification can 
be performed. In this case, relative quantification is employed, using reference genes 
to determine fold-differences in expression of the target gene.  
 
2.2.8.i RNA Isolation and purification 
In this study, total RNA was harvested from the cells and extracted using an RNeasy 
NLW4LDJHQ:HVW6XVVH[8.DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV6DPSOHV
were first lysed, and then an RNeasy mini spin column was used to extract the RNA 
using a variety of buffers and centrifugation steps. Extracted RNA was stored in 30 µL 
RNase free water at 80°C. Steps were performed on ice and utilising a temperature 
controlled centrifuge set at 4°C, to prevent RNA degradation. The concentration of 
RNA within the sample was measured using a NanoDrop spectrophotometer (Thermo 
Scientific NanoDrop 2000) at 260 nm. 
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2.2.8.ii Reverse Transcription 
Reverse transcription of RNA into single stranded cDNA was performed using the 
Superscript II System (Invitrogen) and random hexamer primers, according to the 
PDQXIDFWXUHU¶V LQVWUXFWLRQV 7KH UDQGRP KH[DPHU SULPHUV DQQHDO UDQGRPO\ WR WKH
RNA and the reverse transcriptase enzyme then synthesises cDNA from the primer 
sites using deoxynucleotide triphosphates (dNTPs). This process occurred using a 
PCR thermal cycler (Px2 Thermal Cycler, Thermo Scientific, Surrey, UK), that 
denatured the RNA at 85°C, allowing primer adhesion. The reaction is then heated at 
55°C to allow the reverse transcriptase to form the cDNA. Resulting cDNA transcripts 
were stored in RNase/DNase free water at -20°C. 
 
2.2.8.iii RT-qPCR  
RT-qPCR was performed on a MyiQ RT-PCR detection system (Bio-Rad, Ontario, 
Canada) using iQ SYBR Green supermix (Bio-Rad). To perform the reaction 6 µL 
cDNA sample, 5 µL of each of the forward and reverse primers (final concentration 
300 nM) and 10 µL supermix were added to the wells of a qPCR plate. Preparation of 
samples was performed on ice. The thermal cycling protocol was then run on the RT-
PCR detection system, according to manuIDFWXUHU¶V LQVWUXFWLRQV, with the annealing 
temperatures described in table 2.3. Forty amplification cycles were performed.     
Data analysis was performed using online software based on a four parameter simple 
exponent model [167], that calculate efficiency (E) and threshold cycle (CT). 
Expression levels were calculated using an efficiency corrected comparative 
threshold cycle (CT) method (Eǻǻ&7). All values were normalised to the Rpl32 
ribosomal protein gene, to get fold differences in gene expression.  
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2.2.9 Assessment of Mineralisation 
Mineralisation of cell-secreted matrix was assessed via staining of calcium deposits 
by alizarin red S. The alizarin red dye chelates with calcium to give a bright 
red/orange colour. Fixed cell monolayers were washed twice in distilled water before 
being treated with 2% (w/v) alizarin red S solution in dH2O for 4 minutes. Alizarin red 
solution was removed and cultures were washed repeatedly in dH2O until no further 
colour leached out. Staining could then be imaged (see Section 2.2.11). 
 
2.2.10 Assessment of Alkaline Phosphatase Activity 
ALP is a membrane bound enzyme which catalyses the hydrolysis of phosphate 
monoesters and is found in abundance in bone, liver, kidney and placental tissue 
[168]. Levels of non-specific ALP can be assessed by the p-nitrophenyl phosphate 
(pNPP) assay. ALP acts as a catalyst for pNPP hydrolysis to p-nitrophenol (pNP). 
pNP is chromogenic and has a yellow appearance that can be read at an optical 
absorbance of 405 nm.   
Cell monolayers were washed in 0.2 M tris buffer, and then lysed in a solution of 0.1% 
(v/v) Triton- X100 in 0.2 M tris buffer, and the cell layer collected using a cell scraper. 
Samples were centrifuged at 10,000 x g for 10 minutes and transferred to a 96-well 
plate. A pNPP solution of 1 mg/mL in 0.2 M tris buffer was added. Samples were 
incubated at room temperature for 20 minutes whilst the reaction occurred. 
Absorbance was then read at 405 nm. Assaying of ALP standards was also 
performed to derive a standard curve that could be used to extrapolate ALP 
concentration within the samples. 
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2.2.11 Microscopy and Imaging 
2.2.11.i Microscopy 
)OXRUHVFHQWO\ LPPXQRVWDLQHG FHOO PRQROD\HUV DQG /LYH'HDG VWDLQV ZHUH YLHZHG
using an inverted-microscope (Leica DM-IRB) and images captured using a 
Hamamatsu digital camera and Volocity imaging software (Improvision, Coventry, 
UK).  
Alizarin red stained monolayers were viewed using a Nikon Eclipse 90i stereo 
dissection microscope and imaged as complete wells. Higher magnification images 
were taken using a Nikon Eclipse TS100 inverted microscope with Hoffman contrast 
and attached imaging screen and software (Nikon Digital Sight DS-L1). 
  
2.2.11.ii Image Processing and Analysis 
Image processing was performed to remove non-specific background of 
immunocytochemistry images, using Volocity imaging software. Secondary antibody 
only control images were used as a background subtraction.  
Image analysis of the Alizarin Red stained monolayers, to determine area stained, 
was performed using ImageJ version 1.43U (NIH, USA). Images were thresholded to 
isolate the stained nodules, the image converted to 8-bit, and the percentage area 
VWDLQHG TXDQWLILHG &HOO FRXQWV IRU /LYH'HDG LPDJHV ZHUH DOVR SHUIRUPHG XVLQJ
ImageJ. Stained cells were identified, contrast was adjusted so the brightest part of 
each cell was visible, the image then converted to binary and a watershed applied. 
The number of particles could then be counted as a representative count of each cell.  
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2.2.12 Magnetic-Activated Cell Sorting 
MACS is a method of isolating a cell population of interest or depleting a cell 
population of an unwanted cell type. Cells can be sorted via a particular antigen. An 
antibody is bound to this antigen and attached to a magnetic particle. After binding, 
the cells are passed through a column within a magnetic field. Cells labelled with the 
magnetic particle-conjugated antibody are held within the column and unlabelled cells 
pass through. The column can then be removed from the magnetic field and labelled 
cells eluted. 
In this study, osteogenically differentiated mESCs were sorted for a cadherin-11 (cad-
11) positive population. Osteo-mESCs were cultured in gelatin-coated flasks in 
osteogenic medium for 16 days. Cell monolayers were washed in PBS and cells 
incubated in trypsin for 10 minutes. Due to the high levels of ECM produced by the 
osteo-mESCs, trypsin incubation was not sufficient to remove all cells from the flask, 
so a cell scraper was utilised to ensure all cells had been detached. Trypsin was 
deactivated using serum-containing medium and the cell suspension transferred to a 
falcon tube. Cells were centrifuged at 180 x g for 5 minutes, resuspended in MACS 
buffer (PBS supplemented with 2 mM EDTA and 0.5% (w/v) BSA, degassed under 
vacuum) and passed through a 70 µm cell strainer to remove ECM. Cells were 
counted using a haemocytometer and centrifuged again at 180 x g for 5 minutes 
before being resuspended in primary antibody solution.  
Primary antibody solution was goat anti-human cad-11 (see Table 2.1) at a 
concentration of 2 µg/mL in MACS buffer; 40 µL primary antibody was used per 1 x 
106 cells. Cells were incubated in primary antibody solution for 5 minutes at room 
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temperature, diluted using 10x the volume of MACS buffer, before centrifugation for 5 
minutes at 180 x g. Supernatant was removed carefully and secondary antibody 
added (biotinylated anti-goat, see Table 2.1), at 10 µg/mL in MACS buffer. Per 1 x 107 
cells, 80 µL MACS buffer and 20 µL secondary antibody solution was added. Cells 
were incubated for 10 minutes at 4°C. Cells were then washed by adding 10x volume 
of MACS buffer and centrifuged for 5 minutes at 180  x g. Supernatant was removed 
and 80 µL MACS buffer and 20 µL MACS anti-biotin magnetic microbeads (Miltenyi 
Biotec, Surrey, UK), were added per 1 x 107 cells and incubated at 4°C for 15 
minutes. MACS buffer (10x labelling volume) was added to wash cells and 
suspension centrifuged at 180 x g for 5 minutes, for the final time. Cells were then 
resuspended in 500 µL MACS buffer, up to a volume of 1 x 108 cells.  
6HSDUDWLRQ RI WKH FHOOV WRRN SODFH RQ D 0LQL0$&6 PDJQHWLF VHSDUDWLRQ XQLW
(Miltenyi Biotech). This comprises a metal stand and a powerful magnet. The magnet 
holds a separation column (MS column, Miltenyi Biotech) to the stand, creating a 
magnetic field and magnetizing the column. The column was first washed by passing 
500 µL MACS buffer through. Effluent was discarded and the magnetically-labelled 
cell suspension was passed through the column. Cad-11 positive cells would now be 
labelled with magnetic microbeads and remain in the column. The negative cell 
fraction passed through the column and was collected. The magnet was removed, 
demagnetizing the column and 1 mL MACS buffer added and the cell suspension 
forced through by plunger, creating a cad-11 positive cell fraction. The cad-11 positive 
and negative fractions were then cultured in gelatin-coated 6-well plates in osteogenic 
medium. 
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2.2.13 Production of PLGA/PEG Scaffolds 
PLGA/PEG scaffolds were used in this study as a candidate for bone repair, they 
have previously been described by the Tissue Engineering group, University of 
Nottingham, UK (patent number: PCT/GB08/00329) [169-172]. The scaffolds are 
produced from sintered poly(lactic-co-glycolic) acid (PLGA) blended with 
poly(ethylene glycol) (PEG) microparticles (PLGA/PEG particles). Blending the PLGA 
with the correct ratio of PEG, a plasticiser, reduces the glass transition temperature 
(Tg) of PLGA to 37°C. The PLGA/PEG microparticles form a free-flowing powder at 
room temperature. When mixed with a carrier solution such as water or PBS, the 
microparticles form a particulate paste. This paste is of a consistency that can be 
injected or moulded into any shape or size. At body temperature (37°C), the paste 
solidifies as it sinters and forms a solid porous scaffold. During the sintering process, 
the microparticles soften and reach Tg, become cohesive and adhere to each other. 
At this stage, the hydrophilic PEG begins to leach out of the particles, reducing the 
PEG concentration, leading to an increase in Tg. This causes the particles to re-
solidify forming porous strong scaffolds. A schematic of this process can be seen in 
figure 2.2. To manufacture scaffolds containing anti-inflammatory drugs, the drug is 
solubilised within the carrier solution.  
 
2.2.13.i  Production of temperature-sensitive PLGA/PEG particles 
PLGA (53 kDA, 85:15 DLG 4CA, Lakeshore Biomaterials, USA) and PEG 400 were 
mixed at a ratio of 93.5:6.5, PLGA:PEG (w/v), on a poly(tetrafluoroethylene) (PTFE) 
sheet and melt blended at 80-90°C on a hotplate. The melted PLGA and PEG were 
thoroughly blended by hand using a PTFE spatula and once mixed were taken off the 
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Figure 2.2: Schematic showing formation of PLGA/PEG scaffolds. The 
PLGA/PEG microparticles are mixed with a carrier solution (possibly containing anti-
inflammatory drug) . This paste is then packed into moulds and sintered at 37ιC, 
where the paste solidifies to become a porous scaffold. 
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heat and allowed to cool. Polymer blend sheets were cut into small pieces and  
ground into particles using a bench-top mill (Krups Mill F203), with liquid nitrogen 
cooling. Once ground, the particles were sieved to obtain a 100-200 µm size fraction.  
 
2.2.13.ii Production of diclofenac sodium-loaded PLGA/PEG scaffolds 
Scaffolds were prepared in PTFE moulds to produce cylindrical scaffolds of 12 mm 
length and 6 mm diameter. The PLGA/PEG particles were mixed manually at a ratio 
of 1:0.6, particles to PBS carrier solution. Diclofenac sodium loaded scaffolds were 
produced by mixing the particles in this ratio with PBS containing diclofenac sodium 
at various concentrations (see section 5.2.4) The microparticle/PBS paste was 
packed into the moulds. Moulds were placed at 37°C for 3 hours and allowed to 
sinter, forming a solid scaffold.  
 
2.2.13.iii Measurement of drug release from PLGA/PEG scaffolds 
Diclofenac sodium release from the scaffolds was measured by ultraviolet-visible 
(UV-Vis) spectrophotometry. After scaffolds had dry sintered at 37°C for 3 hours, they 
were removed from moulds and placed into bijoux. Release medium (1.5 mL) was 
added carefully to the bijoux and the scaffolds incubated at 37°C, for drug release to 
begin. In this study, the release medium was either phenol red-IUHH Į0(0
(Invitrogen) or PBS. After certain time-periods, all release medium was removed from 
the scaffold for drug concentration measurements and fresh release medium added. 
Drug concentration measurements were taken using a microvolume UV-Vis 
spectrophotometer (Thermo Scientific NanoDrop 2000) at 276 nm. This wavelength 
was chosen after an absorbance scan was run, showing this as the peak. The 
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NanoDrop spectrophotometer was chosen rather than a conventional UV-Vis plate 
reader, as when reading from a 96-well plate at 276 nm, background absorbance 
caused by the polystyrene was very high. The NanoDrop does not require a plate to 
be used and allows smaller volumes of sample to be read (2 µL), so more readings 
could be taken. Standard diclofenac concentrations were determined, to enable a 
calibration curve to be drawn and to decipher minimum and maximum concentrations 
that could be measured. Concentrations of drug within the sampled release medium 
were determined using the calibration curve. 
 
2.2.14 Statistical Analysis 
Statistical significance between groups was analysed using PASW Statistics 18.0.3 
software. Data sets were tested for normality and comparison tests chosen 
appropriately. Simple paired analysis was performed using uQSDLUHG6WXGHQW¶V7-Test, 
ZLWK YDULDQFHV DQDO\VHG E\ /HYHQH¶V WHVW Multiple group comparisons were 
performed using one-way ANOVA, post hoc tests performed were Tukey, when 
variances were assumed equal, and Games-Howell in cases where variances were 
not assumed equal and sample sizes differed. 
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Chapter 3:  Results 
Effect of Proinflammatory Cytokines 
on Osteogenic Cell Response 
 
3.1  Introduction 
3.1.1 Overview 
The investigation of cell differentiation in vitro, with possible applications to cell 
therapy, is typically performed in favourable environments, where nutrients and 
temperatures are controlled. However, the potential therapeutic target environment is 
characteristically one of tissue damage and inflammation. In order to mimic 
inflammation in vitro, proinflammatory cytokines such as IL-ȕ71)-ĮDQG,)1-ȖDUH
often added to cell culture medium. When considering bone tissue engineering and 
osteogenic differentiation, it is important to consider the response of osteoblasts and 
osteogenic cells to these cytokines. Proinflammatory cytokines have in vitro effects on 
osteoblast proliferation, collagen synthesis, mineralisation and ALP activity [111, 112, 
114, 173, 174]. Other measurements of osteoblast response to proinflammatory 
stimuli include increased prostaglandin and NO production, changes in cell viability 
and expression of various inducible enzymes including iNOS and COX-2 [128, 175, 
176]. 
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3.1.2 Proinflammatory cytokines 
Proinflammatory cytokines are cell-signalling proteins that help to orchestrate local 
and systemic inflammation in response to traumatic injury or infection. This group 
contains IL-1, interleukin-6 (IL-6), interleukin-17 (IL-17), TNF-Į and IFN-Ȗ [126].  
These cytokines are the major signalling molecules in both acute and chronic 
inflammation. This investigation focuses on the cytokines IL-ȕ71)-ĮDQG,)1-Ȗ,/-
ȕ DQG 71)-Į KDYH VLPLODU in vivo inflammatory effects. The only major difference 
between the two cytokines is the involvement of TNF-Į LQ WKH DSRSWRWLF SDWKZD\
[126]. In vivo, the two cytokines work synergistically to attract leukocytes and 
stimulate production of mediators such as PGE2 and NO [127, 128]. Prolonged 
production of IL-ȕDQG71)-ĮFDQFDXVHH[WHQVLYHWLVVXHUHPRGHOOLQJDQGGDPDJH
The other cytokine concentrated on throughout this study, IFN-Ȗ LV SURGXFed 
primarily by NK cells and T-lymphocytes, that interact with macrophages and 
orchestrates leukocyte attraction [129]. IL-ȕ71)-ĮDQG,)1-ȖDOOSRVVHVVWKHDELOLW\
to interact with osteoblasts and other bone cells. Osteoblasts themselves can 
produce IL-ȕ DQG 71)-Į DQG UHFHSWRUV IRU DOO WKUHH F\WRNLQHV FDQ EH IRXQG RQ
osteoblasts and osteoclasts [121, 177]. 
 
 
3.1.3 Prostaglandins and Nitric Oxide 
Prostaglandins, particularly PGE2, play a significant role in modulating the 
inflammatory response, leading to symptoms such as pain, swelling and fever [178]. 
Evidence exists showing that prostaglandins play a role in bone remodelling; but 
during the inflammatory response expression and action of PGE2 is very much altered 
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[149]. Prostaglandins are biologically active lipids, derived from arachidonic acid by 
the action of cyclooxygenase enzymes 1 and 2 (COX-1 and COX-2), producing an 
unstable immediate form, PGH2. PGH2 is converted to PGE2 by PGE synthase 
(PGES). Likewise, PGD2 is converted by PGD synthase. The two isoforms of the 
COX enzymes (COX-1 and COX-2) have distinct roles within the body. COX-1 is 
expressed constitutively in most tissues and has a role in prostacyclin production, 
which in turn is associated with vascular homeostasis [179]. COX-2 is an inducible 
enzyme involved in inflammation; normally undetectable, but can be generated in 
response to  proinflammatory cytokine signalling, particularly IL-ȕ DQG 71)-Į
leading to the generation of increased amounts of PGE2 [180]. 
NO is a signalling molecule involved in a variety of physiological processes including 
vasodilation, neurotransmission and inflammation. The action of NO is determined by 
the site of synthesis, concentration and the environment of release [180]. NO is 
biosynthesised by the nitric oxide synthase (NOS) enzymes. The NOS enzymes 
function by oxidising the guanidine group of L-arginine, in a process that involves the 
oxidation of NADPH (nicotinamide adenine dinucleotide phosphate) and the reduction 
of molecular oxygen, resulting in the formation of L-citrulline and the NO molecule 
[181]. There are three isoforms of the NOS enzyme. Neuronal nitric oxide synthase 
(nNOS) and endothelial nitric oxide synthase (eNOS) are constitutively expressed in 
neural tissue and endothelial tissue respectively. The third isoform, inducible NOS 
(iNOS), is expressed in response to infection, inflammation or trauma. iNOS can lead 
to sustained generation of high levels of NO by osteoblasts, predominantly through 
proinflammatory cytokine signalling [175, 182, 183]. 
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3.1.4 Investigation of the effects of proinflammatory cytokines 
Whereas, the effects of proinflammatory cytokines have been comprehensively 
investigated on primary osteoblasts and osteoblast cell lines, little or no work has 
been performed on ESC-derived osteogenic cells. At the time of this study, there 
were no published comparative studies on ESC-derived and primary osteoblast 
response. The impact of these studies could have importance in production of a 
potential cell therapy for bone disease. The effect of creating a product under 
favourable conditions, that supports cell growth and maintenance of viability, and 
subsequently subjecting it to a damaged/diseased environment, could have a 
significant effect on the success or failure of the final therapy. 
In this chapter, initial steps were taken towards discovering the effect that a 
proinflammatory environment had on the response of ESC-derived osteogenic cells. 
This response was compared to that of primary calvarial cells, a cell population 
containing mainly osteoblasts. Significant differences in the responses of the two cell 
types to exposure to the proinflammatory cytokines IL-ȕ 71)-Į DQG ,)1-Ȗ DUH
described. Changes in combinations of cytokines and cytokine concentration were 
investigated and response in terms of viability, NO production, PGE2 production and 
inducible enzyme expression, was assessed.  
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3.2  Experimental Design 
For more detailed methods describing primary calvarial cell extraction and culture, 
mESC culture, EB formation, osteogenic differentiation and assay protocols see 
Chapter 2: Materials and Methods. 
 
3.2.1 Response of Osteogenic Cells to Proinflammatory 
Cytokines 
This group of experiments aimed to investigate the biochemical responses of primary 
calvarial cells and osteo-mESCs to proinflammatory cytokines. A schematic overview 
of experiments described in sections 3.2.1.ii, 3.2.1.iii and 3.2.1.iv can be found in 
figure 3.1. 
 
3.2.1.i Dose response effect of individual cytokines on cell viability 
Primary calvarial cells were seeded at a density of 10,600 cells/cm2 in 96-well plates. 
EBs were formed from mESCs, dissociated and plated at the same density in gelatin-
coated 96-well plates. Medium on both cell types was substituted with osteogenic 
medium (50 mM BGP, 50 µg/mL ascorbate 2-phosphate) the following day. This 
corresponds to day 0 of the experiment. From day 0, the cells were stimulated with 
the addition to the culture medium of: IL-ȕ DWQJP/QJP/DQGQJP/
TNF-ĮDWQJP/QJP/DQGQJP/,)1-ȖDWQJP/QJP/DQG
ng/mL, alongside an osteogenic control group containing no cytokines. To monitor 
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Figure 3.1: Schematic overview of experiments investigating response of 
osteogenic cells to proinflammatory cytokines. Schematic shows simplified 
experimental design for section 3.2.1, investigating response of primary calvarial cells 
and osteo-mESCs to IL-ȕ71)-ĮDQG,)1-ȖLQWHUPVRIFHOOYLDELOLW\12SURGXFWLRQ
and inducible enzyme expression. 
 
 
 
 
lls 
 ?ɴ ɲ
ɶ
Mouse Embryonic Stem Cells
Embryoid bodies (EBs) Mouse primary calvaria extraction
Dissociation Primary calvarial cell culture
Seeding at 10,600 cells/cm2
Osteogenic culture
Day 0 Day 7 Day 14 Day 21
Addition of proinflammatory cytokines
12 day continuous 
stimulation
72 hour stimulation (NO and PGE2)
48 hour stimulation (immunocytochemistry)
MTS assay on days 
1, 2, 5, 7, 9 and 12. 
Supernatant collection
and cell monolayer fixation.
Assays for NO and PGE2 production. Immunocytochemistry for iNOS and COX-2.
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proliferation and change in cell viability over time, MTS assays were performed on 
days 2, 7 and 14. Each timepoint was represented by a separate 96-well plate. 
 
 
3.2.1.ii Effect of combinations of proinflammatory cytokines on viability of 
osteogenic cells 
Initially the setup to this experiment was identical to the dose response described 
above. From day 0 of osteogenic culture, the primary calvarial cells and osteo-
mESCs were stimulated with various combinations of IL-ȕ  QJP/ 71)-Į 
ng/mL) and IFN-ȖQJP/LQWKHFXOWXUHPHGLXPDORQJVLGHDQRVWHRJHQLFFRQWURO
group containing no cytokines. Cytokine groups included: IL-ȕ 71)-Į DQG ,)1-Ȗ
alone; and combinations of IL-ȕand TNF-Į,/-ȕDQG,)1-Ȗ71)-ĮDQG,)1-ȖDQG
finally, IL-ȕ 71)-Į DQG ,)1-Ȗ 7R PRQLWRU SUROLIHUDWLRQ DQG FKDQJH LQ FHOO YLDELOLW\
over time, MTS assays were performed on days 1, 2, 5, 7, 9 and 12. Each timepoint 
was represented by a separate 96-well plate. 
 
 
3.2.1.iii Nitric oxide and PGE2 production in response to proinflammatory 
cytokines 
Primary calvarial cells and dissociated EBs were plated in 96-well plates, as above. 
Cells were switched to osteogenic medium the following day (day 0). Different 
combinations of IL-ȕ  QJP/ 71)-Į  QJP/ DQG ,)1-Ȗ  QJP/ ZHUH
added to the media at day 0, day 7, day 14 and day 21 of osteogenic culture. 
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Cytokine groups can be seen above, in section 3.2.1.1. Cytokines were applied for 72 
hours at each of these timepoints before cell culture medium was collected for testing, 
and cell monolayers fixed in 10% (w/v) formalin. Supernatants were assessed for 
nitrite concentration via the Griess assay and PGE2 concentration via EIA. DNA 
quantification by Hoechst assay was performed on the fixed cell monolayers; this was 
utilised to correct the nitrite and PGE2 data for cell number.  
 
 
3.2.1.iv Expression of inducible enzymes in response to proinflammatory 
cytokines 
3.2.1.iv.a  Immunocytochemistry 
Expression of the inducible enzymes iNOS, COX-2 and PGES, at various timepoints 
of osteogenic differentiation was investigated by immunocytochemistry. Primary 
calvarial cells and osteo-mESCs were plated in 12-well plates and cultured in 
osteogenic medium from day 0. Proinflammatory cytokine stimulation (IL-ȕ 
ng/mL), TNF-ĮQJP/DQG,)1-ȖQJP/LQFRPELQDWLRQIRUKRXUVZDV
performed at day 0, 7, 14 and 21 of osteogenic culture. Subsequently, cells were 
fixed in a 4% (w/v) solution of PFA and immunocytochemistry for iNOS, COX-2 and 
PGES performed using fluorescently-labelled secondary antibodies. Details of 
antibodies can be found in Chapter 2: Materials and Methods, Table 2.1 and Table 
2.2. Control staining using primary antibody only and secondary antibody only was 
performed. Images were processed to remove background staining based on 
secondary antibody only controls. 
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3.2.1.iv.b  RT-qPCR for iNOS expression 
Primary calvarial cells and osteo-mESCs were differentiated in osteogenic culture 
medium in 6-well plates. Proinflammatory cytokine stimulation (IL-ȕQJP/71)-
Į  QJP/ DQG ,)1-Ȗ  QJP/ ZDV SHUIRUPHG DW GD\  DQG GD\  RI
osteogenic culture for 48 hours. Subsequently, RNA samples were collected and 
RNA extracted. Reverse transcription of 500 ng RNA was performed and real-time 
qPCR completed for the iNOS gene. All values were normalised to the Rpl32 
ribosomal protein gene. For details of RT-qPCR methods and primers see Chapter 2: 
Materials and Methods. 
 
 
3.2.2 Effect of Proinflammatory Cytokine Concentration 
3.2.2.i Effect of decreasing proinflammatory cytokine concentration on cell 
response 
The effect of lowering the concentration of the three cytokines, in combination, was 
investigated via a dose response experiment. Primary calvarial cells and osteo-
mESCs were plated in 96-well plates and the next day culture medium replaced with 
osteogenic. IL-ȕ71)-ĮDQG,)1-ȖLQFRPELQDWLRQDWDUDWLRRIZHUHDGGHG
to the cell culture medium from day 0 of osteogenic culture; concentrations can be 
seen in table 3.1. MTS assays were performed on day 3, 10, 17 and 24 of continued 
cytokine application. To examine effect on cell response, proinflammatory cytokines 
at stated doses were added on day 7, 14 and 21 for 72 hours, supernatant collected 
and tested for nitrite concentration via the Griess assay. 
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Table 3.1: Cytokine concentrations utilised in dose response. 
Dose IL-ȕQJP/ TNF-ĮQJP/ IFN-ȖQJP/ 
A 0.03125 0.3125 3.125 
B 0.0625 0.625 6.25 
C 0.125 1.25 12.5 
D 0.25 2.5 25 
E 0.5 5 50 
F 1 10 100 
 
3.2.2.ii Effect of increasing proinflammatory cytokine concentration on cell 
response 
To investigate the effect of increasing the concentration of proinflammatory cytokines, 
IURP WKH ³VWDQGDUG´ XVHG LQ SUHYLRXV H[SHULPHQWV SULPDU\ FDOYDULDO FHOOV DQG
dissociated EBs were seeded in 12-well plates and cultured in osteogenic medium 
IURP GD\  &HOOV ZHUH VWLPXODWHG ZLWK ³VWDQGDUG´ FRQFHQWUDWLRQ SURLQIODPPDWRU\
cytokines in combination (IL-ȕQJP/71)-ĮQJP/DQG,)1-ȖQJP/
and 10x concentration (IL-ȕ  QJmL), TNF-Į  QJP/ DQG ,)1-Ȗ 
ng/mL)), alongside an unstimulated osteogenic medium control. Cytokines were 
added to media at timepoints day 0 and day 21, applied for 72 hours, before 
supernatants collected and tested for nitrite and PGE2 production. 
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3.2.3 Effect of mESC conditioned medium on primary calvarial 
cell response to proinflammatory cytokines. 
The hypothesis that the mESCs may have an anti-inflammatory effect was 
investigated using mESC-conditioned medium (CM) on primary calvarial cells. 
Undifferentiated mESCs (on feeder layers) and early differentiation osteo-mESCs 
(day 0) were cultured for 72 hours with and without proinflammatory cytokines (IL-ȕ
(1 ng/mL), TNF-ĮQJP/DQG,)1-ȖQJP/7KHFRQGLWLRQHGFXOWXUHPHGLXP
was collected after this period and passed through 0.2 µm filters to remove any cell 
debris. Primary calvarial cells were cultured in osteogenic medium until day 14. At this 
point culture medium was replaced with CM collected from the undifferentiated and 
differentiated mESCs. In some cases, proinflammatory cytokines were added. Control 
medium groups with and without proinflammatory cytokines were included. Viability of 
the primary calvarial cells was assessed by MTS assays on days 3, 7 and 10 after 
CM application. On these days, the supernatant was collected and tested for nitrite 
concentration via the Griess assay. Schematics showing the process of CM collection 
and application to the primary calvarial cells can be found in figure 3.2. 
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Figure 3.2: Schematic showing experimental design for the investigation of 
mESC conditioned medium on primary calvarial cell response to 
proinflammatory cytokines. (A) Schematic showing the process of conditioning the 
medium with undifferentiated and differentiated mESC. (B) Schematic showing the 
process of primary calvarial cell culture and application of the conditioned medium. 
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3.3  Results 
3.3.1 Response of Osteogenic Cells to Proinflammatory 
Cytokines 
3.3.1.i Dose response effect of individual cytokines on cell viability 
Initial studies investigated the effect of different doses of IL-ȕDQGQJP/
TNF-ĮDQGQJP/DQG,)1-ȖDQGQJP/RQWKHFHOOYLDELOLW\
of primary calvarial cells and osteo-mESCs, over a 14 day period. Results showed 
that all three cytokines had a negative effect on the viability of primary calvarial cells 
at 14 days, regardless of concentration (figure 3.3). Initially, at day 2, the cytokines 
had a positive effect on the cell viability of primary calvarial cells. The effects of IL-ȕ
and TNF-Į ZHUH more prominent at the highest dose (10 ng/mL and 100 ng/mL 
respectively), but the effects of IFN-ȖDSSHDUHGWKHVDPHUHJDUGOHVVRIWKHGRVH1R
significant effect on osteo-mESC viability, positive or negative, was seen with 
treatment by any cytokine at any dose (figure 3.4). From this point forward, it was 
decided to use the cytokines at concentrations of 1 ng/mL IL-ȕQJP/71)-ĮDQG
100 ng/mL IFN-ȖDOso supported by available literature [127, 163, 183-187].  
 
3.3.1.ii Effect of proinflammatory cytokines on cell viability 
Primary calvarial cells and osteo-mESCs were cultured with different combinations of 
proinflammatory cytokines added to the culture medium, for up to 12 days, to 
establish effects on viability over time. Results showed that proinflammatory cytokines 
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Figure 3.3: Dose response effect of IL-ȕ 71)-Į DQG ,)1-Ȗ RQ the viability of 
primary calvarial cells. Primary calvarial cells were treated with (A) IL-ȕ%71)-Į
and (C) IFN-ȖDWGLIIHUHQWGRVHV, over a 14 day period. Viability of cells at day 2, 7 
and 14 was measured by MTS assay. Data shown as percentage of control reading 
for that day. Values represented by mean±SD (n=6). Statistical significance against 
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Figure 3.4: Dose response effect of IL-ȕ 71)-Į DQG ,)1-Ȗ RQ the viability of 
osteo-mESCs. Osteo-mESCs were treated with (A) IL-ȕ%71)-ĮDQG&,)1-Ȗ
at different doses, over a 14 day period. Viability of cells at day 2, 7 and 14 was 
measured by MTS assay. Data shown as percentage of control reading for that day. 
Values represented by mean±SD (n=6). 
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had a negative effect on primary calvarial cell viability, which was not seen in the 
osteo-mESC cultures (figure 3.5). In primary calvarial cultures, combinations 
containing IL-ȕ LQLWLDOO\ KDGDVWLPXODWRU\HIIHFWRQFHOOSUROLIHUDWLRQZLWK LQFUHDVHG
cell numbers on day 2, when compared to control. By day 12, cell viability had 
dropped significantly in all cultures that contained a combination of more than one 
cytokine. Combining all three cytokines had a marked negative effect on primary 
calvarial cell viability; cell numbers began to fall at day 5, and continued until day 12, 
when viability compared to control, was less than 40%.  
No significant effects on viability, positive or negative, were seen in the osteo-mESC 
cultures, with IL-ȕ71)-ĮRU,)1-ȖLQDQ\FRPELQDWLRQILJXUH5B). 
 
 
3.3.1.iii NO and PGE2 production in response to proinflammatory cytokines 
The biochemical response of the cells to the presence of proinflammatory cytokines 
was investigated by monitoring production of NO, estimated as nitrite, and PGE2 
production, found within the cell culture medium. Nitrite (figure 3.6) and PGE2 (figure 
3.7) were measured after 72 hours proinflammatory cytokine stimulation, at different 
timepoints of culture, to determine change in response due to osteogenic 
differentiation.  
Results for culture medium collected after proinflammatory cytokine treatment on day 
0 and day 7 of osteogenic culture showed the primary calvarial cells produced 
significantly more nitrite than the control, in groups stimulated with IL-ȕDORQHDQG,/-
ȕ LQ FRPELQDWLRQ ZLWK  71)-Į DQG ,)1-Ȗ ILJXUH 6A and B). This occurred 
particularly in cultures with all three cytokines present in combination. This trend was 
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             A  
 
             B 
 
Figure 3.5: Effect of combinations of proinflammatory cytokines on cell 
proliferation and viability. (A) Primary calvarial cells and (B) osteo-mESCs were 
treated with different combinations of proinflammatory cytokines over a 12-day time 
period. Viability of cells at certain time-points was measured using the MTS assay. 
Data is shown as a percentage of control reading for that day. Experiment was 
repeated in triplicate each with n=6. Values are represented as mean±SEM of the 
three experiments6WDWLVWLFDOVLJQLILFDQFHDJDLQVWFRQWURO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A B 
C D 
Figure 3.6:   Effect of proinflammatory cytokines on NO production. Primary 
calvarial cells and osteo-mESCs were treated with different combinations of 
proinflammatory cytokines at (A) day 0, (B) day 7, (C) day 14 and (D) day 21 of 
osteogenic culture. Proinflammatory cytokine stimulation continued for 72 hours 
before supernatant collection and experiment end. Nitrite concentration in 
supernatant determined by Griess assay. Nitrite concentrations corrected for cell 
number using Hoechst DNA assay values. Values are represented as mean±SEM, 
experiment repeated in triplicate each with n=6. Statistical significance of primary 
calvarial response compared to osteo-mESC (*p.01), statistical significance of 
response compared to control of same cell type (# S. 
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A B 
C D 
Figure 3.7: Effect of proinflammatory cytokines on PGE2 production. Primary 
calvarial cells and osteo-mESCs were treated with different combinations of 
proinflammatory cytokines at (A) day 0, (B) day 7, (C) day 14 and (D) day 21 of 
osteogenic culture. Proinflammatory cytokine stimulation continued for 72 hours 
before supernatant collection and experiment end. PGE2 concentration in supernatant 
determined by EIA. PGE2 concentrations corrected for cell number using Hoechst 
DNA assay values. Values are represented as mean±SEM, experiment repeated in 
triplicate each with n=3. Statistical significance of primary calvarial response 
compared to osteo-mESC (*p.01), statistical significance of response compared to 
control of same cell type (# S. 
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also reflected in PGE2 production (figure 3.7A and B), with maximum PGE2 occurring 
at day 7. The day 0 and day 7 osteo-mESCs showed no significant nitrite or PGE2 
production in any group in response to proinflammatory cytokines, when compared to 
the control and compared to primary calvarial cells.  
Treatment of the cells on day 14 showed little variation in the nitrite production trend 
(figure 3.6C). Primary calvarial cells exhibited increased nitrite production in groups 
treated with a combination of proinflammatory cytokines, reaching a maximum on day 
14. The osteo-mESCs showed no significant nitrite production in any group. However, 
with PGE2 production on day 14 (figure 3.7C), the osteo-mESCs show significantly 
increased levels in the group stimulated with IL-ȕ71)-ĮDQG,)1-ȖZKHQFRPSDUHG
to the control. This is still of a lower level than the primary calvarial cells.   
Proinflammatory cytokine stimulation at day 21, showed increased response from the 
osteo-mESCs in terms of nitrite (figure 3.6D) and PGE2 (figure 3.7D). Significant 
nitrite and PGE2 production was seen in the group treated with all three cytokines; 
there was little difference between this and the levels in the primary calvarial cell 
group.  
The response of both the primary calvarial cells and osteo-mESCs was most 
pronounced when IL-ȕ 71)-Į DQG ,)1-Ȗ ZHUH SUHVHQW LQ FRPELQDWLRQ )URP WKLV
point forward, it was decided to use the three cytokines in combination for all 
experiments, to ensure the optimal signalling effect was achieved. 
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3.3.1.iv Expression of inducible enzymes in response to proinflammatory 
cytokines 
To visualise the response of cells to proinflammatory cytokines and examine the 
production of enzymes responsible for NO and PGE2, immunocytochemistry of iNOS, 
COX-2 and PGES was performed. Staining was carried out on both primary calvarial 
cells and osteo-mESCs, allowing exploration into patterns of protein expression and 
changes with stage of osteogenic differentiation. Cytokines were added to the 
medium on day 0, 7, 14 and 21, for 48 hours, before cell monolayers were fixed. 
Expression of iNOS, the enzyme leading to the production of NO during inflammation, 
can be seen in figure 3.8 (primary calvarial cells) and figure 3.9 (osteo-mESCs). In 
primary calvarial cells, there is no staining in cultures treated with control medium but 
at each of the osteogenic differentiation timepoints, there is a marked increase in the 
level of staining when proinflammatory cytokines are present in the medium. Staining 
mostly occurs in the cell cytoplasm, but does not appear in all cells, indicating a 
heterogeneous cell response. In osteo-mESC cultures, no staining of iNOS is seen in 
day 0 or day 7 groups in control medium or proinflammatory cytokine medium. On 
day 14, iNOS staining begins to appear in small amounts in cells treated with 
cytokines and by day 21, iNOS staining is more evident, reflecting the trend seen with 
the nitrite results. Once again, it appears to be being expressed by some cells but not 
across the entire cell culture.  
There is some staining in the osteo-mESC control medium cells on day 14 and 21, 
but it is much weaker compared to that seen with proinflammatory cytokine treatment 
at day 21. 
COX-2 expression can be seen in the primary calvarial cells in figure 3.10 and the 
osteo-mESCs in figure 3.11. In primary calvarial cell cultures, COX-2 is seen in large 
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Timepoint of 
Stimulation 
Control IL-ȕ71)-Į,)1-ȖVWLPXODWHGIRUhours 
iNOS With Hoechst iNOS With Hoechst 
Day 0 
    
Day 7 
    
Day 14 
    
Day 21 
 
    
Figure 3.8: iNOS immunostaining in primary calvarial cells stimulated with proinflammatory cytokines.  Cells were stimulated 
with IL-ȕ71)ĮDQG,)1-ȖIRUKRXUVDWHLWKHUGD\GD\GD\RUGD\RIRVWHRJHQLFFXOWXUHEHIRUHIL[DWLRQL126H[SUHVVLRQ
in both proinflammatory cytokine stimulated and control cultures was assessed by immunocytochemistry. Representative images shown. 
Scale bar = 90 µm. 
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Timepoint of 
Stimulation 
Control IL-ȕ71)-Į,)1-ȖVWLPXODWHGIRUKRXUV 
iNOS With Hoechst iNOS With Hoechst 
Day 0 
    
Day 7 
    
Day 14 
    
Day 21 
 
    
Figure 3.9: iNOS immunostaining in osteo-mESCs stimulated with proinflammatory cytokines.  Cells were stimulated with IL-ȕ
71)ĮDQG,)1-ȖIRUKRXUVDWHLWKHUGD\GD\GD\RUGD\RIRVWHRJHQLFFXOWXUHEHIRUHIL[DWLRQ L126H[SUHVVLRQ LQERWK
proinflammatory cytokine stimulated and control cultures was assessed by immunocytochemistry. Representative images shown. Scale 
EDUV ȝP. 
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Control IL-ȕ71)-Į,)1-Ȗ 
stimulated for 48 hours 
COX-2 With Hoechst COX-2 With Hoechst 
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Figure 3.10: COX-2 immunostaining in primary calvarial cells stimulated with 
proinflammatory cytokines. Cells were stimulated with IL-ȕ71)ĮDQG ,)1-Ȗ IRU
48 hours at either day 0, day 7, day 14 or day 21 of osteogenic culture before fixation. 
COX-2 expression in both proinflammatory cytokine stimulated and control cultures 
was assessed by immunocytochemistry. Representative images shown.Scale 
bars=46 ȝP. 
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Figure 3.11: COX-2 immunostaining in osteo-mESCs stimulated with 
proinflammatory cytokines. Cells were stimulated with IL-ȕ71)ĮDQG ,)1-Ȗ IRU
48 hours at either day 0, day 7, day 14 or day 21 of osteogenic culture before fixation. 
COX-2 expression in both proinflammatory cytokine stimulated and control cultures 
was assessed by immunocytochemistry. Representative images shown. Scale 
bars=46 ȝP. 
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amounts in proinflammatory cytokine treated cultures, throughout all differentiation 
timepoints. Unlike iNOS, it can also be seen to a small degree in cultures treated with 
control medium only. COX-2 appears to be less widely expressed in primary calvarial 
cultures than iNOS, and at day 14 and 21 is seen predominantly in bone nodule-like 
configurations. Most staining is seen at day 14 and is consistent with PGE2 production 
results. In osteo-mESC cultures, staining of COX-2 is not seen in proinflammatory 
cytokine treated cells until day 14. By day 21, more staining is seen. Weak staining is 
seen in cells cultured in control medium on day 14 and 21. Overall, expression of the 
inducible enzymes reflects and helps support data obtained on NO and PGE2 
production. Staining of PGES, found in Appendix V (figures AV.1 and AV.2), 
correlates with iNOS and COX-2 results. 
Real-time qPCR results for the iNOS gene support the immunocytochemistry (figure 
3.12). Increased levels of expression are only seen in primary calvarial cells when 
treated with proinflammatory cytokines at day 0 and day 21. All expression values for 
untreated primary calvarial cells and osteo-mESCs are low.  
 
 
3.3.2 Effect of Proinflammatory Cytokine Concentration 
3.3.2.i The effect of decreasing proinflammatory cytokine concentration on cell 
response 
Investigation of the response of cells to decreasing cytokine concentrations was 
performed in terms of viability and nitrite production. The ratio of IL-ȕ WR71)-Į WR
IFN-Ȗ  LQ WKH PHGLXP ZDV PDLQWDLQHG EXW FRQFHQWUDWLRQ RYHUDOO ZDV
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Figure 3.12: RT-qPCR of iNOS expression in proinflammatory cytokine treated 
cells. Primary calvarial cells and osteo-mESCs were treated with media containing 
IL-ȕ71)-ĮDQG,)1-Ȗ for 48 hours at day 0 and day 21 of osteogenic culture. Real-
time qPCR was performed for the iNOS gene.  (A) All data (B) magnified data, 
showing data at the lower end of expression, with data value shown. Expression of 
each target gene normalised to Rpl32. Data shown is mean±SD of 3 independent 
experiments (n=3). 6WDWLVWLFDOVLJQLILFDQFHRIH[SUHVVLRQYVFRQWUROS 
***
***
0
0.5
1
1.5
2
2.5
3
Control IL-1ɴнTNF-ɲнIFN-ɶ
Treated
Control IL-1ɴнTNF-ɲнIFN-ɶ
Treated
Day 0 Day 21
R
e
la
ti
v
e
 E
xp
re
ss
io
n
 o
f 
iN
O
S
Primary Calvarial Cells Osteo-mESC
0.0024
1.7764
0.0003
2.6860
0.0002
0.0000
0.0005
0.0010
0
0.001
0.002
0.003
0.004
0.005
0.006
Control IL-1ɴнTNF-ɲнIFN-ɶ
Treated
Control IL-1ɴнTNF-ɲнIFN-ɶ
Treated
Day 0 Day 21
R
e
la
ti
v
e
 E
x
p
re
ss
io
n
 o
f 
iN
O
S
Primary Calvarial Cells
Osteo-mESCs
Chapter 3 Effect of Proinflammatory Cytokines on Cell Response 
  99 
decreased by serial dilution. For each dilution, cell viability was monitored across 
days 3, 10, 17 and 24 (figure 3.13). In primary calvarial cell cultures, at the highest 
concentration of proinflammatory cytokines (Dose F - 1 ng/mL IL-ȕQJP/71)-Į
and 100 ng/mL IFN-ȖD UHGXFWLRQ LQFHOOYLDELOLW\EHJDQDWGD\DQGFHOOQXPEHUV
continued to fall throughout the remaining time. This also occurred in the lower 
concentrations (dose E, D, C, and B). There was no significant effect on primary 
calvarial cell viability with the lowest dose (A - 0.03125 ng/mL IL-ȕ QJP/
TNF-Į DQG  QJP/ ,)1-Ȗ EXW FHOO SUROLIHUDWLRQ GLG QRW FRUUHVSRQG ZLWK WKH
control group. In contrast, in the osteo-mESC cultures (figure 3.13B) there was little 
effect of proinflammatory cytokines on cell viability, at any concentration, whether 
inhibitory or stimulatory. 
Alongside effect on cell viability, nitrite production was also studied. Proinflammatory 
cytokine concentrations were as before, but doses of cytokines were applied at day 7, 
day 14 and day 21 for 72 hours, before medium supernatant samples were taken and 
tested for nitrite concentration (figure 3.14). At the lowest dose of cytokines (dose A), 
no significant nitrite production was seen across any timepoint in the primary calvarial 
cells or at day 21 in the next highest dose (dose B). Nitrite concentration in the 
medium reached a plateau from dose D upwards (0.25 ng/mL IL-ȕQJP/71)-Į
and  2.5 ng/mL IFN-Ȗ ,QSULPDU\FDOYDULDOFHOOVDFURVVDOOGRVHVQLWUite production 
peaked at day 14. 
The osteo-mESCs showed no significant nitrite production at any proinflammatory 
cytokine dose, except day 21 of osteogenic culture at the highest dose (Dose F). 
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Figure 3.13: Dose response effect of proinflammatory cytokines on cell proliferation and viability. (A) Primary calvarial cells and (B) 
osteo-mESCs were treated with increasing concentrations of a combination of IL-ȕ71)-ĮDQG ,)1-ȖRYHUa 24-day time period. Cytokine 
doses: A (Il-ȕQJP/71)-ĮQJP/,)1-ȖQJP/B (Il-ȕ0625 ng/mL, TNF-Į.625 ng/mL, IFN-Ȗ6.35 ng/mL); C (Il-
ȕ125 ng/mL, TNF-Į1.25 ng/mL, IFN-Ȗ12.5 ng/mL); D (Il-ȕ0.25 ng/mL, TNF-Į2.5 ng/mL, IFN-Ȗ25 ng/mL); E (Il-ȕ0.5 ng/mL, TNF-Į5 
ng/mL, IFN-Ȗ50 ng/mL); F (Il-ȕ1 ng/mL, TNF-Į10 ng/mL, IFN-Ȗ100 ng/mL). Viability of cells at certain time points was measured using the 
MTS assay. Data is shown as optical absorbance proportional to cell viability. Values are represented as mean±SD (n=6). Statistical 
significance against control (S). 
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3.3.2.ii Effects of increasing proinflammatory cytokine concentration on cell 
response 
Increasing the dose of proinflammatory cytokines from the standard 1 ng/mL IL-ȕ
ng/mL TNF-Į DQG  QJP/ ,)1-Ȗ ZDV DOVR LQYHVWLJDWHG LQ WHUPV RI ERWK QLWULWH
(figure 3.15) and PGE2 (figure 3.16). In both cases, primary calvarial cells and osteo-
mESCs were stimulated with no cytokines (control medium), medium containing 
standard concentration cytokines and medium containing 10x the standard 
concentration. Proinflammatory cytokine stimulation was performed for 72 hours at 
day 0 and day 21 of osteogenic culture, to investigate effect of cell differentiation. For 
both nitrite and PGE2 production, increasing the dose by 10 times had no effect on 
final concentration indicating that a plateau of response had been reached. Results 
mirrored those that had been seen previously; on days 0 and 21 of osteogenic 
culture, nitrite and PGE2 were produced in significant quantities by primary calvarial 
cells in response to proinflammatory signals. This did not occur in the osteo-mESCs. 
By day 21, the osteo-mESCs were producing significant levels of both nitrite and 
PGE2 in response to the cytokines, at similar levels as the primary calvarial cells. 
 
 
3.3.3 Effect of mESC conditioned medium on the response of 
primary calvarial cells to proinflammatory cytokines. 
To investigate whether mESCs were releasing soluble anti-inflammatory factors into 
culture medium, CM from both undifferentiated and early differentiation mESCs was 
collected, both with stimulation by proinflammatory cytokines and without. CM was 
then used as culture medium on primary calvarial cell cultures with and without 
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Figure 3.15: Effect of increased proinflammatory cytokine concentration on 
nitric oxide production. Primary calvarial cells and osteo-mESCs were treated with  
control media; media containing 1 ng/mL IL-1ȕ, 10 ng/mL TNF-ĮDQGQJP/,)1-
ɶĂŶĚŵĞĚŝĂĐŽŶƚĂŝŶŝŶŐ ? ?ƚŝŵĞƐƚŚĞĐŽŶĐĞŶƚƌĂƚŝŽŶŽĨĂůůƚŚƌĞĞĐǇƚŽŬŝŶĞƐ ? Proinflammatory 
cytokine stimulation occurred for 72 hours at (A) day 0 of osteogenic culture and (B) day 21 
of osteogenic culture. Values are represented as mean±SD, n=6. Statistical significance of 
response compared to cell-specific control (*p<0.01) 
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Figure 3.16: Effect of increased proinflammatory cytokine concentration on 
PGE2 production. Primary calvarial cells and osteo-mESCs were treated with  
control media; media containing 1 ng/mL IL-1ȕ, 10 ng/mL TNF-ĮDQGQJP/,)1-
Ȗ DQG PHGLD containing 10 times the concentration of all three cytokines. 
Proinflammatory cytokine stimulation occurred for 72 hours at (A) day 0 of osteogenic 
culture and (B) day 21 of osteogenic culture. Values are represented as mean±SD, 
n=4. Statistical significance of response compared to cell-specific control (*p<0.01). 
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proinflammatory cytokines. Cell viability (figure 3.17) and nitrite production (figure. 
3.18), over 10 days, was considered. Figure 3.17 shows cell viability results for day 
10. Results for MTS assays performed on day 3 and day 7 can be found in Appendix 
VI (figure AVI.1). Response to CM was compared to that of osteogenic medium (OM) 
with and without proinflammatory cytokines. Cytokines in OM initially had a negative 
effect on cell viability as cell numbers by day 10 had fallen to 40% of OM control. The 
CM from undifferentiated mESCs inhibited this reduction in cell viability, regardless of 
whether mESC medium had been treated with cytokines (figure 3.17A). Although, at 
day 10 there was still some difference between the CM and the OM control. The CM 
from early-differentiation mESCs had a slightly different effect. When the 
differentiated mESCs had not been cultured with proinflammatory cytokines, the CM 
alone had a negative effect on primary cell viability when compared to the OM control 
(figure 3.17B). This detrimental effect on the cells was negated when proinflammatory 
cytokines were added to the CM. In contrast, the CM from differentiated mESCs 
cultured with proinflammatory cytokines did not have a negative effect on cell viability, 
and inhibited the primary calvarial cell death that occurred via the proinflammatory 
cytokines. 
Results showing levels of nitrite production by the primary calvarial cells were clearer 
(figure 3.18). This graph shows the cumulative nitrite concentration in the culture 
medium, over 10 days, with values taken from assays performed on day 3, day 7 and 
day 10. Individual results for these timepoints can be found in Appendix VI (figure 
AVI.1C). Cells produced nitrite in response to IL-ȕ71)-ĮDQG,)1-ȖLQ20PHGLXP
Results show nitrite values from control medium (no added cytokines in primary 
calvarial cell culture) subtracted from the proinflammatory cytokine treated-value. CM 
from undifferentiated and differentiated mESCs inhibited cytokine-induced nitrite 
production, regardless of whether the mESCs had been treated with cytokines. CM 
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Figure 3.17: Effect of mESC conditioned medium (CM) on viability of cells 
treated with proinflammatory cytokines. Medium was conditioned by (A) 
undifferentiated and (B) differentiated mESCs for 10 days, with and without IL-ȕ
(1ng/mL), TNF-Į  QJP/ DQG ,)1-Ȗ  QJP/. Primary calvarial cells were 
cultured for 14 days before conditioned medium applied and subsequent 
proinflammatory cytokine stimulation for some groups. Cell viability determined by 
MTS assay and data shown as a percentage of DMEM control reading. Values are 
represented as mean±SD n=6 (experiment performed in triplicate, representative 
experiment shown). Statistical significance of response compared to DMEM control 
(S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Figure 3.18: Effect of mESC conditioned medium on nitric oxide production of 
cells treated with proinflammatory cytokines. Medium was conditioned by 
undifferentiated and differentiated mESCs for 3 days, with or without IL-ȕQJP/
TNF-ĮQJP/DQG,)1-ȖQJP/. Primary calvarial cells were cultured for 14 
days before conditioned medium applied and subsequent proinflammatory cytokine 
stimulation for some groups. Nitrite production measured at day 10. All groups 
supplemented with IL-ȕ 71)-Į DQG ,)1-Ȗ ZKHQ DGGHG WR SULPDU\ FDOYDULDO FHOOV
Control (no proinflammatory cytokines) readings subtracted from treated groups. 
Values shown as mean±SD, n=6, representative of 3 independent experiments. 
Statistical significance vs. OM with IL-ȕ71)-ĮDQG,)1-Ȗ# S).  
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from differentiated mESCs with no proinflammatory cytokines treatment was the least 
effective of the groups.  
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3.4  Discussion 
The aims of this chapter were to investigate the effect that a proinflammatory 
environment has on the responses of osteogenically differentiated mESCs, and 
compare them to the responses of the more well-described primary calvarial cells. 
Within WKHVWXG\WKHSULPDU\FDOYDULDOFHOOVZHUHXVHGDVD³EHQFKPDUN´IRUUHVSRQVH
to proinflammatory cytokines. Cells responded to IL-ȕ 71)-Į DQG ,)1-Ȗ LQ WKH
medium, by showing reductions in cell viability, producing significantly increased 
amounts of NO and PGE2, with associated increased expression of iNOS and COX-2. 
An elevated level of NO, associated with iNOS, contributes to localised cell and tissue 
damage, and can be involved in bone resorption and inhibition of bone formation 
[163, 166, 175, 183, 184]. PGE2, produced through the COX-2 pathway, is induced in 
osteoblasts by the presence of proinflammatory cytokines, is a potent stimulator of 
bone resorption and can inhibit osteoblast growth and proliferation [176, 188, 189]. 
Levels of NO and PGE2 production, along with the expression of iNOS, COX-2 and 
PGES help explain the marked fall in viability of the primary calvarial cells with 
prolonged exposure to proinflammatory cytokines. Conversely, the apparent lack of 
response and possible deficiency of these signalling molecules and enzymes in early 
differentiation osteo-mESC cultures may explain the stability of these cells in terms of 
viability. 
Many authors have published work demonstrating the similarity of ESC-derived 
osteogenic cells to that of osteoblasts using established differentiation protocols. 
Protein expression, gene expression and mineral deposition have shown to be similar 
[60, 61, 164, 190, 191]. The efficacy of these differentiation protocols has been called 
into question. However, detailed comparative studies have been minimal [192, 193]. 
In this work, it was shown that although there are phenotypic similarities between the 
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cell types, there are distinct differences in biochemistry, as suggested by different 
responses to cytokines.  
The two cells types in this investigation cannot be described as directly comparable, 
as the osteo-mESCs have been shown to be a heterogenous population of cells (see 
chapter 4). Levels of osteogenic differentiation between the two cell types is not 
comparable as the osteo-mESCs start considerably further behind in the 
developmental continuum. However, in vitro the two cells types do both form 
mineralised nodules at 21 days (see figure 4.2), and literature states that at this point 
the ESCs have differentiated to osteoblast-like cells [60, 61, 164, 190, 191]. Thus, this 
was considered to be the final timepoint, and a comparison of in vitro osteogenic 
differentiation and the effects of proinflammatory cytokines is discussed further in 
chapter 4. Although the cells are not directly comparable, it is clear that as a whole 
population, early differentiation osteo-mESCs do not respond to the presence of the 
proinflammatory cytokines by producing nitric oxide, PGE2 and the associated 
enzymes iNOS, COX-2 and PGES. At this stage, the mechanisms contributing to 
these differences have not been determined, but it can be hypothesised that receptor 
and signal transduction pathways may be less developed or active in mESC-derived 
osteoblasts. Currently, there is very little available literature demonstrating the 
expression of receptors for these cytokines by mESCs and whether, if present, the 
receptors are functionally active. ESCs and early ES-derived vascular cells have 
been shown to have a low level of TNF-receptors and it has been reported that 
Nuclear Factor-ț% NF-ț%), a transcriptional regulator that plays a key role in 
immunity and inflammation, has relatively low expression in undifferentiated ES cells 
but activity increases during differentiation [194, 195]. Expression of TLRs, another 
group of receptors associated with the immune and inflammatory response, have 
been shown to be significantly downregulated on hESCs [196]. This lack of evidence 
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of proinflammatory cytokine receptors expressed by osteo-mESCs would be an 
interesting point to address in future work, and if they are not expressed, at which 
point of differentiation this occurs. 
Further evidence for differences in the biochemistry of these cells is supported by the 
finding that conditioned culture medium from both undifferentiated and differentiated 
mESCs can inhibit or reduce the effects of proinflammatory cytokines, on primary 
calvarial cells. ESCs have previously been shown to suppress proinflammatory 
cytokine production by T-cells, and to have immunosuppressive tendencies [197-
200]. The work in this study may link into previous descriptions of ESCs as 
immunoprivileged [201, 202]. The very low levels of response to IL-ȕ 71)-Į DQG
IFN-Ȗ RI WKH RVWHR-mESCs during early differentiation and the increasing response 
over the 21 days, reflects results that show the immunoprivileged state of ESCs 
diminishes as levels of differentiation increase [155, 156, 203]. The immune response 
and inflammation are innately linked through the cells and molecules involved, and 
proinflammatory cytokines, such as IFN-ȖKDYHDODUJHrole in the expression of MHC 
antigens that lead to immune rejection [204, 205]. 
If elucidated, the diminished response of the osteo-mESCs to cytokines, particularly 
in the early stages of differentiation, may show some application in regenerative 
medicine and wound healing, although much more investigation would need be 
performed. Another type of stem cell, the mesenchymal stem cell has had impact, as 
MSCs have been shown to be attracted to the wound microenvironment; homing to 
the site of injured tissue, evading the immune system and promoting wound healing 
[206-209]. MSCs have shown potential to treat inflammatory immune-mediated 
GLVHDVHV VXFK DV *9+' DQG &URKQ¶V GLVHDVH E\ WKH UHOHDVH RI DQWL-inflammatory 
factors such as IL-1ra and TGF-ȕ[151, 210, 211]. MSCs derived from human ESCs 
have been shown to suppress the proliferation of lymphocytes and resist the cytotoxic 
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effects of NK cells in vitro, and have anti-inflammatory effects in vivo [198-200]. If 
osteogenic-cells derived from ESCs could offer these same advantages, they could 
be a candidate for cell therapies. ESCs offer more versatility than MSCs and have an 
excellent proliferative potential. If differentiation protocols could be improved and 
validated, so the threat of tumourigenicity is reduced, the risk of immune rejection and 
damage by inflammation may be moderated if using embryonic-derived cells as a 
therapy.  
In cell therapies, it has previously been suggested that stem cells may play roles in: 
homing to injured areas; acting in an anti-inflammatory manner; using paracrine 
factors to support cell survival, and differentiating to functional cells [198, 212, 213]. In 
this study, it has been   demonstrated that in early differentiation, osteogenic ESCs 
can survive an inflammatory environment, without the biochemical response that 
primary cells produce. The survival of these cells may lead to increased proliferation 
of host cells or inhibition of inflammation, whilst differentiation into functional tissue. 
The findings in this study help to support the promise that osteogenically 
differentiated ESCs have in understanding, and in the longer term, treating 
inflammatory bone disease. 
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Chapter 4:   
Effect of Proinflammatory Cytokines 
on Osteogenic Differentiation of 
mESCs and Primary Calvarial Cells 
4.1  Introduction 
4.1.1 Overview 
Current understanding of the effects of diseased environments on stem cell behaviour 
is limited, and interaction of bone cells within the inflammatory microenvironment is 
poorly understood. The effect that inflammation has on osteogenic differentiation is an 
important factor when considering any cell type as a therapy or model for bone 
disease. The previous chapter discussed the biochemical response of ESCs to 
proinflammatory signalling; in this chapter, the aim was to investigate the effects on 
osteogenic differentiation of the cells and the subsequent formation of in vitro bone 
nodules. 
 
4.1.2 In Vitro Osteogenic Differentiation  
In the body, bone development is highly regulated and the resulting structure is 
organised and hierarchically ordered [214]. In vivo bone development progresses 
through distinct development stages that follow commitment of MSCs to the 
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osteoblast lineage, proliferation of osteoprogenitors and maturity of the differentiated 
osteoblast, leading to the formation of mineralised ECM [68].  
In vitro differentiation of primary osteoblasts and osteoblast cell lines results in the 
formation of mineralised bone nodules, when cultured in the presence of BGP and 
ascorbate [162, 215]. The ECM deposited by osteoblasts in vitro has been shown to 
include collagen-I (col-I), fibronectin, OCN and OPN, and staining for these proteins is 
often strongest around the mineralised nodules [216-219]. In vitro, there is a clear 
progression of osteogenic differentiation, with distinct stages. Osteoprogenitors can 
differentiate into mature osteoblasts only if they undergo growth arrest and begin to 
establish a collagenous ECM. Therefore, after first seeding, cells undergo a 
proliferation phase within the first 1-7 days, subsequently genes associated with cell 
proliferation, such as c-Fos and c-Myc, fall in expression level as a collagen matrix is 
synthesised and deposited [220, 221]. Sequential expression of differentiation related 
proteins then occurs, first with ALP, followed by BSP, OPN and finally, OCN [218, 
221-224].    
Both mouse and human ESCs have also been shown to differentiate osteogenically in 
vitro, exhibiting molecular and structural features resembling bone tissue, by 
formation of mineralised bone nodule structures [60, 190, 225, 226]. The majority of 
osteogenic differentiation protocols induce cell differentiation by including factors in 
the culture medium, such as BGP, ascorbate, dexamethasone, simvastatin, retinoic 
acid, vitamin D3 and BMPs [30, 65, 227-232]. Bone nodules have been shown to stain 
positive for the presence of calcium and phosphate by alizarin red and von Kossa 
staining, respectively. The expression of bone matrix proteins, such as col-I and 
OCN, in ESC cultures has also been shown [30, 60, 225, 233]. 
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4.1.3 Proinflammatory Cytokines and Osteogenic 
Differentiation 
As discussed in Chapter 1, the cytokines IL-ȕ71)-ĮDQG,)1-ȖSOD\UROHVLQ bone 
regulation and are critical mediators of inflammation. The effect of these cytokines, 
particularly in combination, on the osteogenic differentiation of ESCs, has been 
minimally investigated. The effects on bone cells are well described and are 
summarised in chapter 1, table 1.2. The acute inflammatory process plays a critical 
role in fracture healing with proinflammatory signalling occurring for short time periods 
and ending within days, and IL-1 and TNF have both been shown to be expressed 
transiently at sites of bone formation [234, 235]. With this in mind during this study, 
the effects of short bursts of proinflammatory cytokine signalling on osteogenic 
differentiation of the primary calvarial cells and the osteo-mESCs were investigated. 
The consequences of this short burst of cytokine stimulation, in terms of bone nodule 
formation, mineral deposition and ECM production were examined, looking at the 
time-point of osteogenic differentiation of the cells that cytokine stimulation occurs.  
 
4.1.4 Cell-Sorting for Osteogenic Populations 
In both extracted primary bone cell populations and osteogenically-differentiated 
ESCs there is some level of heterogeneity within the cultured cell population. Cell 
sorting techniques can be used to select for certain cell populations based on marker 
expression. Common cell sorting techniques include centrifuge sorting, fluorescence 
activated cell sorting (FACS) and MACS. There is currently no commonly used 
marker of the early osteoblast. Although, Stro-1 and ALP have previously been used 
to generate osteoblast populations from bone marrow and bone tissue extracts [236-
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240], they were unsuitable for this investigation. Stro-1 may only be expressed on 
human cells and ES cells can constitutively express high levels of ALP [241, 242]. 
Cad-11 has previously been used to purify ES cells, and is a good candidate in this 
case [243].  Cad-11 is a cell adhesion molecule strongly associated with bone 
formation and osteogenic differentiation [244, 245]. In this study, MACS was used to 
separate a population of osteoprogenitors from the osteogenically differentiated ESC 
population, using the cad-11 marker. The cad-11 cell sorting allowed the investigation 
of the response of the sorted cell populations to proinflammatory cytokine signalling, 
allowing comparison with the responses of the unsorted osteo-mESCs, described in 
the previous chapter.   
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4.2  Experimental Design 
For more detailed methods describing primary calvarial cell extraction and culture, 
mESC culture, EB formation, osteogenic differentiation and assay protocols see 
Chapter 2: Materials and Methods. 
As discussed in the introduction to this chapter (section 4.1.2) in vitro osteogenic 
differentiation follows a clear progression, with distinct stages [162, 215-224]. To 
reflect this progression, assay timepoints were chosen to reflect the points at which 
literature describes certain differentatiation markers to be expressed.  For example, 
ALP is considered to be an early osteogenic marker and expression peaks between 
day 12 and 14; thus, the ALP assay was performed on day 14. Col-I is the first ECM 
protein to be produced and can be found from approximately day 14 onwards. Cad-11 
is expressed from at least day 16. These were stained for on the same samples at 
day 21, as this allowed for col-I accumulation to be assessed alongside a cellular 
marker. Total time for bone nodule formation during in vitro osteogenic differentiation 
is 21 to 28 days, thus alizarin red staining for calcium deposition, and OCN and OPN 
protein staining was performed at 21 and 28 days respectively. This day 28 timepoint 
was chosen because OCN is the ultimate osteogenic ECM protein to be produced, 
and is often not found until the later stages of differentiation.  
 
4.2.1 Osteogenic differentiation of primary calvarial cells and 
osteo-mESCs 
Osteogenic differentiation of the primary calvarial cells and the osteo-mESCs was 
compared using a range of techniques and markers. Mineralisation potential was 
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assessed by alizarin red staining of the cells, after 21-days growth in osteogenic 
medium (50 mM BGP, 50 µg/mL ascorbate 2-phosphate, 10 µM dexamethasone) or 
non-osteogenic medium. Formation of bone nodules was also assessed by 
immunocytochemical staining for col-I and cad-11 after 21 days osteogenic culture. 
OCN and OPN double-staining in osteogenic and non-osteogenic medium, after 28 
days, was investigated. Details of antibodies can be found in Chapter 2: Materials and 
Methods, table 2.1 and table 2.2.  
Levels of osteogenic markers (Runx2, Col1a1, Opn) after osteogenic culture were 
assessed by RT-qPCR. RNA was extracted after 18 days culture, reverse 
transcription of 400 ng RNA performed and real-time expression analysis carried out. 
Expression of each target gene was normalised to the Rpl32 ribosomal protein gene. 
Details of RT-qPCR protocol and primer sequences can be found in Chapter 2: 
Materials and Methods. 
 
 
4.2.2 Effect of proinflammatory cytokines on osteogenic 
differentiation of osteo-mESCs and primary calvarial 
cells. 
This group of experiments aimed to investigate the effect of short term stimulation 
with proinflammatory cytokines on the osteogenic differentiation of primary calvarial 
cells and osteo-mESCs. A schematic overview of experiments described in sections 
4.2.2.i, 4.2.2.ii and 4.2.2.iii can be found in figure 4.1. 
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Figure 4.1: Schematic overview of experiments investigating the response of 
osteogenic cells to proinflammatory cytokines. Schematic shows simplified 
H[SHULPHQWDOGHVLJQ IRUVHFWLRQ LQYHVWLJDWLQJ WKHHIIHFWRI ³VKRUWEXUVWV´RI ,/-
ȕ71)-ĮDQGIFN-Ȗ exposure, at different timepoints of osteogenic differentiation of 
osteo-mESCs and primary calvarial cells. 
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4.2.2.i Effect of proinflammatory cytokines on mineralisation potential of 
primary calvarial cells and osteo-mESCs 
Primary calvarial cells and osteo-mESCs were plated in 6-well plates. Cells were 
cultured in osteogenic medium (50 mM BGP, 50 µg/mL ascorbate 2-phosphate, and 
10 µM dexamethasone) for 21 days. At timepoints day 0, 3, 7 and 14 of osteogenic 
culture, IL-ȕ 1ng/mL), TNF-Į  QJP/ DQG ,)1-Ȗ  QJP/ ZHUH DGGHG WR
medium for 48 hours. Each timepoint was represented by a separate plate. After 
cytokine treatment, cells were changed back to non-cytokine osteogenic medium and 
cultured until day 28. Due to the anti-inflammatory effects of dexamethasone, during 
proinflammatory cytokine treatment and 24 hours after, cells were cultured in 
osteogenic medium without dexamethasone. Controls were treated identically. After 
28 days, cells were fixed in 10% (w/v) formalin and stained for calcium deposition with 
2% (w/v) alizarin red S. Cultures were imaged using a stereo dissection microscope 
for macro-well images and an inverted light microscope with Hoffman contrast for 
higher magnification images. Percentage area stained by alizarin red in macro-well 
images was quantified using image J software. 
 
4.2.2.ii Effect of proinflammatory cytokines on alkaline phosphatase activity of 
osteogenic cells 
Experiments were performed as above, (mineralisation experiment), with the 
exceptions that 12-well plates were used and the endpoint was day 14. Timepoints of 
cytokine treatment were day 0, 3 and 7 for 48 hours and subsequently cells were 
changed back to control osteogenic medium. ALP activity was assessed at day 14 
using the pNPP assay, and values were corrected for cell number using fluorescent 
Hoechst readings. 
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4.2.2.iii Effect of proinflammatory cytokines on expression of osteogenic 
proteins  
Experiments were performed identically to the mineralisation potential experiment 
with the same timepoints and endpoint at day 28, when cell were fixed in 4% (w/v) 
PFA. Immunofluorescence was performed, with double staining for OPN and OCN, 
and col-I and cad-11. Antibody details and the immunocytochemistry protocol can be 
found in Materials and Methods, tables 2.1 and 2.2. Nuclear counterstaining with 
Hoechst 33258 was performed. Imaging was carried out with an inverted 
fluorescence microscope and image processing was completed to remove non-
specific background using Volocity software. 
 
4.2.3 Cadherin-11 sorting of osteo-mESCs 
MACS was used to sort for preosteoblasts within the osteo-mESC cultures using the 
cad-11 cell surface marker. Osteo-mESCs were cultured on gelatin-coated T75 cm2 
flasks in osteogenic medium (50 mM BGP, 50 µg/mL ascorbate 2-phosphate and 10 
µM dexamethasone) for 16 days. At this point, cells were detached and MACS 
separation performed for cad-11 positive cells. Description of MACS separation 
procedure can be found in Chapter 2: Materials and Methods, along with details of 
antibodies used (tables 2.1 and 2.2) 
 
4.2.3.i Osteogenic potential of cadherin-11 sorted osteo-mESCs 
Cad-11 positive and negative cells were plated separately at a density of 200,000 
cells/well in gelatin-coated 6-well plates. Cells were cultured in osteogenic medium 
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with 10 µM dexamethasone for a further 21 days. Subsequently, half the plates were 
fixed with 4% (w/v) PFA and immunocytochemistry performed for OCN, OPN and 
Col-I. The remaining plates were fixed in 10% (w/v)  formalin and stained for calcium 
deposition with alizarin red S. 
 
4.2.3.ii Response of cadherin-11 sorted mESCs to proinflammatory cytokines 
Cad-11 positive and negative osteo-mESCs were plated separately in gelatin-coated 
6-well plates at a 200,000 cells/well. Cells were cultured in osteogenic medium. At 
day 7 and day 14 after MACS sorting, cells were treated with IL-ȕQJP/71)-Į
(10 ng/mL) and IFN-ȖQJP/$WWKLVSRLQWGH[DPHWKDVRQHZDVUHPRYHGIURP
the medium in both treated and control. After 48 hours cytokine treatment, medium 
samples were collected and cell monolayers fixed in 4% (w/v) PFA. Samples were 
tested for nitrite and PGE2 concentration. Cell monolayers were stained via 
immunocytochemistry for the presence of iNOS. 
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4.3  Results 
4.3.1 Osteogenic differentiation of primary calvarial cells and 
osteo-mESCs 
In vitro osteogenic differentiation of mESCs was compared to the differentiation of 
mouse primary calvarial cells. After 21 days in osteogenic medium, both cell types 
showed formation of specific areas of mineralizing matrix or nodules, as suggested by 
alizarin red staining (figure 4.2A). Under magnification, these nodules appeared to 
have similar structure in both osteo-mESC and primary cultures. Subjective 
observation showed nodules were more abundant in osteo-mESC cultures. Alizarin 
red staining was not seen in non-osteogenic culture medium controls.  
The formation of nodules was further assessed by immunocytochemistry, revealing 
similar localised expression of col-I and cad-11, within nodules formed by both cell 
types (figure 4.2B). Figure 4.2D shows localised expression of ECM proteins OPN 
and OCN by both cell types in nodular areas. In non-osteogenic medium, the 
expression of OPN and OCN was minimal. 
Figure 4.2C shows real-time PCR analysis of expression of Runx2, Col1a1 and Opn 
at day 18 of osteogenic culture. There are significant differences in the level of 
expression of all three genes in the osteo-mESCs when compared to the primary 
calvarial cells, with expression levels of all genes lower in the osteo-mESCs. 
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Figure 4.2: Osteogenic differentiation of osteo-mESCs and mouse primary 
calvarial cells. (A) Representative images of alizarin red staining of bone nodules in 
osteogenic and non-osteogenic medium at 21 days culture (scale bar = 2 mm), high 
magnification image of osteo-mESC and primary calvarial cell bone nodules in 
osteogenic medium VFDOH EDU    ȝP % Representative images showing 
expression of collagen-1 (green), cadherin-11 (red) and nuclei (blue) in bone nodules 
formed by osteo-P(6&V DQG SULPDU\ FDOYDULDO FHOOV VFDOH EDU    ȝP & 57-
qPCR analysis performed on primary calvarial cells and osteo-mESCs at day 18 of 
culture for osteogenic markers Runx2, Col1a1 and Opn. Expression of each target 
gene normalised to Rpl32. Data shown is mean±SD of 3 independent experiments 
(n=3). *Statistical significance of primary calvarial cells vs. osteo-P(6&VS (D) 
Representative images showing expression of osteopontin (red) and osteocalcin 
(green) in osteogenic and non-osteogenic cultures of osteo-mESCs and primary 
calvarial cells. Merge image shows OPN and OCN with Hoechst nuclear staining 
VFDOHEDU ȝP  
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4.3.2 The effect of proinflammatory cytokines on 
mineralisation potential of primary calvarial cells and 
osteo-mESCs 
Cells were treated with proinflammatory cytokines at day 0, 3, 7 and 14 of osteogenic 
culture for 48 hours. Subsequently medium was changed back to osteogenic medium 
without cytokines, and culture continued until day 28, at which point alizarin red 
staining was performed. The effect this short exposure to cytokines had on primary 
calvarial cultures can be seen in figure 4.3 and osteo-mESC cultures in figure 4.4. 
Quantification of staining using image analysis can be found in figure 4.5. Short 
timecourses of cytokine treatment at all timepoints had significant effects on the 
eventual mineralisation of the primary calvarial cells. Treatment for 48 hours on day 0, 
3 and 7 showed almost no alizarin red staining, suggesting  no calcium deposition, on 
day 28, although there did appear to be some nodule formation. Treatment on day 14 
had less effect than other timepoints, but calcium deposition was very much reduced, 
with around 5% staining compared to control. Hoffman contrast images show the 
reduced deposition of calcium.   
The osteo-mESCs were less noticeably affected by the cytokine treatment. Treatment 
on day 0 or 3 showed very little effect on alizarin red staining compared to control. 
Treatment on day 7, showed increased levels of staining across the well. Cytokine 
stimulation on day 14 showed the inverse to the primary calvarial cells, with staining 
levels decreased to around 50% of the control and staining appearing to be less 
concentrated. The non-osteogenic medium controls in both cell cultures (not pictured) 
showed minimal staining.  
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 Osteogenic Medium Proinflammatory cytokine treated at timepoint for 48 hours 
 Day 0 Day 3 Day 7 Day 14 
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Figure 4.3: Effect of proinflammatory cytokines on calcium deposition of primary calvarial cells.  Cells were stimulated with IL-ȕ
71)ĮDQG,)1-ȖIRU 48 hours at either day 0, day 3, day 7 or day 14 of osteogenic culture. Subsequently, culture media was returned to 
control osteogenic media until day 28 and calcium deposition was stained with alizarin red S. Representative images shown. Scale bars: 
Bone nodules=2 mm, Hoffman Contrast = 100 µm. 
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 Osteogenic Medium Proinflammatory cytokine treated at timepoint for 48 hours 
 Day 0 Day 3 Day 7 Day 14 
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Hoffman Contrast 
     
Figure 4.4: Effect of proinflammatory cytokines on calcium deposition of osteo-mESCs.  Cells were stimulated with IL-ȕ71)Į
and IFN-ȖIRU 48 hours at either day 0, day 3, day 7 or day 14 of osteogenic culture. Subsequently, culture media was returned to control 
osteogenic media until day 28 and calcium deposition was stained with alizarin red S. Representative images shown. Scale bars: Bone 
nodules=2 mm, Hoffman Contrast = 100 µm. 
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A 
 
B 
 
Figure 4.5: Quantification of effect of proinflammatory cytokines on calcium 
deposition. Percentage alizarin red staining was quantified for (A) Primary calvarial 
cells and (B) osteo-mESCs. Cells were treated with medium containing 1 ng/mL IL-
1ȕ, 10 ng/mL TNF-Į DQG  QJP/ ,)1-Ȗ for 48 hours at day 0, 3 and 7 of 
osteogenic culture. Subsequently, culture medium was returned to control osteogenic 
medium and experiment was ended on day 28. Values are corrected to proportion of 
osteogenic control. Mean±SD (n=6). 
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4.3.3 The effect of proinflammatory cytokines on the alkaline 
phosphatase activity of osteogenic cells 
Primary calvarial cells and osteo-mESCs were treated with proinflammatory cytokines 
at day 0, 3 and 7 of osteogenic culture for 48 hours. Medium was subsequently 
changed back to osteogenic medium and culture continued until day 14; at which 
point an ALP activity assay was performed. Figure 4.6 shows the effect that this acute 
proinflammatory cytokine treatment has on (A) primary calvarial cells and (B) osteo-
mESCs. Treatment of the primary calvarial cells for 48 hours at all 3 timepoints had a 
significant negative effect on the eventual ALP activity, with treatment on day 0 
having the largest effect. In osteo-mESC cultures, a significant effect was seen only 
with treatment on day 3 and this showed an increase in eventual ALP activity.  
 
4.3.4 The effect of proinflammatory cytokines on the 
expression of osteogenic proteins in primary calvarial 
and osteo-mESC cultures 
Production of ECM proteins associated with osteogenic differentiation was assessed 
by immunocytochemistry for OCN, OPN, col-I and cad-11. Double staining for OPN 
and OCN was performed to assess localised expression on the same sample. Figure 
4.7 shows primary calvarial cells and figure 4.8 shows osteo-mESCs. Cell cultures 
were treated with short exposure to proinflammatory cytokines for 48 hours at either 
day 0, 3, 7 or 14. Cell culture medium was then changed back to osteogenic and 
continued until day 28 to investigate eventual effect on matrix deposition. 
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Figure 4.6: Effect of proinflammatory cytokines on alkaline phosphatase 
activity. (A) Primary calvarial cells and (B) osteo-mESCs were treated with medium 
containing 1 ng/mL IL-ȕ, 10 ng/mL TNF-ĮDQGQJP/,)1-Ȗfor 48 hours at day 
0, 3 and 7 of osteogenic culture. Culture medium was returned to control osteogenic 
medium and experiment was ended on day 14. Alkaline phosphatase activity was 
assessed via pNPP assay and values corrected for DNA concentration. Values are 
represented as mean±SD, n=6, experiment repeated 3 times. **statistical significance 
of response to cytokines compared to  control (p<0.01). 
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Figure 4.7: Expression of osteopontin and osteocalcin in primary calvarial cells 
stimulated with proinflammatory cytokines. Cells were stimulated with IL-ȕ71)ĮDQG
IFN-Ȗ IRU 48 hours at either day 0, day 3, day 7 or day 14 of osteogenic culture. Culture 
medium was returned to control osteogenic medium and OPN (red) and OCN (green) 
expression assessed by immunocytochemistry on day 28. Representative images shown. 
Scale bar=90 µm. 
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Figure 4.8: Expression of osteopontin and osteocalcin in osteo-mESCs stimulated 
with proinflammatory cytokines. Cells were stimulated with IL-ȕ71)ĮDQG,)1-ȖIRU 48 
hours at either day 0, day 3, day 7 or day 14 of osteogenic culture. Culture medium was 
returned to control osteogenic medium and OPN (red) and OCN (green) expression 
assessed by immunocytochemistry on day 28. Representative images shown. Scale bar=90 
µm. 
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In primary calvarial cell cultures in control osteogenic medium, OCN and OPN were 
co-localised around bone nodule areas, with OCN deposited in the centre of the 
nodule and OPN more dispersed. When primary calvarial cells were treated with 
cytokines on day 0, there was no eventual bone nodule formation or deposition of 
OPN and OCN on day 28. A similar result occurred with treatment on day 3, although 
there was a little more evidence of bone nodule formation, as seen in the phase 
contrast image. Proinflammatory cytokine treatment for 48 hours on day 7 appeared 
to allow limited eventual nodule formation and there was marked reduction in staining 
for OPN and OCN. With treatment at day 14, nodules had formed and there was 
evidence of both OCN and OPN staining. 
Figure 4.8 shows staining of OCN and OPN in osteo-mESCs. Phase contrast images 
showed the cultures are densely packed and contained a heterogeneous population 
of cells. In control osteogenic medium, after 28 days, the osteo-mESCs showed co-
localised staining for OCN and OPN in what appear to be nodular areas. Across the 
cytokine treatment timepoints, there were very few obvious differences in staining 
between groups, and nodules appeared to form regardless of proinflammatory 
cytokine treatment. 
Staining for cad-11 and col-I in primary calvarial cultures can be seen in figure 4.9. In 
osteogenic medium controls, col-I can be found in and around the bone nodules and 
is localised in areas where there is a high level of cad-11. As with OCN and OPN 
staining, proinflammatory cytokine treatment on day 0, led to zero nodule formation, a 
large amount of cell death and no col-I or cad-11 staining. When treated on day 3, 
cells survived until day 28 and there was some evidence of nodule formation with a 
few involving cad-11 positive cells. Very little col-I was seen. Treatment on day 7 
allowed nodule formation involving cad-11 cells and some col-I deposition. Cytokine 
treatment on day 14 had a reduced effect on  col-I staining. 
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Figure 4.9: Expression of cadherin-11 and collagen-I in primary calvarial cells 
stimulated with proinflammatory cytokines. Cells were stimulated with IL-ȕ71)ĮDQG
IFN-Ȗ IRU 48 hours at either day 0, day 3, day 7 or day 14 of osteogenic culture. Culture 
medium was returned to control osteogenic medium and cadherin-11 (red) and collagen-I 
(green) expression assessed by immunocytochemistry on day 28. Representative images 
shown. Scale bar=90 µm. 
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Figure 4.10: Expression of cadherin-11 and collagen-I in osteo-mESCs stimulated with 
proinflammatory cytokines.  Cells were stimulated with IL-ȕ 71)Į DQG ,)1-Ȗ IRU 48 
hours at either day 0, day 3, day 7 or day 14 of osteogenic culture. Culture medium was 
returned to control osteogenic medium and cad-11 (red) and col-I (green) expression 
assessed by immunocytochemistry on day 28. Representative images shown. Scale bar=90 
µm. 
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Figure 4.10 shows cad-11 and col-I expression in osteo-mESC cultures. Col-I staining 
was widely dispersed across the cultures, but appeared most strong in areas of cad-
11 staining. There was no obvious negative effect of proinflammatory cytokine 
treatment on levels of cad-11 or col-I staining. There may have been an enhanced 
effect on col-I staining with treatment on day 7, but this was difficult to quantify. 
 
 
4.3.5 Cadherin-11 sorting of osteo-mESCs 
In order to reduce heterogeneity within the differentiated osteo-mESCs and to 
investigate levels of osteogenesis, cell sorting for preosteoblasts was attempted. After 
16 days osteogenic culture, osteo-mESCs were sorted via MACS for the presence of 
cad-11. Figure 4.11 shows box-plots illustrating data distribution of cell sorting. The 
average percentage of cad-11 positive cells was 21.2% and numbers were 
comparable between cell sorting experiments. Figure 4.12 shows phase contrast 
images of cad-11 positive and negative cell populations. Before cell sorting, the 
osteo-mESCs were a densely packed heterogeneous cell population. After cell 
sorting, cell morphology differences can be seen between cad-11 positive and 
negative cells. By day 7, the cad-11 positive cells displayed a morphology more 
similar to that of primary calvarial cells and by day 21, formed what appeared to be 
bone nodules. The cad-11 negative cells showed a mix of distinct cell morphologies 
and over time developed more heterogeneity across the cell population. 
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Figure 4.11: MACS sorting for cadherin-11. Box-plots showing data distribution of 
percentage of cadherin-11 positive and negative cells (n=6). 
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Figure 4.12: Representative phase contrast images of osteo-mESCs before and 
after MACS sorting for cadherin-11. Scale bar=46 µm. 
Chapter 4 Effect of Proinflammatory Cytokines on Osteogenic Differentiation 
  139 
4.3.5.i Osteogenic potential of cadherin-11 sorted osteo-mESCs 
Immunostaining for OCN and OPN after cell sorting can be seen in figure 4.13. In 
cad-11 positive osteo-mESCs, bone nodule-like structures were seen within the 
cultures. Within these nodules, OCN staining was seen around the edge and OPN 
distributed in the nodule centre. In cad-11 negative osteo-mESCs, there was weak 
staining for OCN, but no OPN was seen. No nodule-like structures were observed. 
Figure 4.14 shows col-I staining in cad-11 positive and negative osteo-mESCs. In the 
cad-11 positive cultures, there was a substantial amount of staining in a web-like 
mesh around the cells. Col-I is present in the cad-11 negative cultures but staining 
was globular and less defined, and was sparse across the culture. 
Matrix mineralisation by the cad-11 positive and negative osteo-mESCs was 
investigated by alizarin red staining for calcium deposits. Figure 4.15A shows macro-
well staining of calcium deposition and figure 4.15B shows quantification of the 
alizarin red images. Nodule formation with calcium deposition was seen at much 
higher levels in the cad-11 positive cells than negative. Calcium deposition had begun 
by day 7, but nodule number continued to increase and staining became denser over 
the 21-day period. Very little staining was seen in the cad-11 negative cells. By day 
21, there was some staining for calcium, but this did not appear to be in nodules, 
when compared to the cad-11 positive cells. Figure 4.16 shows higher magnification 
images of the calcium deposition staining, with Hoffman contrast, and fluorescent 
images of the alizarin red stain. These images show that the cad-11 positive cells 
form discrete nodules within the cultures with distinct areas of calcium deposition. The 
cad-11 negative cells showed areas of alizarin red staining, but calcium deposition 
was less dense and nodules were difficult to discern. 
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Figure 4.13: Osteocalcin and osteopontin expression in cadherin-11 sorted 
cells. Cells were sorted for cadherin-11 via MACS and cultured in osteogenic 
medium for 21 days. Representative images show immunocytochemistry of OCN 
(green) and OPN (red). 6FDOHEDUV ȝP. 
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Figure 4.14: Collagen-I expression in cadherin-11 sorted cells. Cells were sorted 
for cad-11 via MACS and cultured in osteogenic media for 21 days. Representative 
images show immunocytochemistry of Col-I expression. 6FDOHEDUV ȝP. 
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Figure 4.15: Calcium deposition by cadherin-11 sorted osteo-mESCs.  (A) 
Representative images of alizarin red staining of casherin-11 sorted osteo-mESCs. 
Cells were sorted via MACS and subsequently cultured in osteogenic media for up to 
21 days. Cells were fixed in 10% formalin at timepoints and stained with alizarin red 
S.  Scale bar=2 mm (B) Images were quantified using imageJ software to show 
percentage area stained. Values represent mean±SD (n=6). 
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Figure 4.16: Bone nodule formation of cadherin-11 sorted osteo-mESCs. Cells 
were sorted via MACS and subsequently cultured in osteogenic media for up to 21 
days. Cells were fixed in 10% formalin at timepoints and stained with alizarin red S. 
Fluorescent images of alizarin red S taken under TRITC filter. Representative images 
shown. Scale bar: (10x)=100 µm, (40x)=40 µm. 
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4.3.5.ii Response of cadherin-11 sorted osteo-mESCs to proinflammatory 
cytokines 
The response of the cad-11 sorted osteo-mESCs to the presence of IL-1ȕ71)-ĮDQG
IFN-ȖLQWKHFXOWXUHPHGLXPZDVLQYHVWLJDWHGWRH[DPLQHGLIIHUHQFHVWRSUHYLRXVGDWD
of non-sorted cells. Cytokines were added to the medium for 48 hours, at either 7 or 
14 days after cell sorting. At these points, medium samples were collected, and cell 
monolayers fixed. 
Figure 4.17 shows nitrite concentrations at (A) day 7 and (B) day 14. Higher 
production of NO occurred in response to proinflammatory cytokines, compared to 
control medium, in both cad-11 positive and negative cells, at both timepoints. 
However, on day 7 and day 14, NO was produced in significantly higher amounts by 
the cad-11 positive cells when compared to the cad-11 negative cells. Total 
concentration of nitrite in the medium was comparatively higher when cells were 
stimulated on day 7 than day 14.  
Figure 4.18 shows PGE2 concentrations in medium at (A) day 7 and (B) day 14. As 
with nitrite, significant amounts of PGE2 were produced by both cad-11 positive and 
negative cells, at both timepoints, in response to the presence of proinflammatory 
cytokines. Conversely, to the nitrite results, PGE2 production in cytokine medium at 
day 7 was higher in cad-11 negative cultures than cad-11 positive, but this was also 
true of cad-11 negative cells in control medium. By day 14, levels of PGE2 produced 
by both positive and negative cells had fallen dramatically, compared to day 7. At day 
14, production in cad-11 positive cells was higher than that of cad-11 negative.  
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Figure 4.17: Nitric oxide response of cadherin-11 sorted osteo-mESCs to 
proinflammatory cytokines. Osteo-mESCs were sorted for cad-11 expression via 
MACS. Sorted cells were treated with IL-1ȕ, TNF-ĮDQG ,)1-Ȗ at (A) day 7 and (B) 
day 14 after sorting. Nitrite concentration was measured in medium 48 hours after 
cytokine treatment. Values are represented as mean±SEM, n=9, ***Statistical 
significance of cytokine treated versus control (S0.001) ###Statistical significance of 
cad-11 negative versus cad-SRVLWLYHS. 
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Figure 4.18: PGE2 response of cadherin-11 sorted osteo-mESCs to 
proinflammatory cytokines. Osteo-mESCs were sorted for cad-11 expression via 
MACS. Sorted cells were treated with IL-1ȕ, TNF-ĮDQG ,)1-Ȗ at (A) day 7 and (B) 
day 14 after sorting. PGE2 concentration was measured in medium 48 hours after 
cytokine treatment. Values are represented as mean±SEM, n=9. Statistical 
significance of cytokine treated versus control ***S0.001)S. Statistical 
significance of cad-11 negative versus cad-11 positive #S0.5). 
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Figure 4.19 shows expression of the iNOS enzyme by the sorted cells, in response to 
proinflammatory cytokines. Results are largely comparative with those of NO 
production shown in figure 4.16. Staining of iNOS was seen only in cad-11 positive 
cells that   had been stimulated with proinflammatory cytokines, not control cultures. 
More staining was seen on day 7 than day 14, but both cultures showed staining 
reminiscent of cytokine-induced iNOS production in the primary calvarial cells (see 
figure 3.8). Staining in cad-11 negative cultures appeared only in cells cultured with 
cytokines. iNOS was staining was marked in some  cells, but was not present 
throughout the culture. This occurred on both day 7 and day 14. 
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Figure 4.19: iNOS expression in cadherin-11 sorted osteo-mESCs stimulated 
with proinflammatory cytokines. Cells were stimulated with IL-ȕ71)ĮDQG,)1-Ȗ
for 48 hours, at day 7  or day 14 after cell sorting. iNOS expression in both 
proinflammatory cytokine stimulated and control cultures were assessed at this time 
by immunocytochemistry. Representative images shown. 6FDOHEDUV ȝP 
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4.4  Discussion 
7KHDLPRIWKLVFKDSWHUZDVWR LQYHVWLJDWHWKHHIIHFWVWKDW µVKRUWEXUVWV¶RUH[SRVXUH
periods of proinflammatory cytokine stimulation may have on the eventual osteogenic 
differentiation of both osteo-mESCs and primary calvarial cells. Osteogenic 
differentiation of the mESCs was also further investigated by cell sorting for putative 
osteoprogenitors with the cad-11 marker.  
In vitro osteogenic differentiation of primary osteoblasts and osteogenically 
differentiated ESCs have both been well described, but there have been few 
comparative studies. In this investigation, both cell types showed expression of 
markers indicative of osteogenic differentiation and formed nodules comprising 
mineralizing matrix, as has been previously described [60, 162, 246]. Both cell types 
expressed proteins associated with osteoblast differentiation such as OPN, OCN and 
col-I, particularly in areas with cellular nodules. Nodules like these are believed to 
show features of embryonic woven bone in their biochemical and morphological 
characteristics [247, 248]. Expression of the cell-to-cell adhesion molecule cad-11, 
found in high levels on osteoblasts, and important in the formation of mesenchymal 
tissues in embryo development, was seen in both cell types [249, 250]. Morphology of 
the osteogenic embryonic stem cell cultures showed a more heterogeneous 
population than that of the primary calvarial cells and within nodules there were a 
larger number of nuclei.  
Many authors have published work showing the similarity of ESC-derived osteogenic 
cells to that of osteoblasts, in terms of protein expression, gene expression, mineral 
deposition and in vivo models, using established osteogenic differentiation protocols 
[60, 61, 164, 190, 191]. The efficacy of these protocols has been called into question 
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and detailed comparative studies have been minimal [61, 192, 193]. In the previous 
chapter, distinct differences in the biochemical response of the two cell types to 
cytokines were demonstrated, despite the phenotypic similarities shown by 
expression of osteogenic markers, in this chapter. This suggests that more in depth 
studies showing possible differences in osteogenic differentiation of ESCs compared 
to primary osteoblasts are required. In 2009, Gentleman et al. used a materials 
science approach to compare mineralised nodules of neonatal mouse osteoblasts, 
bone marrow derived-MSCs and mESCs. They concluded that the bone nodules 
formed by mESCs showed distinct differences to those of the osteoblasts and MSCs 
in terms of formation time, production of the collagen-II intermediary stage and 
Raman spectra of mineral structure. The mESCs showed a less complex structure 
that showed a higher level of crystallinity [192]. Differences in the levels of gene 
expression between the two cell types were found in this study, with the osteo-
mESCs expressing lower levels of Runx2, Col1a1 and Opn. This may be because the 
osteo-mESCs were at a different stage of differentiation to the primary cells or be 
because within the cultures there is a heterogeneous population of cells that dilute the 
osteogenic cell population. 
The cytokines used throughout these studies have well known effects as signalling 
molecules and mediators of the inflammatory response. The role of these cytokines in 
bone regeneration and fracture healing is less well established. In this study, cells 
ZHUHH[SRVHG WR µVKRUWEXUVWV¶RI ,/-ȕ71)-ĮDQG ,)1-Ȗ WUHDWPHQW$Q\HIIHFWVRQ
eventual osteogenic differentiation, depending on the timepoint of cell culture were 
then assessed. Throughout the studies, the primary calvarial cells showed large 
responses to the transient exposure of proinflammatory cytokines, which had knock-
on effects on the final differentiation state. When treated on day 0 or day 3, the cells 
tended to survive the 48 hours in the presence of the cytokines but then viability 
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would begin to drop. Cells did survive for the full differentiation protocol but subjective 
observation showed final cell number was significantly reduced. This had the effect 
that bone nodules did not form and matrix was not deposited. The effect was more 
noticeable on day 0 than day 3. IL-ȕ71)-ĮDQG,)1-ȖKDYHSUHYLRXVO\EHHQVKRZQ
to cause apoptosis of osteoblasts, particularly when applied in combination [183, 184, 
251], this may have caused many of the eventual effects seen on cell differentiation. 
Overall, in this study, cytokine treatment of primary calvarial cells caused decreased 
calcium deposition, ALP activity and inhibited matrix formation (OCN, OPN and col-I). 
The effects of the cytokines seemed to decrease at later stages of differentiation, but 
could still be seen with cytokine treatment at day 14, the latest timepoint performed.       
Many previous reports have focused on the effects of individual cytokines on 
osteoblast differentiation; but when used in combination, more similarly to the in vivo 
environment, effects are often synergistic and can be enhanced [252, 253]. 
Individually, in terms of osteoblast function, IL-ȕ DQG 71)-Į KDYH YHU\ VLPLODU
actions:  inhibition of bone nodule formation, decreased ALP activity, inhibition of 
OCN production and inhibition of col-I deposition, both in mouse and human 
osteoblasts [110, 114, 174, 254-256]. Many of these effects are partially mediated by 
NO, prostaglandins and the COX-2 pathways, which were shown in the previous 
chapter to be stimulated by the presence of proinflammatory cytokines [173, 186]. IL-
1 and TNF can initially act as mitogens, causing increased proliferation of osteoblasts 
and increased DNA synthesis; slowing rates of differentiation [112, 173]. The effect of 
the treatment of osteoblasts with IFN-ȖDUHVOLJKtly different. IFN-ȖKDVEHHQVKRZQWR
cause inhibition of osteoblast proliferation and increased ALP activity, however OCN 
synthesis and col-I deposition are still inhibited [86, 121, 122]. There is also evidence 
that IFN-ȖPD\ LQKLELW VRPH RI WKH ERQH UHVRUSWLRQ FDXVHG E\ ,/-1 [177, 257]. The 
results produced in this investigation substantiate previous results and show that 
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there is an enhanced inhibitory effect by the proinflammatory cytokines when used in 
combination, with the effects of IL-1 most prominent, even though the duration of 
cytokine treatment was short. 
In this study, the mESCs showed a very different response to the presence of 
proinflammatory cytokines when compared to the primary calvarial cells, and the 
importance of timepoint of cytokine signal appeared to be of greater significance. The 
results also mirrored those seen in the previous chapter, with very little visible 
response from the osteo-mESCs when treated with cytokines in the early stages of 
differentiation. The largest effects in the study were seen on calcium deposition of the 
osteo-mESCs. Final levels of calcium deposition were not affected when cells were 
treated at the early timepoints of day 0 or day 3, but when treated at day 7, levels of 
matrix calcium appeared to increase and when treated on day 14, the inverse 
occurred, with levels of calcium staining falling. ALP activity was enhanced only when 
cytokine treatment occurred on day 3. The immunocytochemistry showed very few 
differences in osteogenic matrix deposition in response to cytokines, although there 
may have been enhanced matrix formation with treatment on day 7, which would 
correlate with enhanced calcium deposition. In order to show more definitively 
whether the cytokines were having an effect on the osteogenic differentiation of the 
mESCs, more in-depth studies would need to be performed looking at quantitative 
gene expression or protein expression, and possibly with more timepoints or longer 
exposure to the cytokines. Cytokine signalling had a dramatic effect on the primary 
calvarial cells and has been shown to have a large effect on bone development, thus, 
it would be reasonable to assume that there would eventually be an effect on 
osteogenic differentiation of mESCs. For the moment, these results show that in the 
early stages of differentiation, when no cell sorting has been performed, there is very 
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little effect of short burst proinflammatory cytokine signalling on the osteogenic 
differentiation of mESCs.  
There has been very little study  of the effects of cytokines on osteogenic 
differentiation of ES cells; more has been performed investigating the effect on MSCs. 
Proinflammatory cytokines have been shown to both inhibit and enhance osteogenic 
differentiation of MSCs. Overall, Runx2 and collagen expression appears to be 
inhibited, but ALP and mineralisation has been described as both enhanced and 
repressed [187, 258-260]. I believe that the discrepancy in in vitro results can be 
attributed to varying doses of the cytokine, different stage of differentiation at 
treatment time and varying length of cytokine exposure. These studies were 
performed with only one cytokine and previous studies show that the use of cytokines 
in combination is more realistic and may give differing results. The overwhelming 
conclusion is that considerably more study can be performed looking at the effect of 
proinflammatory cytokines on stem cell differentiation, as there is a wealth of 
knowledge to be gathered.   
Due to how little is known about the efficacy of the current osteogenic differentiation 
protocols for ES cells, and the apparent heterogeneous cell populations that were 
seen in the early differentiation work, it was decided to perform cell sorting for a more 
osteogenic population within the mESCs. There is no definitive, well-characterised 
marker of the early osteoblast and most often, panels of markers are used to 
determine whether osteogenic differentiation has occurred. Osteogenesis of ES cells 
often requires first inducing ES-derived MSCs, sometimes using cell-sorting 
techniques [191, 261]. The intention in this study was to avoid the need to perform 
this step and harvest directly a population of osteogenic cells from the mESC 
cultures. MACS was chosen as the method of choice for cell sorting, due to ease of 
use, but this required the identification of a cell surface marker associated with 
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osteoblasts. Cad-11 has previously been used to purify ES cells, and appeared to be 
a good candidate in this case [243]. Previous immunostaining of the osteo-mESCs 
had shown that the protein was being expressed by day 18, but it was decided to take 
the timepoint of sorting back to day 16, to attempt to purify early differentiation 
osteogenic cells. In the cell sorting experiments a cad-11 positive ratio of about 21% 
was acheived, which was considerably less than had been previously described 
[243]. It is also worth noting that during MACS, there was a substantial reduction in 
the number of cells by the end of the process, and after seeding, many of the cells did 
not attach to the plate. This may have skewed the data somewhat, and in future, it 
would be advantageous to optimise this process further to attempt to achieve higher 
numbers of cad-11 positive cells.  
The MACS data demonstrates the potential of using cad-11 to purify an osteogenic 
cell population from mESCs. The cad-11 positive cells differentiated to osteoblasts as 
intimated by cell morphology, compared to primary calvarial cells, formation of bone 
nodules and expression of osteogenic markers OCN, OPN and col-I. When 
comparing results to the previous results from unsorted osteo-mESCs, nodules were 
more defined, with distinct ECM deposition, particularly with col-I. The cad-11 
negative population showed a more heterogeneous population of cells, and minimal 
bone nodule formation and staining for osteogenic ECM proteins. The success of the 
cad-11 sorting may indicate that if performed on human cells, a STRO-1/ALP/cad-11 
sorting procedure would yield a highly purified population of osteoblasts. However, it 
may be that these markers target a similar population of cells and increasing the 
complexity of the sorting procedure would not improve the purity of cell yield. An 
advantage of using cad-11 as a marker, as opposed to STRO-1, is the level of 
characterisation the cell surface marker has received [244, 250, 262, 263]. 
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To expand the cell-sorting investigation, it was decided to study the effect that the 
proinflammatory cytokines would have on the response of the cad-11 positive and 
negative fractions. Both cad-11 positive and negative cells responded to the presence 
of the cytokines by producing NO and PGE2, similarly to the previous results of the 
primary calvarial cells. These results appear to be very different to the early response 
of the unsorted osteo-mESCs, but by day 7 after cell sorting, the cells would have 
been under osteogenic differentiation for 23 days, and it was shown previously that 
the unsorted cells begin to respond by this point. It is clear that NO response to 
cytokines is higher in the cad-11 positive fraction than cad-11 negative cells. 
However, there was no statistical difference in PGE2 response at 7 days after sorting, 
between cad-11 positive and negative cells, and only a slight difference at 14 days. It 
is also interesting to note that at 14 days after cell sorting, levels of both NO and 
PGE2 production were lower than at 7 days. This decrease in production with 
progressive differentiation also occurred with the primary calvarial cells (see chapter 
3). Staining of iNOS expression in the cad-11 positive and negative fractions allowed 
better visualisation of the response of the cells to the cytokines. In positive cultures, 
iNOS expression appeared to occur across the entire cell population, particularly at 
day 7. Whereas, in negative cultures iNOS was only expressed in certain cells of the 
population, adding weight to the belief that this is still a highly heterogeneous 
environment. Many cell types, such as fibroblasts and epithelial cells [264-266], 
respond to the presence of these cytokines with the production of NO and PGE2, and 
it may be that the cad-11 negative mESCs had differentiated to cells other than the 
osteoblast, despite being cultured in osteogenic medium. These results taken 
together support the belief that in sorting for cad-11, a population of cells that reacts 
more similarly to the early osteoblast has been purified. The cad-11 adhesion 
molecule has previously been associated with inflammation, particularly in the 
synovium, and may play an important part in inflammatory arthritis [267, 268]. So it 
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may be that in sorting for this protein, a population of cells was unearthed that was 
more likely to react to the presence of the cytokines, and therefore selecting a cad-11 
positive population of cells is no optimal when thinking about differentiation of ES 
cells for therapeutic purposes.  
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Chapter 5:    
Control of Inflammation: An in vitro 
osteoblast inflammation model and 
manufacture and testing of anti-
inflammatory releasing scaffolds 
5.1  Introduction 
5.1.1 Overview 
In the case of non-union fractures, large bone-defects or diseases such as RA or OP, 
the environment of implantation for tissue engineered therapy will likely be one of 
inflammation and imbalanced bone healing. There are many drugs available, of 
different mechanisms of action, which can be used to modulate and control this 
inflammatory environment. In this chapter, the effect of these anti-inflammatory drugs 
on a calvarial osteoblast inflammation model is studied. This is then extended into the 
investigation of release of anti-inflammatory drugs from porous scaffolds, and the 
effect of this release on the calvarial osteoblast inflammation model.  
 
5.1.2 Bone and fracture healing 
Bone is a highly vascularised and dynamic tissue that provides structural support and 
protection to the soft tissue of the body [66]. Under normal circumstances, bone has 
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significant capacity for repair and regeneration and is one of the few tissues that can 
heal without a scar [269]. Fundamentally, fracture healing consists of three stages: 
inflammation, repair and remodelling. The initial inflammatory phase plays a critical 
role in healing and many of the processes that occur at this stage may determine the 
outcome of bone repair. Fracture healing involves several cytokines and growth 
factors, including those previously discussed. Within 24 hours of bone injury, 
neutrophils and macrophages will have migrated into the wound site and levels of 
TNF-Į ,/-Į ,/-ȕDQG ,/-6 will reach their peak [270]. These cytokines, alongside 
TGF-ȕDQGSURWHLQVRIWKH%03IDPLO\OHDGWRUHFUXLWPHQWRIPRUHLQIODPPDWRU\FHOOV
promotion of angiogenesis and mesenchymal stem cell differentiation [271]. This 
acute inflammatory phase usually lasts for one week, after which inflammatory 
mediators return to baseline levels [272-274]. During the remodelling phase of 
fracture healing, the expression levels of cytokines such as IL-1, TNF-ĮDQG,/-6 rise 
once more, but do not reach the levels of the acute inflammatory response. Due to 
the complexity of events during the fracture healing process, there can occasionally 
be clinical instances where inflammation fails to resolve the problem, such as 
inflammatory diseases, severe body reactions and non-union fractures [275]. These 
instances provide targets for tissue engineering and regenerative medicine strategies.  
 
 
5.1.3 Non-union fractures and bone defects 
For a fracture to be defined as non-union there is required to have been a period of at 
least 9 months after injury, without fracture healing, during which time multiple 
therapies will have been attempted. Systemic factors that can lead to non-healing of 
fractures include: malnutrition and vitamin deficiency, particularly vitamin B6; diabetes 
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with sensory neuropathy; smoking and nicotine usage; osteoporosis, and the use of 
NSAIDs. Local factors within the bone such as infection, lack of vascularisation, 
biomechanical instability, poor bone contact (large defects or bone displacement) and 
complications after surgery, can also lead to non-unions [276] 7KH FXUUHQW ³JROG-
VWDQGDUG´ WUHDWPHQW IRU QRQ-union fractures and defects is autologous bone grafts; 
however, such grafts are limited due to availability and can have disadvantages such 
as donor site morbidity, additional surgery and chronic pain for the patient [277].  
 
 
5.1.4 Bone substitutes and inflammation 
Many tissue engineering and regenerative medicine strategies have been devised for 
the treatment of non-union fractures and bone defects, predominantly involving the 
SURGXFWLRQRIERQHVXEVWLWXWHV7KHVH³ERQHVXEVWLWXWHV´QHHGVWRSURYLGHELRSK\VLFDO
stability, support cell growth and aid bone regeneration. Both biological and synthetic 
materials for bone repair have been reported, such as collagen [278], demineralised 
bone matrix (DBM) [279], porous metals [280], glass ceramics [281], calcium 
phosphates [282] and synthetic polymers [283].  All these materials have advantages 
and disadvantages. A disadvantage of any tissue-engineered therapy is inflammation, 
adverse tissue response and foreign body reaction, caused upon implantation and 
degradation [284, 285]. Adapting a bone tissue engineering scaffold to release anti-
inflammatory mediators may enhance the properties of the therapy and improve 
success rates upon implantation [286]. 
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5.1.5 Anti-inflammatory drug release 
A critical advantage of local delivery of anti-inflammatory drugs via scaffolds, rather 
than systemic delivery, is the ability to bypass some of the side effects that can occur 
with drug treatment. Anti-inflammatory drugs that have been used in bone disease 
include steroids (glucocorticoids), non-steroidal anti-inflammatory drugs (NSAIDs), 
bisphosphonates and disease modifying anti-rheumatic drugs (DMARDs).   
 
5.1.5.i Glucocorticoids 
Glucocorticoids such as dexamethasone or prednisolone are often used to treat 
chronic inflammation, such as that found in RA. Glucocorticoids bind to glucocorticoid 
receptors (GR) that can be found on virtually all cell types. The act of binding to this 
receptor can  inhibit proinflammatory response through synthesis of anti-inflammatory 
proteins and repression of the NF-țB and AP-1 proinflammatory transcription factors, 
amongst others [287].  Glucocorticoids have wide-ranging effects and can have many 
side effects, including delayed fracture healing [288]. Other side-effects due to 
systemic treatment include hyperglycaemia (steroid diabetes), increased skin atrophy, 
muscle atrophy, eye problems such as glaucoma and cataracts, effects on the 
cardiovascular system such as hypertension, and effects on the gastrointestinal 
system [289]. Due to these properties and side effects, tissue engineering studies 
have focused on strategies to avoid systemic treatment and enable direct delivery of 
the drug to the point of inflammation, via release from polymeric scaffolds [290, 291]. 
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5.1.5.ii NSAIDs 
The term NSAID encompasses a wide variety of drugs, ranging from over-the-counter 
medications such as ibuprofen, diclofenac and aspirin, to prescription only drugs like 
celecoxib. NSAIDs are frequently used as pain relievers due to good analgesic 
qualities and lesser side-effects than opioids. NSAIDs target the COX enzymes that 
lead to prostaglandin production. The majority of NSAIDs block both COX-1 and 
COX-2 activity, but more recently, drugs have been developed that target COX-2 
specifically. There are four different mechanisms to NSAIDs inhibition of COX activity: 
aspirin covalently modifies a residue in the active site and irreversibly inactivates the 
enzyme; ibuprofen and diclofenac compete reversibly for the substrate binding site; 
indomethacin forms a salt bridge between a carboxylate and an arginine amino acid; 
and lastly some drugs can preferentially bind to COX-2 rather than COX-1 [292]. 
Common side-effects of taking NSAIDs include gastrointestinal ulceration and 
bleeding, hepato-renal dysfunction and skin reactions [293]. NSAIDs of all types have 
been reported to have both detrimental effects and no effect on bone healing in 
humans, and results from animal models are equally divided [294-297]. The COX 
enzymes, particularly COX-2, have been shown to play a role in bone regeneration 
and fracture healing, thus it would be reasonable to assume there may be some 
knock-on effect of COX inhibition on fracture healing [298, 299].  
Release of various NSAIDs, to aid in tissue engineering strategies has been shown 
by a variety of groups. Diclofenac has been released from PLGA particles [300],  
piroxicam and diclofenac from supercritical fluid emulsion PLGA particles [301] and 
ibuprofen from PLGA electrospun fibres [302] and polyurethane foam[303] .  
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5.1.5.iii DMARDs and Cytokine-Specific Antagonists 
Due to the negative effects of non-specific glucocorticoids, chronic inflammation is 
increasingly being treated using medications that specifically target proinflammatory 
cytokines. Cytokine specific inhibitors, particularly those that block TNF, are 
particularly effective in treating RA. These include the decoy receptor construct 
etanercept (Enbrel; Pfizer), which binds to free TNF, reducing the amount present in 
inflammation, and monoclonal antibodies such as infliximab (Remicade; Janssen 
Biotech) and adalimumab (Humira; Abbott) that attach to TNF-Į and stop receptor 
binding. Other agents block interleukin activity in inflammation, such as tocilizumab 
(Actemra; Roche), an IL-6 receptor antibody and anakinra (Kineret; Amgen), a 
recombinant IL-1ra protein [145].  Side effects of some of these drugs are yet to be 
elucidated, but can include problems such as increased risk of serious infections, B-
cell depletion and gastrointestinal problems [304]. Little work has been performed 
studying the release of these drugs from tissue engineering scaffolds, but one 
example is the release of IL1-ra from PLGA microspheres for the purpose of treating 
metastatic cancers [305].  
 
5.1.6   In vivo and in vitro models for evaluating anti-
inflammatory tissue engineering strategies 
Current validation methods for testing the properties and effectiveness of anti-
inflammatory drugs released as part of  tissue engineering studies are predominantly 
in vivo animal models such as subcutaneous-suture-induced inflammation, induced 
mono-articular arthritis, wound models, carrageenan-oedema and air pouch models 
[136, 290, 291]. In vitro models include the use of tissue slices, including those of rat 
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mandible [306-308]. In this chapter, a simple in vitro calvarial osteoblast inflammation 
model is used, developed based on observations and techniques investigated in 
previous chapters. This model is then been used to evaluate anti-inflammatory drug 
release from a scaffold intended for bone repair. The in vitro model is not intended to 
replace animal models, but offers a simple initial step to gather information about 
levels of effectiveness of drug release from scaffolds.  
 
   
 
  
Chapter 5 Control of Inflammation 
  164 
5.2  Experimental Design 
For more detailed methods describing primary calvarial cell extraction and culture and 
manufacture of PLGA/PEG scaffolds and assay protocols see Chapter 2. 
 
5.2.1  In vitro calvarial osteoblast inflammation model 
A simple in vitro calvarial osteoblast inflammation model was developed based on 
results from previous chapters. Primary calvarial cells were chosen due to their 
significant response to the presence of proinflammatory cytokines. Cells were 
cultured in monolayer, in well-plates for 14 days in osteogenic medium (50 mM BGP 
and 50 µg/mL ascorbate 2-phosphate). The timepoint of 14 days was chosen as 
during this time the cells will produce osteogenic matrix and a high level of response 
to IL-ȕ71)-ĮDQG,)1-ȖFDQEHLQGXFHG LQWHUPVRI nitrite and PGE2 (see figures 
3.6 and 3.7). The concentration of cytokines added to the medium was generally 0.25 
ng/mL IL-ȕ  QJP/ 71)-Į DQG  QJP/ ,)1-Ȗ XQOHVV RWKHUZLVH VWDWHG
Concentrations were based on the dose response work performed (figure 3.13 and 
3.14). Cell response was monitored via viability measurements (MTS, LDH and 
OLYHGHDGDQG NO and PGE2 production. 
 
5.2.2  Validation of the in vitro calvarial osteoblast 
inflammation model using anti-inflammatory agents 
The anti-inflammatory drugs dexamethasone, diclofenac sodium, ibuprofen, 
prednisolone and piroxicam, and the recombinant protein IL-1ra, were tested for their 
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effect on the calvarial osteoblast inflammation model. Drugs were first dissolved in 
DMSO to improve solubility and DMSO concentration was accounted for non-drug 
controls. Response in both osteogenic control medium and osteogenic medium 
containing IL-ȕ71)-ĮDQG,)1-ȖZDVVWXGLHG. Primary calvarial cells were seeded 
in 96-well plates and cultured in osteogenic medium for 14 days, before being 
supplemented with the anti-inflammatory mediators and proinflammatory cytokines. 
Cell response was investigated after 3 days of drug presence, by MTS assay, nitrite 
accumulation in media and PGE2 production. 
 
5.2.3  Long-term effect of diclofenac sodium on the in vitro 
calvarial osteoblast inflammation model 
Diclofenac sodium was chosen as the anti-inflammatory drug to take into further, 
more in-depth studies, looking at longer-term cell viability and response, and effect on 
osteogenic differentiation. Diclofenac sodium was chosen for several reasons: 
NSAIDs show appealing properties as an anti-inflammatory in bone treatment; 
diclofenac has good solubility in water and stability over time; successful results in 
both PGE2 and nitrite inhibition in initial testing; and finally, more available literature 
describing release of diclofenac via various techniques [300, 309, 310] 
 
5.2.3.i Effect of diclofenac sodium on long-term cell viability 
Primary calvarial cells were cultured in 96-well plates in osteogenic medium, for 14 
days. Medium was subsequently changed to four groups: osteogenic control medium, 
medium with 100 µM diclofenac sodium, medium with proinflammatory cytokines and 
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medium with proinflammatory cytokines and 100 µM diclofenac sodium. MTS assays 
to assess cell viability were performed, on separate plates, on days 1, 3, 5, 7, 14 and 
21. 
 
5.2.3.ii Effect of diclofenac sodium on nitric oxide and PGE2 production 
Primary calvarial cells were plated as for the viability experiment above, and 
investigation performed with identical medium groups. Medium collections were 
carried out on days 0, 2, 6, 9, 13, 16, 20 and 27. Nitrite concentration within the 
medium was tested at all timepoints, via the Griess assay. Collected supernatants for 
days 0-6, 7-3, 14-20 and 21-27, were combined and PGE2 concentration tested by 
EIA.  
 
5.2.3.iii Effect of diclofenac sodium on osteogenic differentiation of primary 
calvarial cells 
Primary calvarial cells were cultured in 6-well plates for 14 days in osteogenic 
medium, before supplementation with 100 µM diclofenac sodium and/or IL-ȕ71)-Į
and IFN-Ȗ &HOOV ZHUH WKHQ FXOWXUHG IRU D IXUWKHU  GD\V LQ WKLV PHGLXP
Immunocytochemistry was performed for expression of OCN with OPN and col-I with 
cad-11. Antibody details found in tables 2.1 and 2.2. Hoechst 33258 nuclear 
counterstaining was performed and staining imaged using fluorescent microscopy.  
Note: Some of the data collection in this experiment was performed with assistance 
from Mr Thomas Heathman, as part of an EPSRC Doctoral Training Centre in 
Regenerative Medicine mini-project. 
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5.2.4  Release of diclofenac sodium from PLGA/PEG scaffolds 
intended for bone repair 
5.2.4.i PLGA/PEG scaffolds 
PLGA/PEG scaffolds were manufactured in moulds producing cylindrical scaffolds of 
12 mm length and 6 mm diameter. Scaffolds were sintered at 37°C for 3 hours before 
being used experimentally. SEM imaging of PLGA/PEG was kindly performed by Dr 
Cheryl Rahman, School of Pharmacy, University of Nottingham. In all experiments, 
scaffolds with different initial drug loading were produced in triplicate batches.  
 
 
5.2.4.ii Measurement of drug release from PLGA/PEG scaffolds. 
PLGA/PEG scaffolds were produced containing diclofenac sodium at concentrations 
of 1000, 800, 650, 450 and 300 µg/scaffold. Control scaffolds containing no 
diclofenac sodium were also manufactured. Scaffolds were placed into bijoux in 1.5 
mL PBS or 1.5 mL phenol red-IUHHĮ0(0, containing pen-strep. Release experiments 
are often performed into PBS, but as the scaffolds would later be used in a cell study 
in medium, phenol red-IUHH Į0(0 ZLWK  (v/v) pen-strep) was utilised. To 
determine drug concentrations released, medium was completely removed from the 
scaffolds and replacHGZLWKIUHVK3%6RUĮ0(0&RQFHQWUDWLRQRIGLFORIHQDFVRGLXP
within the release sample was measured by UV spectrophotometry at a wavelength 
of 276 nm. Concentration of drug was calculated using a standard curve. All scaffolds 
were produced in triplicate and each release sample was measured in triplicate. Initial 
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drug release was measured after 3 hours, daily for 4 days, then at certain timepoints 
until scaffolds had degraded or experiment end. 
Note: Some of the data collection in this experiment was performed with assistance 
from Mr Thomas Heathman and Mr Arif Abed, as part of EPSRC Doctoral Training 
Centre in Regenerative Medicine mini-projects. 
   
 
5.2.4.iii Use of calvarial osteoblast inflammation model to assess diclofenac 
sodium release from PLGA/PEG scaffolds 
To assess success of release of diclofenac sodium, the in vitro osteoblast 
inflammation model was utilised. Plates (24-well) were seeded with primary calvarial 
cells and cultured in osteogenic medium for 14 days. After this time, medium was 
removed and scaffolds placed into transwells above the cell monolayer (see figure 
5.1). Scaffolds with initial loading 0, 300, 650 and 1000 µg of diclofenac sodium were 
studied. Medium (2 mL to cover scaffold) was then replaced with either control 
osteogenic medium or osteogenic medium containing proinflammatory cytokines. 
Initial cytokine concentration was 1 ng/mL IL-ȕ  QJP/ 71)-Į DQG  QJP/
IFN-Ȗ$OOPHGLXPZDVFROOHFWHGDIWHUKRXUVGD\DQGUHSODFHGZLWKFRQWURORU
cytokine medium containing 0.25 ng/mL IL-ȕQJP/71)-ĮDQGQJP/,)1-Ȗ
This medium was collected after 24 hours on scaffold and cells (day 2) and replaced 
with medium containing 0.0625 ng/mL IL-ȕQJP/71)-ĮDQGQJP/,)1-
Ȗ7KLVPHGLXPZDVOHIWIRUDIXUWKHUGD\VGD\ until final collection. Experiments 
ended on day 7 and a Live/Dead assay performed on the cell monolayers. 
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Figure 5.1: Diclofenac sodium release from PLGA/PEG scaffolds experimental 
set-up. Scaffolds were placed into permeable transwells within a 24-well plate 
seeded with primary calvarial cells in osteogenic medium. Anti-inflammatory drug was 
then released into the culture medium. 
Transwell
Drug-Releasing 
Scaffold
Primary Calvarial
Cell Monolayer
Well
Culture 
Medium
Anti-Inflammatory 
Drug
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Media samples from day 1, day 2 and day 7 were tested for nitrite, PGE2 and LDH 
concentration, to determine effectiveness of released drug. These initial studies 
concentrate on the first 7 days of release, corresponding to the occurrence of acute 
inflammation upon scaffold implantation. Concentration of released diclofenac sodium 
was determined using collected medium samples and UV spectrophotometry.  
Note: Some of the data collection in this experiment was performed with assistance 
from Miss Emily Britchford, as part of an EPSRC Doctoral Training Centre in 
Regenerative Medicine mini-project.  
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5.3  Results 
5.3.1 Validation of calvarial osteoblast inflammation model 
using anti-inflammatory agents 
Basic validation of the primary calvarial cell inflammation model was carried out using 
a range of anti-inflammatory mediators. The effect of dexamethasone, diclofenac 
sodium and IL-1ra on cell viability was investigated, in medium with and without 
proinflammatory cytokines, over a range of drug concentrations. The ability of the 
drugs at different concentrations to inhibit cytokine-induced production of NO and 
PGE2 was also assessed.  
 
5.3.1.i Dexamethasone 
Validation results for the corticosteroid dexamethasone can be seen in figure 5.2. For 
cell viability (figure 5.2A), all values have been corrected to percentage of osteogenic 
control. The proinflammatory cytokine control shows a reduced cell viability of 
approximately 30%, and had the most noteworthy effect across all groups. At 
concentrations of over 500 µM, dexamethasone had a significant negative effect on 
cell viability, regardless of the presence of proinflammatory cytokines. At 
concentrations of 500 µM and under, dexamethasone significantly prevented the fall 
in viability caused by the effects of the cytokines. The ability of dexamethasone to 
inhibit NO production induced by IL-ȕ71)-ĮDQG,)1-ȖFDQEHVHHQLQILJXUH%
At all concentrations of dexamethasone, from 100 µM upwards, the levels of 
proinflammatory cytokine-induced nitrite were significantly reduced, with the most 
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A 
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Figure 5.2: Anti-inflammatory effect of dexamethasone. Primary calvarial cells 
were cultured for 10 days in osteogenic media and subsequently supplemented with 
dexamethasone and proinflammatory cytokines. (A) Cell viability, determined by MTS 
assay, after 3 days in either basal osteogenic or proinflammatory cytokine media, with 
dexamethasone at increasing concentrations.  Values are represented as mean±SD, 
n=6. (B) Nitrite concentration in media after 3 days proinflammatory cytokine and 
dexamethasone treatment.  Values are represented as mean±SD, n=6. (C) PGE2 
concentration in media after 3 days proinflammatory cytokine and dexamethasone 
treatment. Values are represented as mean±SD, n=4. For all results: #Statistical 
significance vs. proinflammatory cytokine control (0 µM dexamethasone S
*Statistical significance vs. osteogenic media S 
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notable effect at 500 µM. Dexamethasone inhibition of cytokine-induced PGE2 
production (figure 5.2C) also occurred across all concentrations.  
  
5.3.1.ii Diclofenac Sodium 
The results of the effect of diclofenac sodium on the inflammation model can be seen 
in figure 5.3. At concentrations of 500 µM and over, diclofenac had an inhibitory effect 
on cell viability, with a viability of 30% at 1 mM drug concentration. At a concentration 
of 250 µM, diclofenac prevented the drop in cell viability caused by the cytokine 
medium, but at 100 µM, the concentration of drug was not sufficiently high enough to 
prevent the actions of the cytokines. Proinflammatory cytokine induced nitrite (figure 
5.3B) was inhibited at concentrations of 250 µM and upwards, although at 1 mM this 
may be related to the drop in cell viability. PGE2 production was inhibited by the 
diclofenac sodium at all concentrations (figure 5.3C). 
 
5.3.1.iii IL-1ra 
The presence of IL-1ra in osteogenic medium had no negative effect on cell viability 
at any concentration (figure 5.4A). At the highest concentration of 1000 ng/mL, IL-1ra 
prevented the fall in cell viability caused by the actions of the cytokine medium. At 
500 ng/mL there was some preventative effect but not statistically significant. Below 
500 ng/mL, the presence of IL-1ra did not significantly affect viability. Likewise, IL-1ra 
only inhibited nitrite production at concentrations of 500 ng/mL and above (figure 
5.4B), although PGE2 was inhibited at concentrations of 100 ng/mL upwards (figure 
5.4C). 
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Figure 5.3: Anti-inflammatory effect of diclofenac sodium. Primary calvarial cells 
were cultured for 10 days in osteogenic media and subsequently supplemented with 
diclofenac sodium and proinflammatory cytokines. (A) Cell viability, determined by 
MTS assay, after 3 days in either basal osteogenic or proinflammatory cytokine 
media, with diclofenac sodium at increasing concentrations.  Values are represented 
as mean±SD, n=6. (B) Nitrite concentration in media after 3 days proinflammatory 
cytokine and diclofenac sodium treatment.  Values are represented as mean±SD, 
n=6. (C) PGE2 concentration in media after 3 days proinflammatory cytokine and 
diclofenac sodium treatment. Values are represented as mean±SD, n=4. For all 
results: #Statistical significance vs. proinflammatory cytokine control (0 µM diclofenac 
sodiumS6WDWLVWLFDOVLJQLILFDQFHYVRVWHRJHQLFmedia S 
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Figure 5.4: Anti-inflammatory effect of IL-1ra. Primary calvarial cells were cultured 
for 10 days in osteogenic media and subsequently supplemented with IL-1ra and 
proinflammatory cytokines. (A) Cell viability, determined by MTS assay, after 3 days 
in either basal osteogenic or proinflammatory cytokine media, with IL-1ra at 
increasing concentrations.  Values are represented as mean±SD, n=6. (B) Nitrite 
concentration in media after 3 days proinflammatory cytokine and IL-ra treatment.  
Values are represented as mean±SD, n=6. (C) PGE2 concentration in media after 3 
days proinflammatory cytokine and IL-1ra treatment. Values are represented as 
mean±SD, n=4. For all results: #Statistical significance vs. proinflammatory cytokine 
control (0 ng/mL IL-1ra S 6WDWLVWLFDO VLJQLILFDQFH YV RVWHRJHQLF media 
S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Results for prednisolone, ibuprofen and piroxicam can be found in Appendix  VII, and 
follow the same trends as the drugs described above. Taken together, all results  
validate that the simple bone inflammation model can give valuable information on the 
effects of anti-inflammatory drugs. 
  
5.3.2 Long-term effect of diclofenac sodium on the in vitro 
osteoblast inflammation model 
Diclofenac sodium was chosen as the anti-inflammatory drug to take forward into 
more in-depth studies of the bone inflammation model, for reason discussed in the 
experimental design section. Predominantly, diclofenac was chosen due to good 
performance in initial testing and desirable solubility properties, allowing the removal 
of DMSO from drug preparation steps. Duration of studies was increased, looking at 
cell viability and inhibition of nitrite and PGE2 production. The effect that the presence 
of diclofenac sodium had on osteogenic matrix deposition was also studied.  
 
5.3.2.i Effect of diclofenac sodium on 21-day cell viability 
Primary calvarial cells were cultured in osteogenic medium for 14 days before 
cytokines and diclofenac sodium added. Cell viability was monitored for the following 
21 days and values converted to a proportion of the osteogenic control reading for 
that day (figure 5.5). IL-ȕ 71)-Į DQG ,)1-Ȗ FDXVHG WKH PRVW QRWHZRUWK\ GURS LQ
viability over the 21 day period, to 32%. The presence of 100 µM diclofenac sodium 
caused a slight drop in viability over the 21 days, showing a slight toxicity to the cells. 
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Figure 5.5: Long-term effect of diclofenac sodium on viability of primary 
calvarial cells in proinflammatory cytokine media. Primary calvarial cells were 
cultured in osteogenic media for 14 days before investigation began. Proinflammatory 
cytokines were applied throughout the 21 day period. Diclofenac sodium was added 
to media at a concentration of 100 µM. Cell viability at timepoints was measured by 
MTS assay and absorbance values converted to percentage control. Values are 
represented as mean±SD, n=6. Experiment was repeated in triplicate (representative 
experiment shown). 
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With diclofenac sodium present alongside the cytokines, the fall in viability was less 
severe than cytokines alone, with a viability of 92% at day 14 and 62% at day 21. 
 
5.3.2.ii Effect of diclofenac sodium on proinflammatory cytokine-induced nitric 
oxide and PGE2 production 
The long-term effect of diclofenac sodium on NO (as nitrite) and PGE2 production in 
the bone inflammation model was investigated. Figure 5.6 and 5.7 show cumulative 
production of nitrite and PGE2 respectively, by the primary calvarial cells over a 27-
day period. Across all timepoints, the presence of IL-ȕ71)-Į DQG ,)1-Ȗ FDXVHG
significantly increased nitrite and PGE2 production, compared to control osteogenic 
medium and 100 µM diclofenac sodium alone. Nitrite accumulation in groups treated 
with both cytokines and diclofenac sodium was significantly lower across all 
timepoints than those with cytokines alone. However, nitrite levels in this group 
remained significantly higher than the controls. Diclofenac sodium was more effective 
in inhibiting PGE2 production; accumulated PGE2 concentration in the group treated 
with cytokines and diclofenac was very similar to controls across all timepoints. 
Diclofenac sodium was shown to maintain effectiveness as an anti-inflammatory in 
this model across a 27-day time period. 
 
5.3.2.iii Effect of diclofenac sodium on osteogenic differentiation of primary 
calvarial osteoblasts 
Figure 5.8 shows primary calvarial cell staining for  OPN and OCN, and the effect of 7 
days treatment of 100 µM diclofenac sodium and/or IL-ȕ71)-ĮDQG,)1-Ȗ1XFOHDU
staining with Hoechst has also been performed to show cell distribution/localisation. 
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Figure 5.6: Long-term effect of diclofenac sodium on cumulative nitrite 
production by primary calvarial cells in proinflammatory cytokine media. 
Primary calvarial cells were grown in osteogenic media for 14 days before 
investigation began. Proinflammatory cytokines were applied throughout the 27 day 
period. Diclofenac sodium was added to media at a concentration of 100 µM. Nitrite 
concentration in culture medium at timepoints was measured by Griess assay. Values 
are represented as cumulative mean±cumulative SD, n=6. Experiment was repeated 
in triplicate (representative experiment shown). *Statistical significance vs. IL-ȕ71)-
Į,)1-ȖS6WDWLVWLFDOVLJQLILFDQFHYV. control S 
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Figure 5.7: Long-term effect of diclofenac sodium on cumulative cytokine-
induced PGE2 production by primary calvarial cells. Primary calvarial cells were 
grown in osteogenic media for 14 days before investigation began. Proinflammatory 
cytokines were applied throughout the 27 day period. Diclofenac sodium was added 
to media at a concentration of 100 µM. Combined PGE2 concentration in media at 
timepoints was measured by enzyme-linked immunoassay. Values are represented 
as cumulative mean±cumulative SD, n=6. Experiment was repeated in triplicate 
(representative experiment shown). *Statistical significance vs. IL-ȕ71)-Į,)1-Ȗ
S6WDWLVWLFDOVLJQLILFDQFHYVFRQWURO S 
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Figure 5.8: Expression of osteopontin and osteocalcin in primary calvarial cells 
stimulated with proinflammatory cytokines and diclofenac sodium.  Primary 
calvarial cells were cultured in osteogenic media for 14 days, then for 7 days in 
osteogenic media containing 100 µM diclofenac sodium and/or IL-ȕ71)-ĮDQG,)1-
Ȗ Representative images of osteopontin (red) and osteocalcin (green) expression 
assessed by immunocytochemistry on day 21. Scale bar=90 µm. 
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Compared to osteogenic medium alone, treatment with proinflammatory cytokines 
produced smaller and less abundant nodules with dense OPN staining and little OCN. 
Hoechst staining showed that there were fewer cells within nodules relative to 
osteogenic controls. In diclofenac sodium treated cells, OPN staining was more 
dispersed and OCN staining concentrated within the nodules. In proinflammatory 
cytokine with diclofenac  groups, the nodules were of a similar size and cell density to 
the controls. 
Figure 5.9 shows col-I and cad-11 staining of primary calvarial cells after exposure to 
proinflammatory cytokines and diclofenac sodium. In all groups, marked col-I staining 
was  seen in cad-11 positive regions. Once again, the cytokine treated group 
produced smaller bone nodules with more disperse staining for  col-I than osteogenic 
control groups. Cells treated with diclofenac sodium showed col-I and cad-11 staining 
that was  similar to that of the osteogenic control. When diclofenac sodium was 
present alongside the cytokines, some effects of the proinflammatory cytokines were 
apparent, with col-I staining similar to that of cytokine treatment alone with col-I less 
concentrated around nodules than the control. However, cad-11 appeared to have a 
stronger staining than that of the cytokine only group, more similar to the staining of 
the control medium group.  
 
5.3.3  Diclofenac sodium release from PLGA/PEG scaffolds 
The effect of releasing diclofenac sodium from PLGA/PEG scaffolds was investigated. 
Release rates were monitored and PLGA/PEG scaffolds releasing diclofenac sodium 
were tested using the in vitro osteoblast  inflammation model.  
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Figure 5.9: Expression of cadherin-11 and collagen-1 in primary calvarial cells 
stimulated with proinflammatory cytokines and diclofenac sodium.  Primary 
calvarial cells were cultured in osteogenic media for 14 days, then for 7 days in 
osteogenic media containing 100 µM diclofenac sodium and/or IL-ȕ71)-Į and IFN-
Ȗ Representative images of cadherin-11 (red) and collagen-I (green) expression 
assessed by immunocytochemistry on day 21. Scale bar=90 µm. 
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5.3.3.i PLGA/PEG scaffolds. 
Figure 5.10 shows the formed PLGA/PEG scaffolds and the microstructure of the 
scaffolds. PLGA/PEG microparticles were mixed with PBS/drug solution to form a 
paste and were  packed into PTFE moulds, producing cylindrical scaffolds of 12 mm 
length and 6 mm diameter after sintering. The scaffolds have a porous microstructure 
(figure 5.10B), with pores formed by particles bridging when sintered. The formed 
scaffolds showed swelling after being placed in PBS or medium to release and after 5 
weeks showed little degradation (figure 5.10B). Eventual degradation took about 9 
weeks. 
 
5.3.3.ii In vitro release of diclofenac sodium from PLGA/PEG scaffolds. 
5.3.3.ii.a  Effect of initial loading mass of drug  
The release of diclofenac sodium from the PLGA/PEG scaffolds over time was 
assessed by UV spectrophotometry and converted to mass via a standard curve. The 
cumulative mass release of the scaffolds can be seen in figure 5.11, and this mass 
converted to percentage of initial loading in figure 5.12. These profiles show release 
into phenol-red freHĮ0(06FDIIROGVZHUH ORDGHGZLWKFRQFHQWUDWLRQVRIGLFORIHQDF
ranging from 300 µg/scaffold to 1000 µg/scaffold, to determine effect of initial drug 
loading on release profile. All scaffolds showed a similar release profile, regardless of 
initial loading. Scaffolds showed an initial drug burst release of 55-62%. This burst is 
due to immediate release of the drug adsorbed to the scaffold surface, when the 
scaffold is placed in liquid after sintering. After this burst, drug release slows, with 
approximately another 20% release after day 1 and another 3% on day 2. After day 4, 
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Figure 5.10: PLGA/PEG scaffolds. Temperature-sensitive and biodegradable 
poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG) microparticle 
scaffold. (A) Formed and sintered scaffolds showing swelling and degradation over a 
5 week period (B) SEM image showing the porosity of the scaffold and microstructure 
of the scaffold (inset, image courtesy of Cheryl Rahman). 
200µm
1mm
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Figure 5.11: Cumulative mass release of diclofenac sodium from PLGA/PEG 
scaffolds. PLGA/PEG scaffolds were loaded with various initial concentrations of 
diclofenac sodium. (A) Mass of drug released over the full 68 day time course. (B) 
Mass released over first 4 days. Mass of drug released at each timepoint was 
assessed by UV spectrophotometry and expressed cumulatively over time. Values 
represented by mean of triplicate scaffold release, each measured in triplicate (n=9). 
Error represented by cumulative standard deviation. 
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Figure 5.12: Cumulative percentage release of diclofenac sodium from 
PLGA/PEG scaffolds. PLGA/PEG scaffolds were loaded with various initial 
concentrations of diclofenac sodium. (A) Percentage of drug released over 68 day 
time course. (B) Percentage of drug released over first 4 days. Mass of drug released 
at each timepoint was assessed by UV spectrophotometry and expressed as a 
percentage of initial loading. Values represented by mean of triplicate scaffold 
release, each measured in triplicate (n=9). Error represented by cumulative standard 
deviation. 
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release reached a steady state of around 0.2% per day. From day 42, this rate 
increased slightly to about 0.3% per day as the scaffolds degraded. By day 68, the 
scaffolds had degraded and total percentage release for each scaffold was nearing 
100%, with error. 
 
5.3.3.ii.a  Consistency of Drug Release 
To assess consistency of release between scaffold batches, three different batches of 
650 µg scaffolds were manufactured on different days. Diclofenac sodium release into 
PBS was measured at certain timepoints (figure 5.13). The three batches showed 
consistent release profiles, but differed in the mass of the initial burst. After the burst, 
the mass release was very similar, with batch #1 and batch #3, showing almost 
identical curves. 
 
5.3.3.ii.b  Release into cell culture medium containing FBS 
/DVWO\ UHOHDVH RI GLFORIHQDF VRGLXP LQWR IXOO PHGLXP SKHQRO UHG IUHH Į0(0 
FBS, pen-strep and L-Glutamine), from the transwell system, was investigated to 
ensure that release into the in vitro bone model would be consistent with the release 
curves shown previously. Figure 5.14 shows percentage release from a 650 µg 
diclofenac sodium loaded scaffold. The release profile is very similar to those shown 
previously, with a high burst and a steady, slow release from day 4. There is a larger 
amount of error in these results, due to high background readings from protein in the 
medium, when performing UV spectrophotometry. 
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Figure 5.13: Consistency of mass release of diclofenac sodium from scaffold 
batches. Three different batches of PLGA/PEG scaffolds were manufactured loaded 
with 650 µg diclofenac sodium. Mass of drug released at each timepoint was 
assessed by UV spectrophotometry and expressed cumulatively over time. Values 
represented by mean of triplicate scaffold release, each measured in triplicate (n=9). 
Error represented by cumulative standard deviation. 
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Figure 5.14: In vitro percentage release of diclofenac sodium from transwell 
model into full media. PLGA/PEG scaffolds were manufactured loaded with 650 µg 
diclofenac sodium. Scaffolds were placed into transwells and drug release overtime 
into full osteogenic media monitored. Mass of drug released at each timepoint was 
assessed by UV spectrophotometry and expressed cumulatively. Values represented 
by mean of triplicate scaffold release, each measured in triplicate (n=9). Error 
represented by cumulative standard deviation. 
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5.3.3.iii Diclofenac sodium release from PLGA/PEG scaffolds into in vitro 
osteoblast inflammation model. 
Primary calvarial cell response to the release of diclofenac sodium from PLGA/PEG 
scaffolds, in both osteogenic and proinflammatory cytokine medium was investigated. 
Levels of nitrite, and PGE2 in media samples were measured, to assess the 
effectiveness of the released drug. LDH levels were measured to indicate the 
cytotoxicity of the drug and proinflammatory cytokines. Live/dead images were taken 
on day 7, to show final levels of cell viability. 
 
 
5.3.3.iii.a  Final viability of primary calvarial cells after diclofenac sodium 
release 
Live/dead images were taken of primary calvarial cell monolayer at day 7 and can be 
seen in figure 5.15. Images were quantified to compare different groups and the 
results can be seen in figure 5.16. Images show that in osteogenic medium with no 
scaffold, there are very few dead cells and those are most likely caught in the matrix 
of the living cells. The same is true  of the 0 µg and 300 µg loaded scaffolds. There 
are an increased number of dead cells caused by the 650 µg loaded scaffold, but this 
is not a statistically significant result. Raising the loading to 1000 µg causes a very 
large increase in the number of dead cells and lowers the percentage viability to 
below 20%, indicating the concentration of diclofenac released in the burst is toxic to 
the cell monolayer. In proinflammatory cytokine medium, cells with no scaffold and 0 
µg scaffolds, suffered from a large fall in viability, to around 33% and 23% 
respectively. Release of diclofenac from the 300 µg and 650 µg scaffolds improved 
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Initial diclofenac sodium loading of PLGA/PEG scaffold 
 No Scaffold 0 µg/scaffold 300 µg/scaffold 650 µg/scaffold 1000 µg/scaffold 
Osteogenic 
Medium 
     
IL-ȕ71)ĮDQG
IFN-Ȗ0HGLum 
   
  
Figure 5.15: Live/Dead images of cell monolayers after diclofenac sodium release from PLGA/PEG scaffolds. Diclofenac 
sodium was released into medium of primary calvarial cells from PLGA/PEG scaffolds placed in transwells. Medium on cells was either 
control osteogenic medium, or osteogenic medium containing IL-1ȕ, TNF-Į and IFN-Ȗ. After 7 days release, scaffolds were removed and 
Live/Dead images of cell monolayers taken. Representative images of live staining merged with dead staining shown. Scale bar=46 ȝm. 
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Figure 5.16: /LYH'HDG LPDJH TXDQWLILFDWLRQ RI FHOO PRQolayers after 
diclofenac sodium relase from PLGA/PEG scaffolds. Diclofenac sodium was 
released into medium of primary calvarial cells, from PLGA/PEG scaffolds placed in 
transwells. Medium on cells was either control osteogenic media, or osteogenic 
media containing  IL-ȕ 71)Į DQG ,)1-Ȗ  After 7 days release, scaffolds were 
UHPRYHGDQG/LYH'HDGLPDJHVRIFell monolayers taken. (A) Image quantification 
performed to determine number of live and dead cells *Statistical significance of total 
cell number vs. total FHOOQXPEHU LQJVFDIIROG LQ20S%3HUFHQWDJe of 
live cells in each group (n=9). Statistical significance vs. 0 µg/scaffold in OM (*S
**SS6WDWLVWLFDOVLJQLILFDQFHYVJVFDIIROGLQF\WRNLQHPHGLum 
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viability in cytokine medium 76% and 68% correspondingly, demonstrating that the 
diclofenac inhibited the effects of the cytokines. The 1000 µg loaded scaffold in  
cytokine medium showed an enhanced negative effect with significantly less total 
cells and a cell viability of 3%. 
 
 
5.3.3.iii.b  Effect of diclofenac sodium-releasing PLGA/PEG scaffolds on LDH 
production in the osteoblast inflammation model 
Release of LDH (cytotoxicity marker) over the 7 day diclofenac sodium release can 
be seen in figure 5.17. In control osteogenic medium, cytotoxicity levels are low and 
the presence of the scaffold causes no additional release of LDH into the medium. In 
medium containing IL-ȕ71)-ĮDQG,)1-ȖWKHUHLVLQFUHDVHGOHYHOVRIF\WRWR[LFLW\LQ
WKH³QRVFDIIROG´JURXSRQGD\FRPSDUHGWRWKHJVFDIIROGVLQERWKRVWHRJHQLF
and cytokine medium. Increased cytotoxicity is also seen in the medium of the 650 µg 
and 1000 µg scaffold on day 1 and day  2. LDH levels reach a peak on day 2 in the 
1000 µg scaffold and by day 7, levels are low, presumably because there has been 
maximum cell death previously. All scaffold groups except for 1000 µg show 
significantly increased LDH between days 3 to 7 in cytokine medium, compared to the 
0 µg scaffold in control medium. Taken cumulatively over the 7 days (figure 5.17B), 
the 1000 µg/scaffold shows almost 100% cytotoxicity, most likely due to the 
diclofenac sodium rather than the proinflammatory cytokines. The 650 µg scaffold 
shows significantly more cumulative cytotoxicity than the 0 µg scaffold, but the 300 µg 
does not. 
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Figure 5.17: Effect of diclofenac sodium releasing PLGA/PEG scaffolds on 
cytotoxicity, in the in vitro calvarial osteoblast inflammation model. LDH in the 
media was measured on day 1, 2 and 7, after the scaffold placed in the transwell. (A) 
Cytotoxicity levels each day. (B) Cumulative cytotoxicity over 7 days. Values 
represented as mean±SEM (3 separate experiments, each with n=3). #Statistical 
significance vs. 0 µg/scaffold in cytokine media, (#S S. *Statistical 
significance vs. 0 µg/scaffold in control media, (*S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5.3.3.iii.c  Effect of diclofenac sodium-releasing PLGA/PEG scaffolds on nitric 
oxide production in the osteoblast inflammation model 
Levels of nitrite in the medium were measured after day 1, day 2 and at day 7, to 
HVWLPDWH12SURGXFWLRQDQGFDQEHVHHQLQILJXUH,QWKH³QRVFDIIROG´DQGJ
scaffold groups in control medium, there was minimal NO production, across all 
timepoints. :KHQ SURLQIODPPDWRU\ F\WRNLQHV ZHUH SUHVHQW LQ WKH PHGLXP ³QR
VFDIIROG´ DQG ZLWK  J VFDIIROG VKRZHG VLJQLILFDQWO\ LQFUHDVHG QLWULWH DFURVV DOO
timepoints, correlating with previous work. The 300 µg diclofenac releasing scaffolds 
showed significant inhibition of NO production on day 1, but day 2 and day 7 levels 
were significantly increased, compared to control. The 650 µg scaffolds showed 
inhibition of NO production across all timepoints, although by day 7, concentrations 
were also increased to significantly higher than control. Scaffolds releasing 1000 µg 
diclofenac, showed low nitrite production across all timepoints, but when relating back 
to Live/Dead and LDH results, low nitrite levels from day 2 onwards can be correlated 
with very low cell viability. Cumulative nitrite production across the 7 days (figure 
5.18B) shows that the 300 µg scaffold did not significantly inhibit cytokine-induced NO 
production, although it does appear that levels were reduced. At 650 µg diclofenac 
sodium release, inhibition was more successful. The 1000 µg scaffolds appear to 
inhibit proinflammatory cytokine induced NO production but as mentioned previously, 
this may also be due to low cell number. 
 
5.3.3.iii.d  Effect of diclofenac sodium-releasing PLGA/PEG scaffolds on PGE2 
production in the calvarial osteoblast inflammation model 
Concentration of PGE2 in the medium, across the 7 days diclofenac sodium release 
was measured on day 1, day 2 and day 7 and can be seen in figure 5.19. PGE2 
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Figure 5.18: Effect of diclofenac sodium releasing PLGA/PEG scaffolds on 
nitrite production in the calvarial osteoblast inflammation model. Nitrite 
accumulation in the medium was measured on day 1, 2 and 7, after scaffold placed in 
transwell. (A) Concentration of nitrite at each timepoint. (B)  Cumulative nitrite 
concentration over 7 days. Values represented as mean±SEM (3 separate 
experiments, each with n=3). Statistical significance vs. 0 µg/scaffold in cytokine 
media, (S0001). *Statistical significance vs. 0 µg/scaffold in control media, 
S001). 
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Figure 5.19: Effect of diclofenac sodium releasing PLGA/PEG scaffolds on PGE2 
production in the in vitro calvarial osteoblast inflammation model. PGE2 
accumulation in the media was measured on day 1, 2 and 7, after scaffold placed in 
transwell. (A) Concentration of PGE2 each day LQFOXGLQJ ³QRVFDIIROG´H[SHULPHQWDO
groups. (B) Comparison of concentration of PGE2 HDFKGD\H[FOXGLQJ³QRVFDIIROG´
experimental groups.  (C) Cumulative PGE2 concentration over 7 daysH[FOXGLQJ³QRVFDIIROG´JURXSV.  Values represented as mean±SEM (3  separate experiments, each 
ZLWK Q   6WDWLVWLFDO VLJQLILFDQFH YV  JVFDIIROG LQ F\WRNLQH PHGLD S
*Statistical significance vs. 0 µg/scaffold in FRQWUROPHGLDS 
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concentration across all groups, at all timepoints can be seen in figure 5.19A. When 
DOO JURXSV DUH VKRZQ RQ WKH VDPH JUDSK WKH ³QR VFDIIROG´ H[SHULPHQWDO JURXS LQ
cytokine medium shows a very large amount of PGE2 production, skewing the data. It 
should be expected that similar levels of PGE2 are produced by cells with 0 µg 
scaffolds but this is not seen when assaying the medium. I believe that some of the 
PGE2 released by the cells is adsorbing to the scaffold, and not remaining soluble in 
the medium, causing a large amount of variation in the results.  
To get a more valuable understanding of how the scaffolds are affecting PGE2 
UHVSRQVH UHVXOWVH[FOXGLQJ WKH ³QR VFDIIROG´ FRQWUROV FDQEH IRXQG LQ ILJXUH%
This figure shows that at all timepoints, the 0 µg scaffold showed increased PGE2 
production in proinflammatory cytokine medium compared to control osteogenic 
medium. Significant inhibition of PGE2 was then seen at day 1 by the 300 µg, 650 µg 
and 1000 µg diclofenac-releasing scaffolds, and was reduced across these groups on 
day 2 and day 7, compared to 0 µg scaffolds in cytokine medium. Cumulative PGE2 
concentration (figure 5.18C) in the medium until day 7 showed that all diclofenac 
sodium loaded scaffolds, showed significant inhibition of PGE2 production, in 
proinflammatory cytokine medium. 
 
5.3.3.iii.e  Concentration of diclofenac sodium released from PLGA/PEG 
scaffolds 
Average mass of diclofenac released at each timepoint was calculated from UV 
spectrophotometry data (figure 5.20). Data approximately followed that of previous 
release curves. The largest release occurred over the first 24 hours (day 1) and 
ranged from 60-70%, total loading. This drug would then be removed during medium 
collection and over the next 24 hours, 12-15% total loaded drug would be released 
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Figure 5.20: Diclofenac sodium release from PLGA/PEG scaffolds onto bone 
inflammation model. (A) Average mass of diclofenac sodium released by each 
timepoint, from 300, 650 and 1000 µg loaded scaffolds.  (B) Average percentage 
diclofenac sodium released by each timepoint. Values represented by mean±SEM of 
each timepoint (n=9, 3 separate experiments). 
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into the model, before being removed. Over the next 5 days until day 7, approximately 
another 7-13% diclofenac would be released, until experiment end. 
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5.4  Discussion 
Studies performed in this chapter show further validation of the inflammatory calvarial 
osteoblast model, investigation of the effects of anti-inflammatory drugs on primary 
calvarial cells, and examined the use of PLGA/PEG scaffolds as a release vehicle for 
diclofenac sodium. Early work performed using anti-inflammatory drug inhibition of 
NO and PGE2, enabled simple validation of the calvarial osteoblast inflammatory 
model. Cell response to the drugs mirrored what was expected and remained 
consistent with literature. The glucocorticoids, dexamethasone and prednisolone, 
inhibited both NO and PGE2 production. Glucocorticoids are very potent anti-
inflammatories and work via many different mechanisms. Glucocorticoids, including 
dexamethasone and prednisolone destabilize the mRNA of COX-2 by inhibiting the 
MAPK p38 [311-314]. Whilst affecting PGE2 production, dexamethasone also works 
to inhibit transcriptional activity leading to the production of iNOS, leading to 
decreased NO production. Destabilisation of the iNOS mRNA occurs, reducing the 
half-life by 50% [311, 315]. Although glucocorticoids have powerful anti-inflammatory 
and immunomodulatory effects, prolonged systemic treatment can adversely affect 
fracture healing, cause osteoporosis and increase the risk of fracture [316]. Steroid 
treatment can cause in vivo apoptosis of osteoblasts and osteocytes, and inhibit 
osteoblastogenesis, eventually leading to a decreased BMD [317, 318]. Due to these 
unfavourable side effects, it was decided not to pursue the use of dexamethasone in 
the scaffold release experiments, at this time. Used more predominantly as a 
treatment for RA and serious autoimmune conditions, the powerful anti-inflammatory 
effects would require more control over the method of release, to prevent the 
overwhelming side effects. An alternative reason for not pursuing the use of 
dexamethasone in this system is crossover in the use of the drug as an osteogenic 
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agent during in vitro culture. There is a discrepancy between the actions of 
dexamethasone to enhance in vitro osteogenesis of MSCs and ESCs [60, 319], and 
the negative effects during in vivo bone healing [316, 320]. As this study describes a 
very simple in vitro model, it was thought that this inconsistency in properties might 
add an extra level of complexity to the experiment.   
Diclofenac sodium, ibuprofen and piroxicam were all very effective at inhibiting PGE2 
production and all did so at the lowest concentration. The ability of NSAIDs to inhibit 
the COX-2 pathway, and therefore PGE2 production, has been discussed at length in 
the literature [292, 321]. The ability of NSAIDs to inhibit NO production is not so well 
known, but did occur to a certain degree with ibuprofen and with diclofenac, in longer-
term studies and when released from the PLGA/PEG scaffolds. Aspirin, indomethacin 
and ibuprofen have all been shown to inhibit iNOS activity and NO production in 
macrophages stimulated with LPS and IFN-Ȗ[322, 323]. This process does not cause 
complete inhibition of cytokine-induced NO production, and unlike glucocorticoid 
action, is not caused by inhibition of iNOS mRNA [324]. The diclofenac sodium results 
in this study show partial inhibition of NO production, in agreement with this 
statement. Interactions have previously been shown to exist between the COX and 
NOS pathways in a number of cells including osteoblasts [325-328]; however the 
inhibitory effects of NSAIDs on NO production have been shown to be both COX-
dependent and COX-independent [323, 327]. 
The use of IL-1ra as an anti-inflammatory treatment for RA is in relative infancy. The 
current therapy is a non-glycosylated form of the IL-1ra protein; drug name anakinra 
and marketed under the name Kineret by Amgen. In this study, recombinant mouse 
non-glycosylated IL-1ra was used to simulate the drug. The protein performed very 
well in viability tests and showed no toxicity to the cell model at any concentration. 
Tests for the anti-inflammatory properties were less conclusive. Effective inhibition of 
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both NO and PGE2 production only occurred at the highest concentration of 1000 
ng/mL. Concentrations used were based on available literature and due to the 
expense of using recombinant proteins, it was not possible to try IL-1ra at higher 
concentrations [210, 329]. In clinical studies, anakinra showed moderate but 
statistically significant therapeutic efficacy in RA [330]. Further indirect head-to-head 
comparisons of anakinra vs. other biological DMARDs have suggested that it is less 
efficacious in treating RA than anti-TNF therapies [331, 332]. Considering this, it may 
have been of more interest to investigate the effect of an anti-TNF therapy on the 
inflammation model.  
The initial screening of several types of anti-inflammatory mediator allowed selection 
of drugs to take forward for further screening of the inflammation model. Diclofenac 
sodium was chosen for several reasons: NSAIDs show appealing properties as an 
anti-inflammatory in bone treatment; good solubility in water and stability over time; 
successful results in both PGE2 and nitrite inhibition in initial testing; and finally, more 
literature available describing release of diclofenac via various techniques [300, 309, 
310]. Initial studies had been carried out for 3 days only; it was now necessary to look 
at the response of the cells to longer-term exposure to drug and cytokines. At this 
point, a concentration of 100 µM diclofenac sodium was chosen for in vitro studies, as 
cell viability at this concentration was not affected in the short term, cytokine-induced 
PGE2 production was completely inhibited and there was some inhibition of NO. Over 
21 days, results followed those of the short-term studies; the diclofenac had limited 
effect on cell viability and worked to inhibit the effects of the cytokines. The cell 
viability measurements were important, as anti-inflammatory drugs have previously 
been shown to induce apoptosis and arrest the cell cycle [333, 334]. This can be seen 
to a degree with the diclofenac sodium but only at the very highest concentrations. 
However, when used at therapeutic concentrations (100 µM), NSAIDs such as 
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diclofenac, have been shown to have no toxic effects on osteoblast viability and 
results in this study support this [335]. Over time, PGE2 was blocked effectively and 
although cytokine-induced NO levels remained higher than controls, there was 
inhibition compared to cytokine only. These results gave some indication of how 
diclofenac may act upon release from scaffolds, and the concentrations that would be 
required. An initial release of around 100 µM would not affect cell viability drastically 
but was probably the minimum concentration required for effective blocking of 
inflammatory signals. This would be the equivalent of around 30 µg/mL mass release.  
Short investigations were carried out studying the effect of diclofenac sodium on the 
formation of bone nodules and deposition of osteogenic matrix, building on work 
discussed in chapter 4. The effect of NSAIDs on bone formation and healing is one of 
contention, with some studies showing that in vivo treatment with drugs such as 
diclofenac, do not affect fracture healing [336-338]. Conversely, the majority of 
studies suggest that NSAIDs delay the fracture healing process [339-342]. NSAID 
treatment of in vitro cell cultures has revealed no significant effect on osteogenic 
differentiation of MSCs or osteoblasts [334, 335, 343]. In this investigation, the 
presence of diclofenac appeared to have a minor effect on the deposition of OPN and 
OCN, but not col-I. Cad-11 was present in the nodules, indicating the presence of 
osteoblasts. Results with cytokines in the culture medium supported the work of the 
previous chapter, with smaller nodules formed and less deposition of osteogenic ECM 
proteins, particularly OCN. Diclofenac prevented some of the effects of the cytokines, 
but was not completely effective, suggesting that although anti-inflammatory drugs 
inhibit responses in terms of NO and PGE2, it may be more difficult to maintain the 
correct balance for osteogenic differentiation in vivo. 
With knowledge of the effect of diclofenac on the bone inflammation model more 
secure, the development of a tissue engineered release system could progress. The 
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Tissue Engineering group at Nottingham has a base of knowledge using the 
PLGA/PEG system, and properties and suitability for bone tissue engineering have 
already been well-established [169-171]. The PLGA/PEG scaffold system has been 
shown to be effective in the release of chemotherapy drugs for the treatment of brain 
cancer after surgical resection, and BMP-2 for bone repair [170, 344]. The inclusion of 
anti-inflammatory drug release would enable enhancement of the properties of the 
PLGA/PEG scaffolds in bone repair, rather than only exploiting the scaffold as a drug 
delivery vehicle. The scaffolds are prepared from PLGA/PEG particles that form a 
paste when mixed with a carrier solution, this carrier solution can contain the drug of 
choice, which is then incorporated into the scaffold when the paste hardens at 37°C. 
One current limitation of this system is the solubility of the drug in the carrier. A 
solvent can be used, but at too high a concentration, this starts to affect the polymer 
particles and the drug release. The drug in the carrier adsorbs to the surface of the 
particles and becomes physically entrapped within the pores of the scaffold. Drug 
release from these scaffolds is uncontrolled and occurs via diffusion through the 
pores; release can depend upon drug properties and interaction between the drug 
and the polymer. In the case of diclofenac, release consisted of a very large burst 
within the first few hours, due to drug molecules loose within scaffold, immediately 
releasing into the medium. In some cases, this would have be considered an 
undesirable effect, but in the case of in vivo inflammation this burst release of anti-
inflammatory correlates well with an influx of proinflammatory cytokines to the area 
upon implantation of the scaffold (see figure 5.21). After the burst, release slowed 
rapidly. Day 1 to day 4, drug release can be explained by diffusion of the drug through 
water-filled pores. From day 4, release slowed substantially, but followed an almost 
first-order release profile, as the remaining drug found a way through the scaffold, 
diffusing into the medium.  
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Figure 5.21: Comparison of non-cumulative mass release of drug from 
PLGA/PEG scaffold with in vivo proinflammatory cytokine expression.  (A) 
Temporal expression of proinflammatory signals after bone injury/scaffold 
implantation (schematic adapted from Mountziaris and Mikos [271]) (B) Average non-
cumulative mass released from 650 µg diclofenac sodium loaded PLGA/PEG 
scaffolds over time. 
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Initial loading of the drug had very little effect on the percentage release profile, and 
consistency of release between batches of scaffolds correlated well, only differing in 
initial burst release. The composition of the carrier into which the drug was released 
did not affect the release profile, but as more components were introduced into the 
medium, background readings increased, creating more error in the 
spectrophotometry. The length of time over which the majority of the diclofenac was 
released was about 6 days. This is in keeping with other tissue engineered anti-
inflammatory release strategies that have shown 3-6 days [300-302]. Longer more 
controlled release could be achieved by using other scaffolds, such as PLGA 
microspheres [345, 346]. This system could be adapted to change release profile by 
incorporating the drug into the melt-blend of the PLGA/PEG when producing the 
particles. Drug diffusion out of the scaffold would then become more difficult as the 
drug has to travel through the particles themselves.  
Diclofenac sodium release onto the cell inflammation model was performed from 
transwells. This allowed the cell monolayer to be kept separate from the scaffold, in 
order to maintain simplicity and not to introduce an extra level of complexity with 
migration of cells onto the scaffold or biomechanical effects of scaffold surface. The 
transwell system allowed drug release into the cell culture medium, which could freely 
diffuse through the pores of the membrane to the cell monolayer. The system had 
disadvantages; the scaffold swelled as water was imbibed and it became constrained 
by the edges of the transwell, possibly affecting release. Nevertheless, as 
experiments were kept to a maximum of 7 days, this effect had little time to come into 
consequence. The medium level had to be kept above the scaffold to ensure drug 
release; consequently, the final concentration of drug was diluted slightly. These 
disadvantages aside, the simple system worked successfully to demonstrate that 
diclofenac sodium release was effective as an anti-inflammatory mediator.  
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Cell viability in the model, was used as an indicator of effective concentration of drug. 
A balance between the mass of drug released to achieve an effective anti-
inflammatory dose with the maintenance of cell viability had to be attained. The 
highest scaffold loading of 1000 µg/scaffold showed almost complete cell death by 
day 7 of release, and LDH results suggested that the majority of this had occurred by 
day 2. Most probably, this was a property of the large burst release. This large cell 
death rendered results of PGE2 and nitrite obsolete, as low values only indicated low 
cell numbers. There was more success with scaffolds loaded with 300 µg or 650 µg 
drug. Results indicate that an initial loading between the two would give optimum 
results for cell viability and inhibition of inflammatory markers.  
The in vivo environment is vastly different to the one created in this study, but it was 
attempted to reflect it by starting with a large concentration of proinflammatory 
cytokines that then decreased from day 1, and was low up until day 7. Medium was 
replaced a certain to timepoints to prevent accumulation of the drug in the system 
having too much effect on cell viability. An issue that emerged as the system 
developed was adsorption of PGE2 and medium proteins, such as the 
proinflammatory cytokines, to the PLGA/PEG scaffold. This was reflected most 
obviously in results for PGE2, but could also be seen in nitrite and LDH readings, 
resulting in lower values when scaffolds were present. This issue would continue into 
be an issue that would carry over to in vivo work, with the presence of a scaffold 
affecting the natural environment of wound healing. Protein adsorption can illicit the 
immune responses and affect cellular processes [347, 348]. Much work has been 
performed using surface modification to reduce this property [349, 350]. Overall, the 
model performed well in showing that the drug was effective after release. 
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Chapter 6:    
Discussion 
The overall aim of this study was to consider bone tissue engineering strategies in the 
context of inflammation; looking at both the effect and control of inflammatory 
signalling. Often, the potential effects of introducing bone regeneration strategies into 
environments of disease and damage are overlooked, despite the fact that many of 
the signalling pathways in inflammation have effects on bone development and 
healing.  
The first objective of this investigation was to develop an in vitro simulation of the 
inflammatory environment, which could be used throughout the study. 
Proinflammatory cytokines such as IL-ȕ 71)-Į DQG ,)1-Ȗ KDYH EHHQ XVHG
extensively to represent inflammatory signals in in vitro osteoblast and MSC cultures, 
and effects of these cytokines have been discussed throughout the preceding 
chapters [259, 351-353]. In many of these reported studies, only one cytokine is used 
to stimulate the cells, rather than the combination of cytokines that was used in the 
majority of these experiments. In developing the in vitro inflammatory environment, 
the greatest response of the primary calvarial cells, in terms of NO and PGE2, was 
seen when the three cytokines were present in combination in the medium. This did 
not elicit a response from the early differentiation osteo-mESCs, even when 
concentration was increased to 10 times what is normally described in the literature. 
For this reason, it was decided to consistently use the three cytokines in combination, 
to be sure of a high level of response from the primary calvarial cells that could be 
easily compared to that of the osteo-mESCs. Using more than one cytokine also 
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simulated an environment more similar to that of in vivo inflammation, although a very 
simplified one, without the cells of the immune system and of increased cytokine 
concentrations.    
The novelty of this work lay in the investigation of the response of osteo-mESCs to 
proinflammatory cytokines. To give the results context, they were compared to the 
responses of the primary calvarial cells. The primary cells consistently produced NO 
and PGE2, in response to the inflammatory signalling, regardless of stage of 
osteogenic differentiation. There was also an effect on osteogenic matrix production 
and bone nodule formation in response to short bursts of cytokine stimulation, at all 
stages of osteogenic culture. The interesting results lay with the osteo-mESCs that 
did not produce NO or PGE2 in response to the cytokines, until the very latest stages 
of osteogenesis. Unfortunately, it was not possible to fully elucidate the mechanisms 
accountable for this lack of response during the course of this investigation. It may be 
postulated that it is cytokine-receptor or inflammatory pathway related. Interestingly, 
the mESCs did show signs of anti-inflammatory properties, with mESC CM showing 
inhibition of the cytokine-induced effects on the primary calvarial cells. Along with 
work describing the possible immunotolerance of ESCs, these results may help 
promote the potential that ESC-derived cells have in regenerative strategies, and in 
possible modulation of the immune and inflammatory response [354, 355]. 
Another objective of the study was to examine the osteogenic differentiation of the 
mESCs, comparing it to differentiation of the primary cells. The protocol used for 
osteogenic differentiation was a standard protocol featuring BGP, ascorbate and 
dexamethasone, which has been described many times throughout the literature [30, 
60, 61]. The only consideration faced was the use of dexamethasone, as it also has a 
function as a potent anti-inflammatory; a property shown to great effect in chapter 5, 
inhibiting the effects of the cytokine signalling on the calvarial osteoblast inflammation 
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model. This predicament was overcome by removing the dexamethasone when 
cytokines were present in the cell culture medium, and for at least 24 hours after, for 
any residual signalling effects to occur. In hindsight, it may have been less 
problematic to use a different molecule for the osteogenic induction, such as 
simvastatin, which has been shown to induce osteogenic differentiation of mESCs 
[228]. ESCs have also been shown to produce bone nodules in the presence of just 
BGP and ascorbate, without an osteoinductive molecule such as dexamethasone, 
and this was the case for this investigation in experiments that required continuous 
culture with proinflammatory cytokines [60]. 
In comparing the differentiation of the two cell types, some major differences were 
seen. Alizarin red staining showed very different configurations of the stained bone 
nodules within the cultures. Subjective observation indicated that there were far more 
nodules in osteo-mESC cultures. There have been differences shown in the speed of 
nodule formation, and composition and configuration of mineralised matrix produced 
by osteo-mESCs, compared with MSCs and primary osteoblasts [61, 192]. Perhaps 
with further investigation, the results in this study would have reached the same 
conclusion. 
In support of the osteogenic differentiation of mESCs, this study showed col-I, OCN 
and OPN deposited in the matrix and the presence of cad-11 positive cells. None of 
this was seen within the control cells cultured in non-osteogenic medium. This 
indicates that there is osteoinduction occurring within the mESC cultures, but results 
do not compare to that of primary cells, possibly due to the dilution of the ESC-
derived osteogenic population, with other cell types. Heterogeneity within ESC 
cultures has been reported as an issue when considering production of cell therapies; 
particularly the danger of contamination with undifferentiated ESCs, which could go 
on to form teratomas [356-358]. Therefore, an ESC therapy will require a pure 
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population of the cell of interest. The most likely way to achieve this is by using cell-
sorting techniques such as FACS or MACS. In this investigation, MACS proved 
successful in selecting a population of cells, positive for the marker cad-11. This 
population then went on to show osteogenic differentiation that was more similar to 
that of the primary calvarial cells, than the unsorted osteo-mESCs. The disadvantage 
of this sorting procedure, was the low yield of cells that showed positive for cad-11 
and the amount of cells lost in the MACS process. As this experiment was an initial 
trial, to determine whether the MACS process and the cad-11 marker were suitable, 
the results were in fact very promising. If continuing with this line of investigation, it 
would be of interest to fully optimise the process, identifying the ideal stage of 
osteogenic culture to perform the sorting procedure on the mESCs. The inclusion of 
alternative markers and improvement of the experimental process, so cell loss was 
minimised, would also be advantageous. It may have been interesting to perform the 
MACS selection process on the primary calvarial cells, as these also show a 
heterogeneous population in culture. 
In chapter 5, the focus of the study was adjusted from effect of inflammation, to 
possible methods of control of inflammation. There are currently many drugs and 
therapies available to help control the symptoms of inflammatory bone disease. 
Tissue engineering and regenerative medicine offer the opportunity to address the 
imbalance in bone healing and inflammation, that can be the cause of the disease or 
non-healing. In this study, a method of drug release was shown from a polymeric 
scaffold that had already been designed for the purposes of bone regeneration. This 
system was very simple but showed itself to be effective in initial in vitro studies, 
involving the calvarial osteoblast inflammation model. I believe that one of the key 
factors in creating a regenerative therapy for bone that will modulate inflammation, 
lies in creating a balance between allowing enough of the natural healing 
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inflammation process, but not permitting it to overwhelm the regenerative capacity of 
the therapy or upset the balance of bone healing. This will require careful thought 
about the type of incorporated anti-inflammatory drug, the method and concentration 
of release and knowledge of the mechanisms of inflammation within the ailment. To 
extend the work performed in this study, it would have been interesting to use the 
inflammation model to test other mechanisms of drug release, such as polymeric 
microparticles that offer more control over the release rate [27]. These microparticles 
could then have been incorporated into the PLGA/PEG system. This would also allow 
the investigation into other drug types, as with this system, drug solubility is not such 
as issue. It may also be more realistic to the in vivo environment to move to a 3D 
model of inflammation, and culture the cells upon the scaffold, where drug and 
cytokine interactions will be altered from the 2D environment. 
This investigation has opened up many future avenues of research following both 
engineering and biological paths. There is a wealth of knowledge that could be gained 
by further investigating the ESC response to inflammatory signalling. The work 
performed in this study used mouse cells and the most obvious step is to transfer to a 
human cell model, which would be more applicable to human disease. There could be 
much potential in looking at cytokine receptor expression on the cells and exploration 
of the changes that occur during ESC differentiation, that eventually lead to a 
cytokine-induced cell response. Alternative techniques could be used to look further 
into gene and protein expression during osteogenic differentiation of the cells, and the 
possible effects of the inflammatory cytokines.  
I think it is important to continue to examine the efficacy of osteogenic differentiation 
protocols, to ensure confidence that the cells being produced are of an osteoblastic 
lineage. There is also much scope for the development of efficient cell sorting 
protocols for ESCs, which lead to purified populations of ESC-derived osteogenic 
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cells. From a tissue engineering perspective, improved knowledge of bone 
inflammation and disease, and cell response to these environments, could lead to 
improved therapeutic results when using tissue engineered strategies. Overall, it is 
very important that researchers consider the disease environment when designing a 
regenerative strategy and aim to redress the balance of inflammation that prevents 
natural healing . 
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Appendix I ± Batch Testing of Serum 
Foetal bovine serum (FBS) batch testing was carried out to determine optimal serum 
for growth and osteogenic differentiation of mESCs and mouse primary calvarial cells. 
Methods 
Six batches of FBS, from different suppliers, were tested on both cell types. See table 
AI.1 for sera details. Mouse primary calvarial cells were plated in 6-well tissue culture 
treated plates and changed to standard primary calvarial osteogenic medium (50 mM 
BGP and 50 µg/mL ascorbate 2-phosphate) containing each serum type. After 21 
days culture in the osteogenic medium, cells were fixed in 10% (w/v) formalin and 
stained with alizarin red S. Mouse embryonic stem cells were induced to form EBs in 
SNL culture medium containing each of the sera. EBs were dissociated and cells 
plated in monolayer in gelatin-coated 6-well plates. Cells were cultured for 21 days in 
osteogenic medium (50 mM BGP, 50 µg/mL ascorbate 2-phosphate, 10 µM 
dexamethasone), with different groups for each sera. 
Table AI.1: Batches of serum for testing. 
Sera Source Product Code Lot Number 
A Sigma F9665 109K3398 
B Sigma F9665 070M3397 
C BioSera FB-1001H S08371S1810 
D BioSera FB-1001H S08370S1810 
E PAA Standard FBS A15-104 
F PAA Gold FBS A15-152 
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Results 
Results of alizarin red staining of the mouse primary calvarial cells can be seen in 
figure AI.1. Images of staining show that nodules did not form when cells were 
cultured in serum A or F. Most successful nodule formation was seen in the when 
cells cultured with serum B and D. Quantification results indicated that serum B would 
be the optimal serum for osteogenic culture of mouse primary calvarial cells. From 
these results all further primary calvarial cell culture was performed with serum B, 
purchased from Sigma-Aldrich, product code F9665, lot number 070M3397. 
Results for osteo-mESC staining can be seen in figure AI.2. Cells did not grow in 
serum A. In serum B and F, cell did stain bright red for calcium deposition, only 
background staining can be seen. Most successful sera for osteogenic differentiation 
of mESCs were serum C and D. Serum D, purchased from Biosera, product code 
FB1001H, lot number S08670S1810. was chosen for all further culture of mESCs.  
  
 Appendices 
  239 
 
  
A 
   
   
 
B 
 
Figure AI.1: Serum batch testing results for mouse primary calvarial cells. (A) 
alizarin red S staining for bone nodule formation. (B) Quantification of alizarin red 
staining. 
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Figure AI.2: Serum batch testing results for osteo-mESCs (A) alizarin red S 
staining for bone nodule formation. (B) Quantification of alizarin red staining. 
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Appendix II ± Cryopreservation 
Protocol 
Cryopreservation 
Cryopreservation of mouse primary calvarial cells, mESCs and SNLs was routinely 
performed. Cryopreservation medium for all cells consisted of FBS containing 10% 
(v/v) DMSO. In all cases, cells were detached from culture flask surface using 
trypsin/EDTA treatment, trypsin was inactivated with serum-containing medium and 
centrifuged (calvarial cells ± 300 x g, mESCs and SNLs ± 180 x g). The pellet was 
then resuspended in a small amount of cryopreservation medium and counted. Cells 
were suspended in the correct volume of cryopreservation medium to achieve a 
freezing density of 1,000,000 cells/mL for primary calvarial cells and SNLs and 
2,000,000 cells/mL for mESCs. Cells were transferred to cryovials and placed into 
dedicated storage boxes for cryopreservation (CoolCell, Sanyo). These boxes allow 
the cell suspension to freeze at a consistent rate of -1°C/minute, increasing cell 
viability upon reanimation. Boxes were placed into a -80°C freezer for 24 hours, 
before cryovials transferred to liquid nitrogen storage. 
Cell Reanimation from Storage 
Cells were removed from liquid nitrogen storage and defrosted as rapidly as possible. 
When reanimating mESCs, immediately after thawing, the cell suspension was 
transferred to a volume of pre-warmed mESC medium and transferred to an SNL 
feeder layer for immediate culture. For SNLs and primary calvarial cells, after 
thawing, cell suspension was transferred to a volume of pre-warmed cell culture 
medium, centrifuged to remove DMSO, before being resuspended in medium, and 
transferred to a T75 cm2 flask for further culture. 
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Appendix III ± Trypan Blue Exclusion 
 
Cell counts were performed using a trypan blue exclusion technique to estimate cell 
viability. When mixed with a cell suspension, trypan blue will penetrate the non-viable 
cells due to loss of membrane integrity and stain blue. Viable cells will remain 
colourless. This can then be seen under a haemocytometer. Equal volumes of 0.5% 
(w/v) trypan blue solution were mixed with a volume of cell suspension and 10 µL 
transferred to a haemocytometer. The cells were then counted under an inverted light 
microscope, disregarding the non-viable cells. Number of viable cells could be 
calculated and plated at the correct cell density for experiments.  
 
 
Appendix IV ± Paraformaldehyde 
PFA was used as a cell fixative. To make a 4% (w/v) solution, first a 0.2 M phosphate 
buffer (pH 7.4) was made by dissolving 21.8 g Na2HPO4 and 6.4 g NaH2PO4 in 1 L 
distilled water. This was diluted to a 0.1 M solution with distilled water. To make the 
PFA, 40 g paraformaldehyde powder was added to 1 L of 0.1 M phosphate buffer. 
This was heated to 60-65°C whilst stirring, until dissolved. Drops of 1 M sodium 
hydroxide were added until the solution turned clear. The solution was then cooled, 
tested for pH 7.4 with pH paper and passed through 0.22 µm filters. The solution was 
aliquoted and stored at -20°C, until use. 
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Appendix V ± PGES 
Immunocytochemistry 
Results for PGES immunostaining can be seen in figure AV.1 (primary calvarial cells) 
and figure AV.2 (osteo-mESCs). PGES staining can be seen in the primary calvarial 
cells only when stimulated with proinflammatory cytokines, not in the control culture 
medium. This occurs at all differentiation timepoints. In osteo-mESC cultures, no 
PGES in seen in control medium or proinflammatory cytokine medium at day 0 or day 
7. PGES staining can be seen to a small amount in day 14 proinflammatory cytokine 
medium and can be seen in large amounts when stimulated on day 21, in nodule-like 
areas.  
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Timepoint 
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Control IL-ȕ71)-Į,)1-ȖVWLPXODWHGIRUhours 
PGES With Hoechst PGES With Hoechst 
Day 0 
    
Day 7 
    
Day 14 
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Figure AV.1: PGES expression in primary calvarial cells stimulated with proinflammatory cytokines. Cells were stimulated with 
IL-ȕ71)ĮDQG,)1-ȖIRUKRXUVDWHLWKHUGD\GD\GD\RUGD\RIRVWHRJHQLFFXOWXUHEHIRUHIL[DWLRQPGES expression in 
both proinflammatory cytokine stimulated and control cultures was assessed by immunocytochemistry. Representative images shown. 
Scale bar = 46 µm 
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Timepoint 
of 
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Control IL-ȕ71)-Į,)1-ȖVWLPXODWHGIRUhours 
PGES With Hoechst PGES With Hoechst 
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Figure AV.2: PGES expression in osteo-mESCs stimulated with proinflammatory cytokines. Cells were stimulated with IL-ȕ
71)ĮDQG,)1-ȖIRUKRXUVDWHLWKHUGD\GD\GD\RUGD\RIRVWHRJHQLFFXOWXUHEHIRUHIL[DWLRQPGES expression in both 
proinflammatory cytokine stimulated and control cultures was assessed by immunocytochemistry. Representative images shown. Scale 
bar = 46 µm. 
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Appendix VI ± mESC Conditioned 
Medium 
Full result set showing the effect of mESC CM on viability and NO production of 
primary calvarial cells, in response to proinflammatory cytokines. Figure AVI.1 A and 
B show MTS assay results for day 3, day 7 and day 10. Figure AVI.1 C shows non-
cumulative nitrite results for day 3, day 7 and day 10 medium collections.  
 
 
Figure AVI.1: Effect of mESC conditioned medium on primary calvarial cells 
treated with proinflammatory cytokines. (A and B) Viability of primary calvarial 
cells over 10 days, in OM with IL-ȕ71)-ĮDQG,)1-ȖDQGYDULRXV&0(A) CM from 
undifferentiated mESCs, cultured with and without cytokines, and with and without 
supplemented cytokines when added to primary calvarial cells. (B) CM from 
differentiated mESCs, with and without IL-ȕ 71)-Į DQG ,)1-Ȗ ZLWK DQG ZLWKRXW
supplemented cytokines when added to primary calvarial cells. Data shown as 
percentage of primary calvarial cell viability in control OM. Values shown as 
mean±SD, n=6, representative of 3 independent experiments. *Statistical significance 
YV20FRQWUROS6WDWLVWLFDOVLJQLficance vs. OM with IL-ȕ71)-ĮDQG,)1-Ȗ
S (C)Nitrite production by primary calvarial cells treated with CM from 
undifferentiated and differentiated mESCs, with and without cytokines. All groups 
supplemented with IL-ȕ 71)-Į DQG ,)1-Ȗ ZKHQ DGGHd to primary calvarial cells. 
Control readings with no proinflammatory cytokines have been subtracted from 
treated groups. Values shown as mean±SD, n=6, representative of 3 independent 
experiments. #Statistical significance vs. OM with IL-ȕ71)-ĮDQG,)1-ȖS 
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Appendix VII ± Anti-Inflammatory 
Effect of Prednisolone, Ibuprofen and 
Piroxicam 
Basic validation of the primary calvarial cell inflammation model was carried out using 
a range of anti-inflammatory mediators. The results for prednisolone, ibuprofen and 
piroxicam can be seen in figures AVII.1, AVII.2 and AVII.3, respectively. Viability 
results for prednisolone (Figure AVII.1 A) show that the drug was not toxic to the cells 
at any concentration. However, prednisolone was only successful at inhibiting the 
toxic effects of the cytokines at a concentration of 100 µM. Prednisolone was only 
successful at inhibiting cytokine-induced-NO production at the highest concentration 
of 100 µM but inhibited cytokine-induced PGE2 production at all concentrations. 
Ibuprofen results (Figure AVII.2) showed the drug was most effective at improving cell 
viability in the presence of cytokines when at a concentration of 250±500 µM. This 
also correlated with a reduction in cytokine-induced NO and PGE2 production. 
Piroxicam (Figure AVII.3) was toxic to the cells at a concentration of 500 µM. The 
most effective results for piroxicam occurred at a concentration of 100 µM. Although, 
at this concentration cytokine-induced NO production was not inhibited. Piroxicam 
was a potent inhibitor of PGE2 production by the primary calvarial cells in the 
presence of proinflammatory cytokines, across all concentrations. 
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Figure AVII.1: Anti-inflammatory effect of prednisolone. Primary calvarial cells 
were cultured for 10 days in osteogenic media, before media supplemented with 
prednisolone and proinflammatory cytokines. (A) Cell viability, determined by MTS 
assay, after 3 days in either basal osteogenic or proinflammatory cytokine containing 
osteogenic media, with prednisolone at increasing concentrations.  Values are 
represented as mean±SD, n=6. (B) Nitrite concentration in media after 3 days 
proinflammatory cytokine and prednisolone treatment.  Values are represented as 
mean±SD, n=6. (C) PGE2 concentration in media after 3 days proinflammatory 
cytokine and prednisolone treatment. Values are represented as mean±SD, n=4. 
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Figure AVII.2: Anti-inflammatory effect of ibuprofen. Primary calvarial cells were 
cultured for 10 days in osteogenic media, before media supplemented with ibuprofen 
and proinflammatory cytokines. (A) Cell viability, determined by MTS assay, after 3 
days in either basal osteogenic or proinflammatory cytokine containing osteogenic 
media, with ibuprofen at increasing concentrations.  Values are represented as 
mean±SD, n=6. (B) Nitrite concentration in media after 3 days proinflammatory 
cytokine and ibuprofen treatment.  Values are represented as mean±SD, n=6. (C) 
PGE2 concentration in media after 3 days proinflammatory cytokine and ibuprofen 
treatment. Values are represented as mean±SD, n=4. #Statistical significance vs. 
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Figure AVII.3: Anti-inflammatory effect of piroxicam.  Primary calvarial cells were 
cultured for 10 days in osteogenic media, before media supplemented with piroxicam 
and proinflammatory cytokines. (A) Cell viability, determined by MTS assay, after 3 
days in either basal osteogenic or proinflammatory cytokine containing osteogenic 
media, with piroxicam at increasing concentrations.  Values are represented as 
mean±SD, n=6. (B) Nitrite concentration in media after 3 days proinflammatory 
cytokine and piroxicam treatment.  Values are represented as mean±SD, n=6. (C) 
PGE2 concentration in media after 3 days proinflammatory cytokine and piroxicam 
treatment. Values are represented as mean±SD, n=4. #Statistical significance vs. 
SURLQIODPPDWRU\ F\WRNLQH FRQWURO  QJP/ S 6WDWLVWLFDO VLJQLILFDQFH YV
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S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